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ABSTRACT

TUM OR RESPONSE TCF-4/0-CATEN IN REGULATORY ELEM ENTS
FOR ENHANCING CAN CER GENE THERAPIES
Saurabh Kumar Gupta
Old Dominion University, 2005
Chair: Dr. Richard R. Drake
M utations in the adenomatous polyposis coli gene are frequently associated with
progression o f colon carcinoma and most other types o f epithelial carcinomas. This
usually results in stabilization o f P-catenin protein levels, followed by transactivation o f
Tcf-4/ P-catenin responsive genes. The effectiveness o f a Tcf-4/ P-catenin transcriptional
enhancer element in combination with a c-fos or carcinoembryonic antigen promoter was
tested for it’s ability to act as a tum or specific regulator o f gene expression in a panel o f
human tum or and normal cell lines. Luciferase reporter assays indicated enhanced
activity o f the Tcf-4/ P-catenin transcriptional element only in tum or cell lines, with
minimal activities in normal colon cell lines. The Tcf-4/ P-catenin enhancer and c-fos
promoter linked with the herpes virus thymidine kinase suicide gene in combination with
ganciclovir was further evaluated in the normal and tumor cell lines. The Tcf-4/p-catenin
elements conferred tum or specific expression o f HSV thymidine kinase (HSV-TK) gene,
resulting in selective metabolism o f ganciclovir and cell killing o f only tum or cell lines.
There was no detectable expression o f HSV thymidine kinase expression in normal colon
cell lines. Additionally, recombinant adenoviral constructs were made to deliver the gene
expression cassette, containing the HSV-TK expressed from a Tcf-4/c-fos enhancer/
promoter combination, to the tum or cells. No expression was detected in the normal
colon cells as opposed to significant levels o f HSV-TK gene expression observed in
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tumor cells. Furthermore, various chemical and genetic modulators were also screened in
an effort to identify newer methods to regulate the activity o f the proposed recombinant
enhancer/promoter combinantions. These data suggest that Tcf-4/ P-catenin enhancer
can be effectively coupled with a suitable tumor-specific or tumor-related mammalian
promoter for selective expression o f therapeutic genes for gene therapy o f epithelial
cancers. This approach also offers a potential promoter cassette approach linked with the
Tcf-4/ p-catenin enhancer to better individualize treatment to cancer patients.
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CHAPTER I
INTRODUCTION

Colorectal Tumorigenesis
Colorectal cancer is one o f the most common malignancies among populations in
the United States and Western Europe, and one o f the leading causes o f worldwide
morbidity and mortality due to cancer. The life time colorectal cancer risk in the general
population is 5%, but this figure dramatically rises with age: by the age o f 70,
approximately h alf o f the Western population will have developed an adenoma (1). In
general, the incidence o f colorectal cancer is high in developed countries, with incidence
rates varying up to 20-fold between high- and low-risk geographical areas throughout the
world (1). These variations in colorectal cancer incidence are most likely to be a result o f
environmental and dietary modifying factors. Colorectal carcinomas arise through a
series o f well characterized histopathological changes that result from specific mutation
‘hits’ o f a select set o f oncogenes and tum or suppressor genes. However, it is still a
matter o f debate regarding the exact sequence o f events that leads intestinal epithelial
cells to develop into aggressive carcinoma. Currently, it is estimated that 85% o f all
sporadic colorectal tumors have inactivating mutations in the APC (Adenomatous
Polyposis Coli) gene (2) and the other 15% are believed to harbor defects in DNA
mismatch repair pathway genes (3). Therefore, in general there are two widely accepted
basic models o f colorectal tumorigenesis, one driven by mutations in the tum or uppressor
APC gene, and the other caused by defects in DNA mismatch repair pathway genes.

This dissertation follows the format o f the journal Cancer Research.
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Histopathology o f Colorectal Cancer
Throughout the entire length o f the large intestine, tubular glands or crypts are
lined by a m onolayer o f columnar epithelial cells. These invaginations effectively
increase the surface area o f colon and rectum. At the base o f each crypt, a small number
o f stem cells are present which asymmetrically divide to give rise to four different types
o f epithelial cells: columnar absorptive cells, goblet cells, neuroepithelial cells and paneth
cells. Dividing cells are present in the lower third o f the crypt, whereas the differentiated
types are present in the upper two-thirds. The cells continuously migrate upwards and are
eventually exfoliated into the lumen by an apoptotic mechanism. This process o f
epithelial renewal takes 3-6 days. Therefore, a delicate balance between mitotic rates and
cell loss exists in these cells. The earliest signs o f colorectal neoplasia are aberrant crypt
foci, or ACF, which are only visible by microscopy. ACF usually include a small number
o f crypts and can be composed o f cells with either normal morphology (nondysplastic),
or dysplastic cells. The latter cells are more likely to develop into a benign tum or mass
(polyp) protruding into the lumen from the intestinal epithelium. Polyps can also be
classified into two types: hyperplastic (nondysplastic) and adenomatous (dysplastic).
Hyperplastic polyps show normal cellular morphology whereas adenomatous polyps are
characterized by abnormalities in both inter- and intracellular organization. The
epithelium, in such adenomatous polyps, is organized in multiple layers, nuclei are
enlarged, and their alignment at the basal membrane is lost (4).
It is widely accepted that these adematous polyps generally arise as a result o f
genetic changes initiated by mutations in either APC gene or in genes involved in DNA
mismatch repair pathway.
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Genetic Model for APC-Driven Colorectal Tumorigenesis
Mutational inactivation o f APC gene is considered a key initiating event which
results in cascade o f genetic alterations results in development o f m ajority o f colorectal
carcinomas. Therefore, it is very important to understand the role the basic biology o f
APC gene in context o f colorectal carcinoma.
Biology o f AP C
The APC gene was initially identified by positional cloning o f the FAP (familial
adenomatous polyposis) locus (5). Later, clues regarding APC functional came from
studies which identified P-catenin as a binding partner o f APC (6). p-catenin was
originally identified as an essential intracellular component o f the cadherin adhesion
complexes. It is now well established that P-catenin is an important component o f the
wingless/wnt signal transduction pathway. The canonical wnt signaling pathway has been
characterized from combined work in flies, frogs and mammals. In unstimulated cells, i.e.
in the absence o f the extracellular wnt signal, free P-catenin is bound and phosphorylated
in a so-called destruction complex, consisting o f the scaffolding proteins axin and
conductin, glycogen synthase kinase 3 P (GSK-3P) and APC (7). Phosphorylation o f Pcatenin by this complex labels it for ubiquitination and subsequent proteolytic
degradation. In the presence o f a Wnt signal bound to frizzled receptors (8), GSK-3P is
inactivated in the destruction complex by a still poorly defined mechanism involving an
intracellular protein termed Dishevelled (9). As a consequence, unphosphorylated Pcatenin becomes stabilized and can shuttle to the nucleus. Once in the nucleus, P-catenin
can bind to DNA-binding proteins o f the T-cell factor (TCF) family, to serve as an
essential co-activator o f transcription (10). P-catenin not only functions as a Wnt
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transducer, but it also plays an important role in cellular house-keeping functions. For
example it is an essential component o f the adheren junctions, where it provides the link
between E-cadherin and a-catenin (11). Together these studies demonstrate that APC can
regulate cell adhesion and gene transcription by regulating the stability and sub-cellular
localization o f P-catenin. In addition, APC directly associates with microtubule
cytoskeleton (12). This function is apparently unrelated to its capacity to regulate the Wnt
signaling pathway.
A PC, fi-catcnin and Cancer
Disruption o f any o f the several physiological roles played by APC can be
potentially linked with cancer; it seems that the main tumor suppressing function o f APC
resides in its capacity to properly regulate intracellular P-catenin levels. Moreover,
although the vast majority o f colorectal tumors carry mutations in APC, most tumors with
an intact APC gene were found to contain activating mutations in P-catenin that alter
functionally significant phosphorylation sites (13). In addition mutations in other
members o f the Wnt pathway have been shown to be associated with cancer including
conductin (14) and axin (15).
Mutational activation o f APC gene is regarded as one o f the earliest events in
initiation o f colorectal tumorigenesis (16-18), ultimately resulting in a nuclear Pcatenin/TCF-4 transcription complex. The first two identified downstream targets o f this
transcription complex, MYC and C yclin-D l, are clearly relevant for tumor formation
because o f their role in proliferation, apoptosis and cell-cycle progression (19-21).
Changes in the level o f expression o f MYC and cyclin-Dl are likely to affect the rate o f
renewal o f normal colon epithelium by increasing the overall proliferation rate. Other wnt
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target genes such as matrilysin (22), CD44 (23) and urokinase-type plasminogen activator
receptor (24) appear more likely to play a role in tum or promotion rather than initiation.
Similarly, genes like Gastrin (25) and Cox-2 (26) which are believed to have tumor
promoting roles are targets o f wnt signaling pathway.
In epithelial cells lining the intestinal crypts, nuclear P-catenin expression is
higher in the lower proliferative compartment o f colon crypts, while it is decreased in the
upper two-thirds o f the crypt. In contrast, APC staining is dramatically increased in post
replicative cells in the upper portions o f the crypts as the migrating cells mature upwards
on the crypt-villi axis. This inverse relationship between levels o f expression o f APC and
P-catenin is in agreement with the function o f P-catenin in maintaining stem cell
properties and controlling differentiation in the intestine (27). In the bowel, Tcf-4 is the
main transcription factor which transduces P-catenin signaling in the nucleus (28). Tcf-4 /- mice cannot sustain an intestinal stem cell compartment, strongly suggesting that
activation o f downstream targets such as MYC and cyclin-Dl are required to maintain
proliferative capacity (27, 29-31). Moving upwards along the crypt villus axis, an
increase in APC mutations is therefore likely to result in the enlargement o f the stem cell
compartment and diminished differentiation. Indeed, it is generally accepted that
colorectal tumors arise from the stem cells that are located at the base o f the crypt.
A P C driven colorectal tumorigenesis
The most widely accepted model o f colorectal tumorigenesis is that tumors
initiate as the result o f mutation in a single gene in a single progenitor cell. Subsequent
mutations in the progeny o f this cell and waves o f clonal expansion give rise to daughter
cells that have the growth advantage typical o f cancer. This whole process is driven by
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clonal selection. In accordance with K nudson’s hypothesis, the mutational targets o f this
multi-step process are oncogenes and tum or suppressor genes known to directly affect the
rate o f cell growth or cell death (32). Besides these growth regulating genes, other gene
classes may be affected by mutations, including nucleotide excision repair genes (33), the
Bloom ’s syndrome gene BLM (34) and DNA mismatch repair pathway genes (35). The
common function for all the above wild type genes is to maintain genetic stability.
Alterations o f these genes increase the effective rate o f mutations in cancer which in turn
fuels tumorigenesis by providing variation for the forces o f selection to act upon.
Different types o f genomic instability results in inactivation o f different set o f oncogenes
and tumor suppressor genes. The net outcome o f inactivation o f different set o f genes
always results in targeting o f a crucial growth regulating pathway. Colorectal
tumorigenesis provides a classic example o f this phenomenon, in that the inactivating
mutations in APC cause p-catenin to transactivate downstream growth regulatory genes,
giving cells with APC mutations a growth advantage compared to non-mutated
neighboring cells (32, 36).
Assuming APC mutations are a primary initiating event in colorectal
tumorigenesis, and that this provides some growth advantage to the initiator cell, this
single mutation is not sufficient to initiate the waves o f clonal expansion needed for a
tumor to mature. Colorectal tumors are known to harbor hundreds o f mutations, but
current technology does not allow the dissection o f the evolutionary history o f a tumor
and sequentially arrange one mutation after another with reference to tumor
metamorphosis. However, with the knowledge o f known mutations in oncogenes and
tumor suppressor genes, a model has been constructed by Vogelstein and colleagues.
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According to this model, at least four sequential genetic changes need to occur to ensure
colorectal cancer evolution. One oncogene (K-RAS) and three tumor suppressor genes
(APC, TP53 and SMAD4) are the main targets o f these genetic changes. At least seven
genetic hits are required according to this model: one in oncogenic K-RAS and six
additional ones to inactivate both the alleles o f the mentioned tum or suppressor genes
(32, 37). All the mentioned tum or suppressor genes are found mutated in most o f the
colorectal tumors whereas K-RAS mutations are found in approximately 50% o f cases
(38-40). It appears that a synergistic action o f the mutated APC and K-RAS genes
underlies clonal expansion and dysplasia in colorectal tumors. However, because only
50% o f colorectal tumors are observed to have K-RAS mutations, other unidentified
genes might be able to substitute for K-RAS functions.
Another important concept for describing colorectal tumorigenesis is ‘loss o f
heterozygosity’ (LOH): In cells that carry a mutated allele o f a tum or suppressor gene,
the gene becomes fully inactivated and loses a part o f the chromosome carrying the wild
type allele. LOH studies have been very instrumental in identifying tum or suppressor
genes which are involved in colorectal tumors (40-43). LOH in chromosome 5q, 17p and
18q are found with high frequencies and are most likely to be associated with the
following tum or suppressor gene: APC (5q), TP53 (17p) and SMAD4(18q).
Chromosome 17p is lost in 75% o f the colorectal cancers but infrequently in benign
tumors, suggesting that loss o f p53 occurs later in tumor progression and is not crucial for
initiation (40, 44). The other TP53 allele is almost invariably found to have mis-sense
mutation, in line with Knudson’s two hit hypothesis. Chromosome 18q is also frequently
found lost in 50% o f adenomas and 75% o f malignant colorectal cancers (43). Several
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candidate tum or suppressor genes map to this location, including SMAD2 and SMAD4.
SMAD4, also known as DPC4 (deleted in pancreatic cancer) (45) encodes a key signaling
molecule with in tumor growth factor-P pathway (46). SMAD4 loss has been observed in
colorectal and pancreatic cancer (45, 47). SMAD2 also maps to chromosome 18q locus
and encodes another m ember o f the TGF-P signaling pathway. It is also found mutated in
a subset o f colorectal tumors. However, the precise role o f SMAD2, SMAD4 and other
genes mapping to the 18q locus in tum or progression is not properly understood.
Additional studies are needed to elucidate the mechanism o f involvement o f these genes
in colorectal tumorigenesis.
The model for colorectal tumorigenesis proposed by Vogelstein and colleagues
states that inactivation o f both alleles o f the APC gene triggers the adenomatous process
by providing the tum or cell with a growth advantage to allow clonal expansion.
Additional mutations, e.g. K-RAS, are needed to support adenoma growth and expansion.
Subsequent malignant transformation and clonal expansion is driven by additional
mutations and allelic loss in TP53, SMAD4 and other 18q tumor suppressor genes.
Although, additional unidentified mutations might be necessary for colorectal cancer
development, this model predicts that at least seven genetic hits are needed. This is
reflected in the fact that it takes about 20-40 years for the whole process o f developing an
aggressive colorectal tumor from a smallest observed lesion, the aberrant crypt foci.
Genetic Instability
Thus, natural selection with waves o f clonal expansion seems to be a major force
underlying clonal evolution o f a tumor. However, it has been argued that endogenous
mutation rates are not sufficient to achieve the high number o f genetic alterations found
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in human cancers. This implies that another selection force in the form o f genetic
instability might be crucial in tumor development. Indeed, it has been hypothesized that
‘genomic instability’ in the form o f a mutator phenotype is an essential requirement for
cancer to occur (48). Two forms o f genetic instabilities have been described in colorectal
cancers: M icrosatellite instability (MIN or MSI) and chromosomal instability (CIN). MSI
is widely present in sporadic colorectal tumors having impairments in DNA mismatch
repair (M MR) genes. In contrast, 85% o f colorectal tumors that include APC mutations,
no MSI is evident (49). The reasons behind this difference will be described in detail
below. CIN is a hallmark o f most colorectal cancers, but is not very well understood at
molecular level. Most colorectal cancers can be characterized for the presence o f
abnormal chromosomal content that is they are aneuploid. There is evidence that supports
the idea that aneuploidy arises in these cancers because o f CIN due to an accelerated rate
o f gain or loss o f chromosomes. CIN is postulated to allow cells to rapidly acquire
genetic changes that are required for tumorigenesis (50). How CIN originates in a cell is
not clearly understood, and there are several different mechanism proposed to explain
how cells might achieve aneuploidy. One proposed view is that CIN is not genetic and
propagates the idea that CIN is result o f aneuploidy (51). According to this hypothesis,
following a random tetraploidization event, the chromosomal complement is inherently
unstable and CIN is a trivial consequence o f the near doubling o f the genetic content.
Another hypothesis is that CIN is genetic in origin, and there are at least two lines o f
evidences supporting it. First, the CIN phenotype is dominant as it can be conferred on a
chromosomally stable diploid cell which is fused with a CIN cell (52). Second, a fraction
o f cancer contains mutations or abnormal expression patterns o f spindle checkpoint genes
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such as BUB1 and MAD2 (53-57). Targeted mutations in these genes in non-CIN lines
can convert them to CIN phenotype with resultant aneuploidy, presumably because o f
disruption o f the cell’s normal error checking mechanisms which prevent mis-segregation
o f DNA during mitosis.
In addition, it has recently been reported that APC mutations can give rise to CIN
(58, 59). Experimental evidence have shown that the C terminus o f APC is involved in
maintaining chromosomal stability during mitosis (58, 59). During metaphase, APC
localizes to kinetochores o f chromosomes, where in association with the microtubule
associated protein EB1, it facilitates the binding o f the spindle microtubule to the
kinetochore. In cells that express a truncated form o f APC; the interaction between
kinetochores and spindle microtubules is disrupted leading to chromosomal instability.
However, the idea o f APC being the cause o f CIN has been challenged by the Vogelstein
group. They argue that APC mutant cells actually tend to polyploidize in whole genome
increments rather than show the increased rates o f loses and gains o f one or few
individual chromosome that is a characteristic o f cancers. Further, they advocate that
some well characterized human cancer cell lines with APC mutations have chromosome
complements that have remained stable and invariant over thousands o f cell divisions in
vitro.
Although the molecular basis o f CIN is yet to be elucidated, it does not undermine
the fact that genetic instability in the form o f CIN and clonal selection go hand in hand to
promote tumorigenesis. An important issue in the current discussion is at what point in
tumor developmental history does CIN originate? Does genetic instability precede
mutations in rate-limiting oncogenes and tumor suppressor genes or does it simply
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underlie tum or progression? There is evidence to support the idea that genetic instability
occurs in very early stages o f tumor progression (60). An important study by Shih, et al
evaluated 32 tiny adenomas with an average diameter o f 2 mm. Using highly quantitative
methods they found that more than 90% o f these lesions had allelic imbalances o f one or
more o f the five chromosomes tested. In this study chromosome 5q, where APC resides,
was excluded because o f the expectations that alterations at this locus initiated the tumor.
More than two-thirds o f the tiny tumors showed at least one allelic imbalance o f the other
chromosome tested. Interestingly, in some tumors, the allelic imbalances were not found
in the entire population o f neoplastic cells whereas chromosome 5q allelic imbalance
generally seemed to affect most neoplastic cells in the tumor. This study suggests that
APC mutations may precede genomic instability. However, it does not necessarily
conclude that an APC mutation result in genomic instability, but it does strengthen the
viewpoint that APC plays a multifunctional pivotal role in colorectal tumorigenesis.
Alternative Pathway for Development o f Colorectal Cancer
Over the past decade, researchers have compared colorectal cancers from two
inherited disorders: familial adenomatous polyposis (FAP) and the hereditary non
polyposis colorectal carcinoma (HNPCC). Several distinct differences were observed.
HNPCC tumors do not necessarily show APC deletions and are chromosomally stable. In
addition, they have characteristic defects in DNA mismatch repair (M MR) machinery
resulting in microsatellite instability (MSI). Subsequently it was shown that 15% o f
sporadic colorectal cancers exihibit the presence o f MSI (61, 62). This feature arises
through defective DNA mismatch repair or due to failure to express a mismatch repair
gene. These observations prompted the idea that there is an alternative pathway o f
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colorectal tumorigenesis which is characterized by the presence o f MSI, in contrast to
CIN found in m ajority o f colorectal tumors. Microsatellites are tandem repeats o f small
DNA sequences showing length polymorphisms and are found throughout the human
genome. Because o f their repetitive nature, microsatellites are prone to strand slippage
and replication errors. (63). The principal task o f MMR is to remove nucleotides that
have been mis-incorporated into the newly synthesized DNA strand by DNA polymerase.
Thus a disruption in the DNA mismatch repair system can result in MSI.
DNA Mismatch Repair Systems and Mutations in Colorectal Cancer
The DNA mismatch repair system is responsible for correcting base pairing errors
during replication o f DNA. It also repairs any mismatches post replicatively which
escape the proof reading mechanism o f DNA polymerase. The principal players in
mammalian MMR are the homologues o f the bacterial mutS and mutL proteins. The
repair system requires the co-operation o f many genes from the mutS (hMSH2, hMSH3,
hMSH6) and mutL families (hM LH l, hMLH3, hP M S l, hPMS2) (64). Briefly, hMSH2
serves as the scout that recognizes and binds directly to the mismatched DNA sequence
(65, 66). It forms a heterodimeric complex with hM SH6 if a single base pair mismatch is
recognized or with hMSH3 if there is a two to eight nucleotide deletion o f insertion. A
second heterodimeric complex o f hM LH l and hPMS2 is then recruited to excise the
mismatched nucleotides. Although heterodimers o f hM L H l/hPM Sl and hM LH l/hM LH 3
also form, their specific roles remain to be defined. Genetic alteration in mismatch repair
genes results in defective DNA mismatch repair. The severity o f defect is co-related with
the specific gene altered. hMSH2 or hM LH l mutations result in high levels o f MSI
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(MSI-H), whereas, inactivation o f hM SH6 leads to partial impairment o f the mismatch
repair machinery (MS1-L) (67, 68).
Mutations in mismatch repair genes may occur in germline or somatic DNA. It
has been observed that an inherited germline mutation does not result in widespread
tumor formation in most organs (69). One possible scenario is that the wild type allele
may provide sufficient DNA mismatch repair function. However, individuals with
inherited germ line mutations in a mismatch repair gene can show a predisposition to
early onset tumors primarily in the colon and endometrium. The biological basis for this
organ specificity is unknown. The direct consequence o f mismatch repair is the so called
mutator phenotype which promotes tumor formation by providing a favorable
environment for mutations to occur. The subsequent mutations which possibly occur in
oncogenes and tum or suppressor genes provide a selective growth advantage to the
budding tumor. Ensuing accumulation o f mutations is the result o f MSI and selection
pressure working synergistically. For colon, HNPCC is defined as an MSI-H phenotype
and is characterized by germ line mutations in hMSH2 or hM LH l (61, 62). The MSI-H
phenotype also occurs sporadically in 15% o f colorectal tumors. In sporadic cases, the
MMR deficiency is due to epigenetic and bi-allelic silencing o f hM LM hl by de novo
methylation o f its promoter site in more than 90% o f the colorectal tumors showing
MMR deficiency. (70-72).
M odel fo r Colorectal Tumorigenesis Characterized By M SI-H Phenotype
MSI-H cancers, like other cancers, are thought to develop through accumulation
o f inactivating or activating mutations in genes that regulate cell growth and/or cell death.
Inherited or sporadic mutations in MMR genes results in the development o f a certain
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type o f instability widely accepted as MSI, since they are unable to repair spontaneous
errors that normally occur at microsatellite sequences during DNA replication (61, 62,
73). Besides mutations, epigenetic mechanisms which silence the MMR gene express can
also result in impairment o f MMR machinery. As a consequence, thousands o f mutations
are accumulated in these cells at such repetitive sequences that are known to be widely
distributed throughout the genome (74).
The nature o f genetic instability in MSI-I tumors predict that genes with repetitive
coding sequences might be possible targets for inactivating and activating mutations in
tumors with MMR deficiency. In line with this idea, it was reported that the TGF-P
growth factor receptor II gene, which has 10 poly (A) coding repeat, was mutated in
MSI-H tumors. A number o f studies have reported mutations in a series o f other target
genes with possible roles in human carcinogenesis that have been found to be altered in
colorectal MSI-H tumors by the same underlying mechanism. These include alterations in
cell growth genes such as IGFIIR (75) and pro-apoptotic genes such as BAX (76) or
caspase-5 (77). In addition, mutational inactivation o f APC or p53 have also been
reported in such tumors (3, 78)
All these alterations are known to occur with in the context o f a high background
o f genetic instability. In MSI-H tumors it is very complex to build a sequential model for
colorectal carcinogenesis. It is very difficult to establish which mutations really play a
role in MSI-H carcinogenesis and at what point in the evolutionary history o f the tumor
they occur. This is because genetic alterations are also expected to occur in non-specific
genes which do not have any expected role in tumorigenesis. However, a generalized
model has been proposed (79). hM LH l or hMSH2 mutations in normal colon epithelium
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results in establishing a high basal level o f genomic instability. This initial underlying
genomic instability, combined with subsequent rounds o f clonal selection, results in
accumulation o f mutations in cell growth and/or death related genes. For example,
mutations in the TGF-P receptor and APC can directly aid in selection by providing a
growth advantage to mutator cells. Similarly, inactivation o f BAX and FAS promote cell
survival. Simultaneously, mutations in genes which directly or indirectly affect genomic
instability get selected which effectively raises the level o f genomic instability in these
tumors. The cumulative result o f all these events carries the normal epithelial cell through
the stages o f adenoma and early carcinoma. In the final stages, early carcinoma picks up
hMSH6 or hMSH3 mutations to develop into advanced carcinoma. This model has not
been experimentally verified. Nevertheless, it does conform to generally accepted
pathway for tumorigenesis in which natural selection and an underlying genetic
instability contribute in tumor development.

Conventional Therapies for Cancer
Radiotherapy for Cancer
Radiotherapy is now commonly accepted as one o f the effective forms o f cancer
treatment. Currently, it is being used to treat a variety o f malignant tumors o f different
origin and stage. Ionizing radiations (IR), from various sources like linear accelerators,
brachytherapy etc. are primarily used for the purpose o f radiotherapy. Such IR is defined
as corpuscular or electromagnetic radiations which are capable o f producing ions, directly
or indirectly, in its passage through matter. The absorbed dose o f ionizing radiation is
measured as the Gray (Gy, 1 joule o f energy absorbed by 1 kilogram o f material).
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Radiation therapy is primarily delivered with high-energy photons (GAM M A-RAYS and
X-RAYS) and charged particles (electrons). All IR causes ionization o f atoms in the
biological target material by electrons that travel through the target material colliding
with atoms and thereby releasing packets o f energy. The success o f IR for treating cancer
depends on its ability to selectively kill tum or cells. This is mediated by IR-induced DNA
damage, which also explains the mutagenic and carcinogenic activities o f IR. The
damage o f DNA is induced directly by ionization o f DNA or indirectly by the generation
o f free radicals, and is manifested by single- and double-strand breaks in the sugarphosphate backbone o f the DNA molecule. In addition IR also causes cross linking
between DNA strands and chromosomal proteins The IR caused genotoxic stress
cumulatively results in activation o f DNA repair, coupled with arrests at cell-cycle
checkpoints. This allows the cells to repair the DNA damage before they can proceed to
mitosis. In m ajority o f tumors the cellular machinery responsible for detecting and
repairing DNA damage is impaired. This is due to mutations in p53 gene and other genes
involved in DNA damage repair pathway. Tumors are generally highly sensitive to
gamma radiations because o f loss o f negative growth regulation and genomic stability.
Following IR exposure, tumor cells do not usually die o f apoptosis as most tumors lose
the ability to apoptose. The antitumor effect o f radiation is realized through mitotic
catastrophe or in senescence-like irreversible growth arrest. IR induced tumor mitotic
catastrophe is a collective result o f a series o f pathological events that occur after aberrant
mitosis and usually result in cell death. Such mitosis does not produce proper
chromosome segregation and cell division but leads to the formation o f large non-viable
cells with several nuclei, containing fractions o f broken chromosomes.
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Radiation therapy has been very helpful in treating patients with tumors limited to
rectal walls and it has been proposed that radiotherapy may be used as single modality
treatment approach in elderly patients with rectal tumors. In a series o f rectal tumor cases,
radiotherapy has been shown to significantly improve patient survival and the authors
have proposed that conservative treatment o f rectal cancer may be a valid alternative to
radical surgery (80). However the use o f radiotherapy alone for rectal cancer treatment
has been questioned and it has been proposed that adjuvant radiotherapy in combination
with surgery may be a better alternative in some patients (81). Local reoccurrence and
metastasis o f colorectal cancer following surgery has led to the development o f the
adjuvant cancer therapy concept. Adjuvant therapy is commonly used as a broad term
encompassing all types o f treatment used in conjunction with surgery and aimed at
destroying microscopic metastatic disease which cannot be removed by surgery. Many
adjuvant therapy trials, for treatment o f colorectal cancer, have been conducted over the
past 30 years and it is highly recommended in patients who are risk o f developing
recurrence following surgery.
IR can kill tumor cells effectively, but the dose that can be given is limited by the
fact that damage to normal tissue must be minimized. Effective clinical schemes o f
radiation therapy and years o f experiences have resulted in development o f effective
radiotherapy regimens. However, even with all the precautions taken to minimize
exposure o f normal cells to IR, it is impossible to have absolutely safe radiation treatment
because the invasive nature o f cancer growth means that IR must also be delivered to the
areas that immediately surround the tumor. This eventually results in normal tissue
toxicity and death o f normal healthy tissue. Moreover, exposure to IR during treatment
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can result in development o f secondary cancers and the risk o f cancers increases as the
total dose o f radiation increases. These secondary cancers can be very aggressive and
respond poorly to therapy. For example Radiation associated bone tumors and sarcomas
develop with-in the radiation field typically after a latency period o f ten years and are
refractory to therapy (82).
Chemotherapy for Colorectal Cancer
In addition to radiation and surgical treatments, there are several drugs which are
currently being used as chemotherapeutic agents for the treatment o f colorectal cancer.
These chemical agents are broadly categorized on the basis o f the chemical nature and
mode o f action.
5-FU remains the most widely used chemotherapeutic agent for the treatment o f
colorectal cancer. It is a pro-drug, an analogue o f uracil, that is converted to 5-fluoro-2’deoxyuridine monophosphate (5-FdUM P) through a de novo pyrimidine pathway.
5-FdUMP combines with methylenetetrahydrofolate to form a ternary complex with
thymidylate synthase (TS), thus interfering with DNA synthesis by inhibiting the
conversion o f deoxyuridylate to thymidylate. Additional mechanisms o f action include
direct incorporation into RNA to interfere with RNA transcription and, to a lesser extent,
direct incorporation into DNA (83). The therapeutic efficacy o f 5-FU can be further
enhanced by the addition o f leucovorin calcium (LV, also known as folinic acid). The
half-life and stability o f the 5-FdUMP -thym idylate synthase- methylenetetrahydrofolate
ternary complex is increased in the presence o f greater concentrations o f reduced folates,
such as LV (84). Therefore LV/5-FU combination is increasingly being used in adjuvant
chemotherapy for colorectal cancer treatment.
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However, the therapeutic benefits o f 5-FU are severely limited by a liver enzyme
named dihydropyrimidine dehydrogenase (DPD). It is estimated that more that 80% 5-FU
is inactivated by DPD (85) reducing the biological availability o f 5-FU to target cancer
cells. In addition, expression o f DPD also determines the 5-FU related toxicities. DPD
activity varies between 8-21 fold among individuals. Patients with lower DPD activities
cannot efficiently inactivate 5-FU and form excessive amounts o f active metabolite lead
to severe haematopoietic, neurological and gastrointestinal toxicities that can be fatal (8688). Therefore in the context o f using 5-FU for colorectal cancer chemotherapy, DPD can
be a double edged sword, when present in excessive amount it reduces the bioavailability
o f 5-FU by detoxification and lower amounts o f DPD promote widespread toxicities.
Oral fluoropyrimidines are considered as a more acceptable alternative to 5-FU.
Due to its poor bioavailability and rapid catabolic clearance by dihydropyrimidine
dehydrogenase, 5-FU is unsuitable for oral delivery. Alternative oral fluoropyrimidines
have been developed using a 5-FU prodrug (capecitabine) or combinations with
inhibitors o f DPD. Capecitabine is well absorbed by the gastrointestinal tract and
undergoes a three-step enzymatic conversion to 5-FU. First metabolized in the liver by
carboxylesterase to 5 ’-deoxy-5-fluorocytidine, capecitabine
is converted in the liver and tumour tissues by cytidine deaminase to 5 ’-deoxy-5fluorouridine. A tumour-selective phenomenon is facilitated by higher intra-tumoral
levels o f thymidine phosphorylase, the enzyme responsible for the final conversion step
to 5-FU (89)
Irinotecan (also known as C PT-11) is a semi-synthetic derivative o f the natural
alkaloid camptothecin which targets the activity o f topoisomerase I. Topoisomerase I
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plays a key role in replication by relaxing the supercoiled DNA helix with reversible and
transient single stranded DNA breaks. The conversion o f irinotecan to its active
metabolite, SN-38, is mediated by irinotecan carboxylesterase-converting enzyme. SN-38
then stabilizes the D NA -topoisom erase complex which results in replication arrest and
apoptosis (90). The major toxicity o f irinotecan is delayed-onset diarrhoea. Intestinal 0glucuronidase hydrolyses a detoxified SN-38 metabolite to active SN-38, which causes
intestinal epithelial damage and diarrhoea. Another characteristic toxicity is an acute
cholinergic syndrome characterized by diaphoresis, salivation, lacrimation, abdominal
cramps and bradycardia (91)
Oxaliplatin is a third-generation platinum with a 1, 2-diaminocyclohexane carrier
ligand which forms DNA adducts and resultant strand breaks. Unlike other platinums,
oxaliplatin has activity in colorectal cancer. It is thought that this may be due to the bulky
1,2-diaminocyclohexane ligand which, when retained by the oxaliplatin-formed DNA
adducts, may alter the mechanisms o f DNA repair (92, 93). Oxaliplatin has a distinctive
neurotoxicity which can be categorized into two types. The first is an acute, cold-induced,
sensory neuropathy characterized by dysaesthesias and paraesthesias during or soon after
infusion. The second is a delayed-onset, dose-dependent neuropathy occurring hours to
days after treatment. The latter typically occurs in 10-15% o f patients after a cumulative
dose o f 780-850 mg/m2, with at least partial reversibility in 75% o f affected patients
within 3-5 months o f treatment discontinuation. Both the acute and delayed neurotoxicity
may be attenuated by prolonging the infusion time from 2 to 6 h (94).
Chemotherapy, like radiotherapy, is also associated with occurrence o f secondary
cancers. Exposure to alkylating agents have been shown to increase the risk o f bone (95)
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and bladder cancer (96). DNA topoisomerase II inhibitors are known cause chromosomal
translocations which increase the risk o f occurrence o f leukeamia (97). Given the
toxicities associated with conventional therapies, it is crucial that other strategies like
gene therapy should be given consideration. One o f the advantages in pursuing gene
therapy for cancer treatment which aids in reducing the normal cell toxicity is its
flexibility to limit the therapy to a loco-regional context o f the tumor. Thus, undesired
systemic effects o f the therapy are avoided. In addition, gene therapy, by its innovative
vector designing, has the potential for selective targeting o f cancer cells which would
further help in minimizing the therapy associated injuries.

Cancer Gene Therapy
In the past decade several advances have been made in the area o f human gene
therapy. In particular, gene therapy for the treatment o f cancer has emerged as a
promising approach. At present, gene therapy for cancer amounts to more than 63% o f all
the human gene therapy trials (Journal o f gene medicine website). Most tumors are the
result o f a continuing process o f accumulation o f mutations in the backdrop o f genomic
instability. Therefore tumors are genetically unstable and thus they are extraordinarily
adaptable to environmental changes. In addition tumors are very heterogenous in many
respects, including genetic mutations, expression o f oncoproteins, immunogenicity,
response to environmental changes etc. Given extreme tumor heterogeneity, conventional
therapies like radiotherapy and chemotherapy often have limited success in treating
cancers. Gene therapy has the potential to address different obstacles in curing cancer as
it has several advantages over conventional therapies. Various issues such as toxicity,
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drug resistance and inability to target widely disseminated tumors, are associated with
conventional chemo and radiation therapies. Chemotherapeutic toxicity mainly occurs
because o f the inability o f the therapeutic drug to distinguish between normal and tumor
cells. Also, tumors are genetically unstable and are extraordinarily adaptable to drug
insult, which results in acquired resistance to cellular toxins and chemotherapeutic
agents. Moreover, tumors induce immunological tolerance or inhibit the effecter
mechanism o f the immune response (98). In contrast, gene therapy strategies have the
potential to target the tumor cells specifically, which in turn would reduce the toxicity
load on the normal cells. Further, therapeutic vectors can be designed to deliver and
express the desired therapeutic genes specifically in the tumors, independent o f the tumor
cell division and cell cycle stages. A variety o f gene therapy strategies can be designed by
incorporating different therapeutic genes, providing the flexibility o f either 1) killing the
cell 2) substituting the mutated gene responsible for neoplastic transformation or 3)
immunomodulating the host immune response to target and eliminate the tumor.
There are several factors that make colorectal cancer in particular an attractive
target for gene therapy. Most cancers disseminate early in natural history, in contrast
colorectal carcinoma is often confined to specific organs (such as the liver) or
compartment (such as peritoneal cavity). As many as 30% o f the patients suffering from
CRC have macroscopic relapses in liver (99), compared with for example, breast cancer,
in which metastases in multiple sites (such as bone, liver and lung) are much more likely
to occur. This could offer an advantage through regional delivery o f therapeutic vector to
maximize tum or exposure and minimize systemic toxicity. There is more information o f
the sequence o f genetic and epigenetic events that characterize the transformation o f

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

23

colon epithelium to premalignant adenomas and then invasive carcinoma than there is for
the development o f any other tumor. These data can be used to construct rational gene
therapy vectors for example tumor suppressor pathway genes such as p53 and
retinoblastoma (RB) can be potentially used for designing tumor selective replicating
adenoviruses. Similarly, there is a large database o f CRC associated onco-fetal antigens
(100). The promoters o f which might be used to restrict transgene expression to tumors
and allow a further means o f assessing tumor response to treatment. In addition, one the
most important argument justifying gene therapy approach for treatment o f colorectal
cancer is; wnt signaling pathway is frequently found selectively activated in majority o f
colorectal carcinomas due to mutations in APC/p-catenin genes resulting in
transactivation o f the promoters o f TCF-4/ P-catenin responsive genes. These promoters
are characterized by the presence o f a TCF/ P-catenin enhancer which binds to the
heterodimeric complex o f TCF-4/ P-catenin. These downstream target genes of, wnt
signaling in colorectal carcinoma, are fairly well known. Therefore characterization o f
such promoters which are a target o f aberrantly activated wnt signaling in colorectal
carcinoma cells can be very helpful in designing o f colorectal cancer selective gene
expression promoters for the purpose o f gene therapy. In particular, by using Tcf-4
enhancer elements, colorectal carcinoma selective gene expression promoters could be
designed for targeting the therapeutic gene to CRC cells and increasing the therapeutic
efficacy. Finally, CRC and its adenoma precursors are more often amenable to biopsy o f
both early and late disease than other tum or types, which can add an important
mechanistic element to proof-of principle clinical trials, such as demonstration o f viral
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replication, transgene expression, induction o f apoptosis and tum or infiltration by
lymphocytes.
Gene Therapy for Colorectal Cancer
Gene Correction or Replacement
The multi-step development o f CRC from a single stem cell to a malignant tumor
is well described in literature (32). This involves sequential mutations in tumor
suppressor genes and several oncogenes. At its most basic level, gene replacement
therapy would involve the use o f viral vectors to re-introduce wild type genes for
phenotypic correction. There are obvious stoichiometric flaws in this reasoning in that it
would be impossible to correct all mutant genes (as many o f them are yet to be
discovered) in every cancer cell. However, common mutations in CRC, such as those o f
the tumor suppressor TP53 (45-60% o f CRC cases) or the proto-oncogene KRAS (5060%) have been assessed as therapeutic targets.
There are in vitro and in vivo studies which show that adenovirus mediated
delivery o f p53 gene has an antiproliferative affect on colorectal cancer cells. This effect
o f p53 can be hypotheticaly explained in several ways. For example p53 could be antiangiogenic and down regulate the vascular endothelial growth factor expression and up
regulate thrombospondin ( a known anti-angiogenic fector), generating a by stander effect
which kills the tumors cells due to lack o f nutrients (101). Also, p53 has been shown to
Further, p53 gene transfer could lead to increased survival following intratumoral
administration o f p53 gene carrying adenovirus (102). Replacement o f the p53 gene has
also been show to sensitize CRC cells to conventional cytotoxic agents such as 5fluorouracil (5-FU), presumably by reconstituting the apoptotic pathway (103). KRAS

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

25

has been implicated in maintaining uncontrolled proliferation o f CRC cells; therefore it is
a logical strategy to target KRAS for CRC treatment. In a rat model o f liver metastasis,
developed by using a KRAS mutated CRC cell line, significant tum or regression was
shown to occur after hepatic arterial administration o f a replication deficient adenovirus
encoding an intracellular antibody specific for KRAS (104)
Virus-Directed Enzyme-Prodrug Therapy (VDEPT)
In this approach an enzyme encoding gene which can convert an inactive, non
toxic prodrug to an effective cytotoxic species is used as the therapeutic gene to target
cancer cells. Currently there are VDEPT strategies being pursued for the purpose o f CRC
gene therapy: 1) HSV-tk/GCV 2) cytosine deaminase/5-fluorocytosine 3) nitroimidazole
reductase (NTR)/CB1954. The use o f HSV-tk/GCV system for cancer gene therapy has
been explained in detail on page 23.
Cytosine deaminase (CD) is an enzyme that catalyzes the deamination o f cytosine
to uracil. This reaction converts an inert prodrug, 5-fluorocytosine (5-FC), to a highly
toxic chemotherapeutic agent, 5-fluorouracil (5-FU) (105). This enzyme is found in many
bacteria and fungi but not in mammalian cells (106-108). Consequently, mammalian cells
are resistant to the toxic effects o f 5-FC. The cytotoxic effects o f 5-FU occur following
its conversion to 5-fluoro-2-deoxyuridine-5-monophosphate (5-FdUM P) (through a de
novo pyrimidine pathway). 5-FdUMP is an irreversible inhibitor o f thymidylate synthase
and thus inhibits DNA synthesis by deoxythymidine triphosphate (dTTP) deprivation.
The CD -5FC suicide gene system has been studied as a potential gene therapy strategy in
a number o f solid tumors. The CD gene was transferred to colon carcinoma cells in vitro,
and these altered cells were implanted in mice as xenografts. The mice were then treated
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with systemic 5-FC. High local concentrations o f 5-FU were produced by conversion o f
5-FC to 5-FU in the tumors (109). Adenovirus-mediated transfer o f the CD gene together
with systemic administration o f the prodrug 5-FC caused suppression o f colon cancer
metastatis to the liver (110-112). Phase I trials have been undertaken with direct
intratumoral inoculation o f a replication deficient adenovirus encoding cytosine
deaminase and oral administration o f 5-FC. Initial reports indicate that the virus is well
tolerated, and biopsies have indicated cancer-associated expression o f cytosine deaminase
(113).
One o f the most promising suicide gene systems is the Escherichia coli enzyme
nitroreductase in combination with the prodrug CB1954 [5-(aziridin-l-yl)-2,4dinitrobenzamide], CB1954 is a weak, monofunctional alkylating agent that was
synthesized during the 1960s. The nitroreductase enzyme DT diaphorase converts
CB1954 to its 4-hydroxylamino derivative (114), which after acetylation via thioesters
such as acetyl coenzyme A (CoA), becomes a powerful bifunctional alkylating agent. The
activated prodrug is then capable o f forming poorly repaired DNA crosslinks. Human DT
diaphorase is not capable o f performing this conversion, thereby limiting toxicity to
transformed cells. The advantage o f the nitroreductase-CB1954 suicide gene system is
that killing mediated by activated CB1954 is not dependent on cell cycle phase,
potentially allowing quiescent tumor cells to be killed. Selective killing o f nitroreductaseexpressing cells following CB1954 administration in vitro (115, 116) and in vivo (117)
has been demonstrated. In addition, the bystander effect seen with the HSV-TK
gancyclovir suicide gene system is also seen with the nitroreductase-CB1954 system.
Mixed populations o f nitroreductase-expressing and nitroreductase-none expressing cells
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were killed after treatment with CB1954 (115). One study has also demonstrated a
synergistic effect when cells expressing both nitroreductase and TK. were treated with a
combination o f CB1954 and gancyclovir (116). In a phase I clinical trail, involving
patients with CRC, Nitroreductase/CB1954 suicide gene system was tested with out any
significant side effects (118).
Immunogcnctic Strategics
The idea o f Immunogenetic therapy for CRC, either antibody based or cell
mediated, is gaining a lot o f attention these days. As opposed to most o f the gene-therapy
approaches which involve regional targeting o f the tumor, immunogenetic approaches
have the potential to modify the tum or microenvironment for generating an effective anti
tumor immune response. Further, the promise o f immunotherapy lies in the fact that
although it can be delivered locally, it can generate a signal that can be amplified (for
example, by T-cell proliferation) and disseminated through the vasculature and tissues by
lymphocyte trafficking, thereby exposing the tumor cells to the cytotoxic mediator at
sites distant from the area o f gene vector inoculation. There are several immunogenetic
approaches which have been used to target CRC.
Manipulating MHC expression: It is well known that most cases o f advanced
CRC downregulate MHC class I molecules as one means o f escaping immune
surveillance. In a phase I clinical trial, involving 15 CRC patients negative for HLA-B7,
a plasmid encoding HLA-B7 was injected directly into the hepatic metastatic nodules o f
CRC. HLA-B7 expression was shown to be present in tumor biopsies o f 12 patients and a
total o f 50% patients mounted an HLA-B7 specific cytotoxic T-lymphocyte response.
There were side effects but no tum or regression was reported (119).
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Delivery o f Interleukin-2 (IL-2): IL-2 has been used extensively as a single agent
or in combination o f other cytokines to target cancer. IL-2 administration in patients has
shown very limited anti-tumor benefits which are associated with toxicity. There are
reports which suggest IL-2 related activity upon genetic introduction o f IL-2 into
autologous tumor cells, fibroblasts or immune effector cells in syngeneic mouse models
(120, 121). IL-2 has also been explored in humans for its anti-tumor effects. Clinical
trials have involved ex vivo transduction o f autologous fibroblasts (122) with IL-2 (which
were then mixed with autologous irradiated CRC cells before subcutaneous injection),
transduction o f autologous cytokine induced killer cells with IL-2 and direct intratumoral
injection o f IL-2-encoding plasm id-lipid complexes (123). These trials have been
characterized by evidence o f increased immune reactivity (IL-2 detection, CTL
responses, and induction o f cytokines such as IFN-y and GM-CSF (granulocytemacrophage colony-stimulating factor), but no evidence o f tumour regression.
Carcinoembryonic antigen (CEA) vaccines: CEA is a cell surface glycoprotein
which is found overexpressed in 85% o f CRC cases. CEA is tum or specific onco-fetal
antigen and has the potential to be used as an antigen for making anti-tumor vaccines.
The gene encoding CEA has been incorporated into several vectors for the purpose o f
making a vaccine for CRC. In a phase I clinical trial patients were immunized with
vaccinia-CEA vaccine involving CEA vaccine and generation o f cytotoxic T
lymphocytes specific for CEA was demonstrated (124). Several other clinical trials
involving CEA vaccines have been carried out and in most cases the vaccine was shown
to well tolerated (125-128). However, despite o f these ongoing efforts CEA encoding
tumor vaccines have not, so far, shown any clinically significant anti-tumor effects.
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Adenovirus for Therapeutic Gene Delivery
One o f the major challenges in gene therapy is efficient delivery o f the therapeutic
gene to the target cells. The biggest physical hurdle that gene therapy technologies have
to overcome is the cell membrane which is impermeable to charged macromolecules such
as DNA and RNA (129) While there a multitude o f biological, physical and chemical
procedures being used to facilitate the delivery o f trans-genes, adenoviral vectors, in
particular, have shown an enormous amount o f potential for clinical delivery o f the
trans-gene to the target cells. Adenoviruses are double stranded DNA viruses belonging
to the parvovirideae family and are known to cause upper respiratory ailments in humans.
The virion is a small, non-enveloped particle with a spike, icosahedral m orphology (130).
Serologically, adenoviruses have been classified into nearly 50 distinct serotypes (131).
The different serotypes have been subgrouped (A through E) based on genomic size,
organization, %GC content etc (132). M ajority o f the adenoviral vectors commonly used
as gene delivery vehicles, are based on human adenovirus o f serotypes 2 and 5 o f the
subgroup C (133). There are several major advantages o f adenoviral vectors, which make
them suitable for efficient transfer o f trans-gene: high titer (10l2-1013 virus particles per
ml) o f recombinant viruses can be produced; ability to infect postmitotic cells; ability to
infect a wide variety o f cell types; ability to accommodate up to -8 kb o f foreign DNA,
including expression cassettes or other regulatory sequences; and safety precedents exist,
as adenovirus based vaccines have been used in humans without any serious life
threatening side effects (134). In addition, adenoviruses infect a variety o f cell types
including fibroblasts, epithelial cells, stromal cells, endothelial cells and hepatocytes o f
human, canine, rodent origin. Most o f these adenoviral vectors have been rendered
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replication deficient by deletion o f their essential genes (135). To generate a defective
adenovirus for gene transfer application, the El gene, important for viral gene expression
and replication, can be removed. Thus, El-deleted viruses can be propagated only in a
cell line that provides the El gene products in trans, such as 293 cells (136). The E l deleted adenoviral vectors, however, express low levels o f viral antigens following
infection and result in a low level o f DNA replication, especially at a high m ultiplicity o f
infection. Synthesis o f adenoviral gene products often stimulates an immune response to
the infected cells and results in a loss o f therapeutic gene expression 1-2 weeks after
injection (137, 138). To overcome the problems o f reduced therapeutic gene expression
and host cell toxicity, newer generation adenoviruses with E3 and E4 regions deleted
have been constructed (139). Such replication incompetent vectors are widely used for
gene delivery in vivo and are in clinical trials for cancer and other diseases like cystic
fibrosis (140). There are, however, some limitations o f adenoviral vectors: lack o f
sustained expression, as the viral DNA does not integrate into the host genome;
antigenicity against viral proteins by both humoral and cytotoxic T-lymphocytes (CTLs);
and possible toxicity at high doses (134). The lack o f sustained expression is not likely to
present a problem for acute applications like cancer as transient expression o f therapeutic
genes may be favored. The humoral response may be blocked or reduced by co
administration o f immunosuppressive agents or cytokines. Alternatively, the use o f
adenoviruses o f different serotypes may allow for repeated administration, even in the
presence o f neutralizing antibodies (141).
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Herpes Simplex Virus Thymidine Kinase Gene/ Ganciclovir and Suicide Gene
Therapy
Frederic M oolten was the first to conceptualize the idea that HSV-tk / GCV
system can be potentially used for gene therapy (142). This was followed by work done
by the same group showing that HSV-tk/GCV treatment generated enough
phosphorylated GCV to inhibit mammalian DNA replication(143). Thereafter, a few
years later many researchers started to apply this system and other prodrug activating
enzymes for gene therapy (108, 144). In this chapter I will summarize: 1) how the HSVtk/GCV system works 2) HSV-tk/GCV system mediated bystander affect 3) what are the
current strategies being followed to enhance the therapeutic efficacy, 4) various clinical
trials undertaken.
Mode o f Action o f the HSV-Tk/GCV System
GCV is an acyclic analog o f the nucleoside 2 ’-deoxyguanosine. It is used as an
antiviral agent for treating human herpes infections (herpes simplex type 1 and type 2,
varicella zoster virus and Epstein-barr virus) (145). The antiviral property o f GCV is
dependent on its intracellular phosphorylation by a viral encoded thymidine kinase. The
triphosphate derivatives o f GCV act as a competitive inhibitor o f deoxyguanosine
triphosphate, inhibiting viral DNA synthesis (146, 147). In cells infected with HSV or
varicella zoster virus, viral thymidine kinase catalyzes the production o f ganciclovir
mono-phosphate (147, 148). Subsequent conversion o f GCV-monophosphate to GCVtriphosphate is aided by cellular guanylate kinase (149) and several other cellular kinase
enzymes, such as phosphoglycerate kinase (150). Tri-phosphorylated forms o f GCV are
analogous to 2 ’ deoxyguanosine and bind to DNA polymerase 6. Once bound to DNA
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polymerase GCV triphosphate is either incorporated into DNA or inhibits the polymerase
itself. Although GCV has hydroxyl groups found in endogenous nucleosides permitting
chain elongation, the lack o f a complete sugar ring makes GCV a poor substrate for chain
elongation. As a result, chain termination almost always occurs immediately after GCV
incorporation into DNA and leads to cell death (151).
Mechanisms o f HSV-Tk/GCV Mediated Cell Killing
In reference to cancer gene therapy mediated by HSV-tk/GCV system there is
evidence which supports that, depending on the cell type, tumor cell killing can occur via
both apoptotic (152) and non-apoptotic mechanism (153). Support for the involvement o f
the apoptotic pathway in HSV-tk/GCV mediated cell killing comes from the fact that
expression o f Bcl-2 is able to inhibit HSV-tk/GCV caused cell death (154). In addition
apoptosis has been shown to occur in human hepatocarcinoma cells upon treatment with
HSV-tk/GCV (155). Moreover, the level o f apoptosis was observed to be dependent on
the p53 status o f the cell as it was found to be reduced in p53 negative cells as compared
to p53 positive cells. In contrast, HSV-tk/GCV mediated apoptosis as seen in CHO cells
is shown to be dependent upon activation o f mitochondrial damage pathway, independent
o f p53 status (156).
The effect o f HSV-tk/GCV mediated cell killing on cell machinery has also been
explored by researchers. It has been shown in B16F10 murine melanoma cells, that the
cause o f cell death, upon expression o f HSV-tk and followed by GCV treatment, seems to
be due to the irreversible cell cycle arrest at the Gi-M transition and is independent o f
apoptosis (153). On the contrary in similar model systems it was demonstrated that cell
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killing by the HSV-tk/GCV strategy showed an S-G2 phase arrest with signs o f apoptosis
(157).
The HSV-Tk/GCV Bystander Effect
In addition to direct cell killing, a bystander effect (BE) has also been observed.
BE is the ability o f the HSV-tk expressing cells to induce sensitivity, upon GCV
treatment, in neighboring non HSV-tk expressing cells. BE is one o f the most important
aspects o f using HSV-tk/GCV system for cancer gene therapy. It was originally described
by Moolten and Mells in 1990 when they observed that cells transduced with HSV-tk
gene and treated with GCV induced sensitivity in neighboring cells (143). Preliminary
experiments, analyzing BE demonstrated that for some cell types in culture, when only
10% o f the cells were expressing HSV-tk, treatment with GCV could result in 100% cell
death. This was soon validated by in-vivo experiments showing that 10-50% o f the total
cell population expressing HSV-tk is enough to produce complete tumor regression upon
GCV treatment (158-160).
Almost immediately it was established that BE requires cell to cell contact
between cells expressing and non-expressing the HSV-tk gene (158). This observation
was strengthened by experiments which demonstrated that conditional media from cells
expressing HSV-tk and treated with GCV did not confer cytotoxicity to non-expressing
HSV-tk cells (161). On the whole these experiments suggested that the BE o f the HSVtk/GCV system results from direct cell to cell contact.
The mechanism o f BE caused by HSV-tk/GCV is fairly well understood. It is
generally accepted that BE occurs by transfer o f phosphorylated GCV from HSV-tk
expressing cells to non-HSV-tk expressing cells via cell to cell gap junctions. This idea is
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further reinforced by the fact that the magnitude o f the BE is correlated with the extent o f
gap junctional intercellular communication (GJIC) present between two cells (162). Gap
junctions are semi-channel like structures (called connexons) present in the cell
membrane. Connexons are made up o f proteins belonging to a multigene family o f
distinct but functionally related proteins called connexin (Cx) (163). Expression o f
connexins in cells which do not form gap junctions has been shown to induce GJIC and
resultant BE (164). In addition, there are certain drugs such as retinoic acid (165),
apigenin (164) or lovastatin (166) which are known to positively regulate the formation
o f gap junctions and increase the extent o f BE when added to tum or cells. In contrast,
drugs like 18-a-glycirrethinic acid (AGA) (167) which negatively regulate gap junctions
are known to inhibit BE. Further, the role o f gap junctions in HSV-tk/GCV system has
also been shown in vivo. Subcutaneous tumors derived from Cx43 (connexin 43 gene)
transfected glioma cells showed that after GCV treatment only 25% o f the HSV-tk
expressing cells were enough to eliminate the tum or (168). Although it is clear that gap
junctions play the major role in mediating the HSV-tk/GCV BE, there are in vitro studies
which do not correlate between gap junctions and the extent o f BE. For example studies
have shown that in some instances it is not possible to inhibit BE by inhibiting GJIC
either in cells lines derived from lung cancer (169) or in colon tumor cell lines (170).
Further there is evidence that supports that GJIC may not be solely responsible for BE.
This phenomenon has been illustrated in SW620 colon cancer cells. These cells when
expressing the HSV-tk are able to efflux phosphorylated GCV metabolites to the extra
cellular medium (171). It’s been postulated that the efflux phenomenon could either be
due to the presence o f ATP dependent anionic transporters or to the presence o f proteins
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which confer drug resistance. The authors propose that two recently identified multi-drug
resistance proteins MP-4 and MRP-5, which efflux phosphorylated nucleotides may be
responsible for effluxing phosphorylated GCV. In addition, another mechanism to
explain HSV-tk/GCV mediated BE have also been proposed. According to this
hypothesis, apoptotic vesicles generated in HSV-tk expressing cells containing toxic
metabolites are phagocytated by neighboring non-HSV-tk expressing cells (158).
The in vivo mechanism o f HSV-tk/GCV mediated BE has also been explored.
Other than GJIC, the immune response generated due to the expression o f non human
proteins or due to the death o f transduced cells have been proposed to cause BE. It is
hypothesized that non-human proteins can stimulate recognition o f tum or antigens,
trigger the immune response and finally end up with the death o f non-transduced cells
(172). In addition, some studies suggest that the immune response generated against the
HSV-tk/GCV system can induce a distant BE. Treatment with GCV o f tumors expressing
HSV-tk can mediated regression o f tumors which do not express HSV-tk and which are
located in other part o f the animal (173). This distant BE suggest that local treatment with
HSV-tk system could prevent the growth o f dissemination and possible metastasis (152).
Strategies to Enhance the Therapeutic Response o f HSV-Tk/GCV System
Over the past decade several efforts have been made to improve the efficacy o f
HSV-tk/GCV system for gene therapy purposes. These strategies can be broadly divided
into two categories: 1) HSV-tk mutants 2) Combined approaches.
HSV-Tk Mutants
One limitation o f the HSV-tk therapy is the low sensitivity o f cells to GCV or
other nucleoside analogs. A popular strategy is to improve potency o f the suicide effect.
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by engineering the HSV-TK protein. The basic rationale behind this approach is to
construct and characterize an HSV-TK mutant that preferentially phosphorylates specific
nucleotide analogs. Black et al have created several mutants o f HSV-tk which were
screened for GCV or ACV phosphorylation in mammalian cells and have identified
mutants which are more sensitive to ACV or GCV (174). One particular mutant Sr39
when evaluated in a xenograft model prevented tum or growth at prodrug dosages that did
not affect wild type HSV-tk (175). Further, using a HSV-tk mutant generated by Black et
al in 1999 it was shown that tumor cells expressing this mutant resulted in an increase o f
GCV sensitivity. This sensitivity was nine to five hundred folds higher when compared to
wild type HSV-tk (176)
Combined therapies
It is generally accepted that in cancer therapy multidrug regimens are superior to
single agent therapy. This has prompted various investigators to test different
combinations o f strategies to enhance the cytotoxic effects o f the HSV-tk/GCV system.
The HSV-tk/GCV system has been used in combination with other gene directed enzyme
prodrug therapy (GDEPT) strategies in search o f enhanced anticancer effects. HSVtk/GCV when used in combination with the cytosine deaminase / 5- fluorouracil (CD/5FU) system to treat 9L gliosarcoma cells reduced cell survival both in vitro and in vivo.
The effects o f the two components appeared to be synergistic and related mechanistically
to the enhancement o f CV phosphorylation by thymidine kinase following 5-Fluorouracil
treatment (177). The combination o f these suicide genes has also been shown to sensitize
the tumor cells to radiation with potent antitumor effects (178).In another study the HSVtk/GCV system has been combined with cytochrome P450 2B1 / cyclophosphamide
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GDEPT. It’s been postulated that these two GDEPT act synergistically. HSV-tk/GCV
gene therapy inhibits the repair o f cellular cross-linking o f DNA caused by
P4502B1/cyclophosphamide (179). In addition this synergism has been shown to require
co-expression o f both genes in the same cell. In an attempt to achieve enhanced tumor
cell killing, several chemotherapeutic agents have been combined with the HSV-tk/GCV
system. Drugs like topotecan (topoisomerase I inhibitor) results in synergistic
cytotoxicity in HSV-tk expressing murine MC38 and human HT29 colorectal cancer
cells, both in vitro and in vivo (180). Moreover, a synergistic effect was observed when
GCV and topotecan were administered in combination with a replication competent
adenovirus expressing HSV-tk (181).
UCNOl (a protein kinase c inhibitor) when used in combination with HSVtk/GCV resulted in increment o f apoptosis and tumor cell killing in human colon cancer
cells (182). This apoptotic enhancement was associated with the increased levels o f
proapoptotic proteins Bcl-XL. However, when HSV-tk/GCV was combined with Taxol
o f Campthecin, an antagonistic effect was observed. Furthermore, in glioblastoma model
a synergism between the HSV-tk/GCV and temozoloamide (TMZ, and alkylating agent
used to treat gliomas, has been shown (183).
These results clearly show that the combination o f certain, but not all
chemotherapy drugs and HSV-tk/GCV may result in increased cytotoxic effects.
H SV -Tk/G C V and Radiotherapy
The combination o f HSV-tk/GCV prodrug therapy and radiotherapy has been
attempted in several studies. The rationale behind these approaches is that radiation
induces membrane damage which may facilitate the bystander effect o f HSV-tk/GCV
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gene therapy whereby cytotoxic nucleotides analogs diffuse from HSV-tk expressing
cells to neighboring non HSV-tk expressing cells. In addition, cells would not be able to
repair radiation-induced DNA damage in the presence o f cytotoxic nucleotide analogs.
One o f the earliest studies showed that the addition o f radiation improves the
effectiveness o f HSV-tk/GC gene therapy for the brain tumors (184). Similar synergistic
effects were observed when a fusion construct containing both suicide genes HSV-tk and
cytosine deaminase, was used to transfect 9L glioma cells followed by drug treatment
(178, 185). Combination o f HSV-tk/GCV therapy and radiation was shown to be
synergistic when used to target head and neck cancer xenografts in nude mice (186).
Further, in prostrate cancer cells, it was demonstrated that HSV-tk/GCV system and
radiotherapy act synergistically in tum or cell killing which increases with higher doses o f
radiation (187).
HSV-Tk/GCV System and Induction o f Immune Response
There are findings suggesting the existence o f an antitumor immune response
when HSV-tk/GCV therapy is used for in vivo treatments. The phenomenon o f the
bystander effect which is characteristic o f HSV-tk/GCV system is also believed to have
an immunologic component (172). There are two important features o f this HSV-tk/GCV
mediated antitumor immune response: 1) the bystander effect is mediated by the immune
/inflammatory system, 2) the killed tumor cells can generate an antitumor response since
GCV is not immunosuppressive (188, 189). The other crucial part o f bystander effect
which occurs through GJIC involving transfer o f toxic drug m etabolite has been
explained earlier on page 25. Findings supporting a role for the immune system include
demonstration o f cytokine release leading to the haemorrhagic necrosis and to an
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infiltration o f immune cells into the tumor after the HSV-tk/GCV therapy (172, 190,
191). This cytokine release with in the tumor also leads to up-regulation o f immune
regulatory molecules such as B7.1, B7.2 and ICAM (192). These findings have led to the
hypothesis that the bystander effect changes the tum or microenvironment from one that is
immuno-inhibitory to one that is immunostimulatory. This is because HSV-tk expressing
cells die through apoptosis, during which they release soluble factors such as 1L-1, which
further affect the tumor microenvironment.
One o f the potential ways o f increasing the BE is to use biological response
modifiers such as cytokines to augment the immune / inflammatory response generated
by the HSV-tk/GCV therapy. In one particular study, immunotherapy in combination
with HSV-tk/GCV suicide gene therapy was tested in a experimental metastatic breast
cancer model. Adenoviral vectors were used to transfer transgenes for HSV-tk along with
either cytokine gene: GCM-CSF and IL-2 to the established breast tumors. Upon 10 days
o f GCV administration an enhanced reduction in tumor volumes was observed (193). IL12 has been demonstrated to be highly efficient in enhancing the antitumor response in
combination with HSV-tk/GCV therapy. Studies in colon carcinoma using adenoviruses
as vectors for gene delivery have proven to be highly efficient in inhibition o f tumor
growth and in the increase o f survival time (194).
Clinical Trials
Several phase I and phase II clinical trials have been implemented in the last
decade using the HSV-tk/GCV gene therapy strategy. Results from only few o f these
studies have been published.
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1) Mesothelioma: Adenoviral vectors encoding the HSV-tk gene under the control o f
sarcoma virus promoter were administered in variable doses to patients with
mesothelioma. Transient fever and minor changes in liver function tests were the most
common adverse effects noticed. In addition, local skin reaction due to adenovirus
infection was observed in 60% o f the patients. Tumor cell transduction was confirmed by
PCR and immunoblotting. Furthermore, in this study authors did mentioned the existence
o f humoral and cellular immune responses against the adenoviruses but it did not produce
any clinical effects (195). Further results were not reported.
2) Melanoma: Patients with malignant melanoma were treated with intratumoral
injections o f retroviral vectors encoding for HSV-tk which was followed seven days later
by administration o f GCV. Adverse effects like transient fever and skin reaction were
noticed. A moderate decrease in tumor size was constantly observed for the period o f
administration o f GCV but all tumors progressed there after (196)
3) Brain tumors: Gene therapy for malignant gliomas utilizing HSV-tk/GCV system is
currently a very hot area in the field o f cancer gene therapy. Glioblastomas have one o f
the highest mortality rates among cancers and remains very challenging to manage as
patients have an average survival rate o f 32-56 weeks after being first diagnosed. The
earliest clinical trials involving treatment o f brain tumors with HSV-tk/GCV suicide gene
therapy did not meet with any significant success. In one study, malignant glioma
patients received multiple injections o f a retroviral vector (coding for HSV-tk) producing
cells. A follow up assessment o f gene transfer by in situ hybridization showed that
effective transfer was very limited and did not produce any antitumor effects (197). A
clinical trial following a similar therapy protocol involving patients with primary or
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recurrent malignant gliomas did not result in any conclusion which could advocate the
use o f HSV-tk/GCV suicide gene therapy to treat brain tumors (198). A French group
evaluated the effect o f injecting retroviral producing cells after debulking surgery for
recurrent gliomas. Almost two weeks after GCV treatment, tumors showed necrosis in
three o f eight patients. However all patients showed disease progression on long term
follow up. Limited antitumor response was attributed to poor transfer o f the therapeutic
gene to the tum or (199).
Recently partial success in treating malignant gliomas using HSV-tk/GCV suicide
gene therapy has been reported. Eleven patients with recurrent malignant gliomas after
surgical resection and radiotherapy were included in this clinical trial. Adenoviral vectors
expressing HSV-tk were used for the gene delivery and no adenoviral vector shedding or
systemic toxicity was noticed in this study. Additionally, HSV-tk expression as assessed
by PCR was negative after 3 months o f adenoviral injections. Ten o f eleven patients
survived for an average o f 112.3 weeks from the day o f diagnosis (200).
In summary HSV-tk gene transfer to a variety o f neoplasms can be safely
achieved in vivo by intratumoral injections using adenoviral or retroviral vectors. GCV
administration after HSV-tk gene transfer does not result in significant toxicity.
Although, significant success in brain tumor regression has not been achieved,
nevertheless recent studies have shown interesting results.
Imaging Gene Expression
There is another aspect o f HSV-tk suicide gene therapy which is worth
mentioning. One o f the hurdles in human gene therapy is the inability to establish in each
patient whether gene transfer has been achieved, what tissues have been transduced and
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are actively expressing the transgene and what is the magnitude o f the transgene
expression? In combination with positron emission tomography (PET), the HSV-tk gene
has shown the potential to resolve the above mentioned problems. PET is a non invasive
imaging technique which follows the fate o f a previously administered, radiotracer to
obtain accurate, quantitative and dynamic information about the location o f the
radionucleotide in the patient. The principle behind the approach is HSV-tk once
successfully expressed in a cell, is able to phosphorylate the radiotracer (for e.g. 8[18F]fluoroganciclovir) which gets trapped inside the HSV-tk-expressing cells only and
can be visualized externally with a PET camera (201). Several radio labeled thymidine
and ganciclovir derivatives have been proposed as probes for imaging o f HSV-tk enzyme
activity with PET, including [124I]FIAU (202), and 9-[(l-[18F]Fluoro-3-hydroxy-2propoxy)methyl]guanine ([18F]FHPG) (203). These radiopharmaceuticals are better
substrates for the HSV-tk enzyme than for human thymidine kinases. PET imaging,
offers a potential method o f high resolution and sensitivity which allows noninvasive
quantification o f HSV-tk expression (204).

Wnt Signaling And P-Catenin/Tcf-4 Transcriptional Regulation
The APC driven model for colorectal tumorigenesis suggests that wnt signaling
pathway is aberrantly activated in majority o f colorectal tumors. Besides, there is
evidence indicating that wnt signaling pathway is also found to be activated in other
tumors for example, prostrate and breast (205-207). The differential activation o f this
pathway in cancer cells makes it an attractive target for designing tumor specific gene
expression promoters. The canonical Wnt signaling pathway has been shown to be well
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conserved in evolution and is currently best described in invertebrate systems like
Xenopus and Drosophila where it plays a significant role in development. The pathway is
comprised o f a family o f secreted Wnt glycoproteins which signals by binding to cell
surface co-receptors, frizzled and LRP5/6, (low-density lipoprotein receptor related
protein) (8, 208). One o f the major effectors o f this pathway is P-catenin which forms
transcriptionally active complexes with the Tcf/Lef (T cell / Lymphoid enhancer factor)
family o f proteins when a Wnt signal is received at the cell surface. This heterodimeric
complex transactivates various Wnt responsive genes, which contribute in making
developmental decisions. In parallel, the Wnt signaling pathway has been shown to be
activated in a majority o f human cancers o f epithelial origin and is marked by a
transcriptionally active P-catenin / T cf-L ef complex. Genes transactivated by Wnt
signaling are considered to contribute to the pathogenesis o f human cancers (24). Pcatenin is a multifunctional protein, and apart from it’s oncogenic role, it is known to
associate with proteins like cadherins and other catenins, participating in processes like
cell adhesion (209). The Wnt signal increases the levels o f monomeric p-catenin in cells
by destabilizing the complex o f proteins which are responsible for glycogen synthase
kinase-3p mediated phospholyration o f P-catenin. This is well documented in Xenopus
and Drosophila (210-212). However, in human cancers it has been shown that, mutations
in the key proteins responsible for P-catenin degradation can also lead to
upregulation/stabilization o f P-catenin, even in the absence o f a Wnt signal. Stabilized Pcatenin forms a transcriptionally active complex with Tcf-Lef and consitutively
transactivates Wnt responsive genes (10). A variety o f proteins are involved in regulation
o f P-catenin levels including the tum or suppressor gene APC (Adenomatous Polyposis
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Coli), which is found to be associated with P-catenin and mutated in more than 85% o f
colorectal tumors (13) In these carcinomas elevated levels o f P-catenin coupled with
transcriptionally active complex o f P-catenin/Tcf-4 were found (213).
In vitro studies done on cell lines derived from colon tumors have shown that
introduction o f wild type APC effectively reduces the levels o f P-catenin in conjunction
with disruption o f transcriptional activity o f P-catenin / Tcf-4 complex (213). APC is also
associated with at least two other proteins, Axin and glycogen synthase kinase-3P (GSK3P), which contribute towards regulation o f P-catenin. Axin has binding sites for APC,
GSK-3P and P-catenin and it functions as central scaffolding in the multiprotein complex
(214). The APC-Axin complex is believed to associate and regulate the activity o f GSK3P, which in turn phosphorylates APC-Axin increasing their affinity for P-catenin (215).
GSK-3P, a serine threonine kinase, associates and phosphorylates P-catenin on the Nterminal serine/threonine residues. Phosphorylated P-catenin is recognized and tagged by
the P-Trcp protein; P-catenin further gets covalently modified by addition o f ubiquitine.
Ubiquitinated P-catenin is degraded by the proteasome destruction pathway (216, 217).
Therefore, an N terminal serine/threonine residue mutation in P-catenin renders it
refractory to A PC ’s regulatory tumor suppressive effect resulting in stabilization o f Pcatenin (218). Hence the ability o f GSK.-3P to phosphorylate P-catenin is crucial for its
destruction. How the wnt signaling pathway communicates with GSK.-3P is not clearly
understood. However, studies from invertebrate model systems have suggested that at
least two proteins, disheveled (Dvl) and FRAT provide a link between Wnt signal and
GSK.-3P. FRAT is associated with Dvl which is turn is bound to Axin, Dvl / FRAT
complex, upon receiving a Wnt signal, inhibits GSK-3P resulting in non-phosphorylation

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

45

and stabilization o f P-catenin (219). The mechanism o f inhibition o f GSK.-3P by Dvl
/FRAT complex is not clearly understood; but possibly occurs by disruption o f the AxinAPC scaffolding (7).
Therefore, with the underlying principle that canonical Wnt signaling pathway is
constitutively activated in a large number o f adenocarcinoma, it is reasonable to
hypothesize those recombinant promoters incorporating Tcf-4 enhancer elements will be
specifically active in such Wnt signaling positive tumors and not in normal cells.
B-catenin/Tcf-4 Transcriptional Regulation
The APC and P-catenin mutations result in the formation o f a constitutively active
P-catenin/Tcf-4 complex, which transactivates a number o f cancer promoting genes. This
occurs by binding o f the P-catenin/Tcf-4 complex to the Tcf-4 enhancer regions in the
promoters o f these target genes. A few genes activated by this complex have been
identified and include c-Myc (19), c-jun and fra-1(24), cyclin D (20, 215) and matrilysin
(MMP7) (22). It appears that LEF-1 family o f transcription factors, o f which Tcf-4 is a
member, act as DNA scaffolding proteins that alone do not affect transcription (220).
They must interact with a partner protein (like P-catenin), and this complex leads to gene
regulation via interaction with basal transcription machinery (221). p-catenin has been
shown to translocate into the nucleus independent o f any association with Lef/Tcf
binding (222), and other non-DNA binding proteins may be involved in forming or
stabilizing the P-catenin and Tcf-4 interactions (222). Because the Lef/Tcf interactions
appear to interact with DNA as a true enhancer element and do not activate transcription
independently (220), it is possible for gene therapy purposes to couple the Tcf-4 enhancer
with other promoter elements that may not affect overall gene expression activities.
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Another unique aspect o f Tcf-4/ P-catenin regulation is the modulation o f responsive
genes by chemical modulators like butyrate, phorbol esters, doxorubicin and retinoids.
Short chain fatty acids like butyrate and trichostatin A have been reported to increase
Tcf-4/ P-catenin mediated gene expression (223, 224). This is consistent with the reported
role o f these compounds in the homeostasis o f the colonic mucosa through induction o f
cell maturation pathways, cell cycle arrest, differentiation and apoptosis (224). Recent
microarray analysis o f butyrate and trichostatin A treated colon tumor cells indicated
activation o f a distinct subset o f genes in cell differentiation processes, including
elevation o f Tcf-4/ P-catenin responsive genes (224). Addition o f the phorbol ester PM A
has also been reported to increase Tcf-4 mediated gene expression (225). Conversely, the
addition o f doxorubicin (226) or retinoids (227) led to decreased Tcf-4/ P-catenin
mediated gene expression. Therefore, modulation o f the transcriptional activity o f the
recombinant Tcf-4/ P-catenin enhancer /promoters may provide an opportunity to
regulate the level o f expression o f therapeutic genes under clinical situations.

Promoters for Design of Recombinant Tumor Specific Gene Expression DNA
Elements
There are several oncogenes which are found up-regulated in cancers and are
believed to give direct or indirect growth advantage to the cancer cell. Promoters o f such
oncogenes are usually found to be the target o f mitogenic signaling pathways resulting in
their constitutive transactivation. Further, these oncogenic promoters are not expected to
be activated in normal cells. Therefore, such promoters are an ideal candidate for
designing o f tum or specific gene expression promoters. However, most o f these
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promoters are weak activators o f transcription and may not allow achieving desired levels
o f therapeutic gene expression in the target cell. This issue could be effectively solved by
coupling an enhancer element to such promoters to increase their activity. In this study
Tcf-4 / P-catenin enhancer element are coupled with the minimal oncogenic promoters
described in this section.
c-fos Promoter
c-fos is a transcription factor belonging to the AP-1 family o f proteins, which are
known to play an important role in cell proliferation and survival (228). AP-1
(activating protein -1 ) is a collective term referring to dimeric transcription factors
composed o f Jun, Fos or ATF (activating transcription factor) subunits that bind to a
common DNA site, the AP-1 binding site. AP-1 activity is induced by a variety o f
biological, chemical and physical stimuli. These include growth factors, cytokines,
neurotransmitters, polypeptide hormones, cell matrix interactions, bacterial and viral
infections, and a wide variety o f physical and chemical stresses. This multitude o f
stimuli, largely regulates the abundance and the activity levels o f AP-1 proteins (229).
The abundance o f AP-1 proteins is most commonly regulated by controlling the
transcription o f their genes (230) and by modulation o f their stability (231, 232).
Regulation o f c-fos is a classic o f example how AP-1 proteins can be regulated by
different signaling mechanisms. The c-fos promoter is the target o f several signal
transduction pathways, which regulate c-fos levels in response to external stimuli.
Stimulation o f cells with different stimuli induces c-fos very rapidly (233). Several cis
elements are known to mediate c-fos promoter induction: first, proximal to the c-fos
TATA box is a CRE which binds to CREB (CRE-binding protein), inducing c-fos via
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cAMP- and Ca2+- dependent signaling pathways in response to neurotransmitters and
polypeptide hormones (234). A Second cis element is the sis-inducible enhancer (SIE)
which is recognized by the STAT (signal transducer and activator o f transcription) group
o f transcription factors. These stimuli activate the mitogen activated protein kinase
(MAPK) cascades that enhance AP-1 function through the phosphorylation o f distinct
substrates. In addition, fos promoters can be induced by activated extracellular-signalregulated kinase (ERIC) in response to serum and various growth factors (235). Based on
these studies it can be concluded that the c-fos promoter is a target o f various cell
signaling cascades induced by cell growth and proliferation promoting agents. For typical
cancer disease models it is well established that various growth and proliferation
promoting signaling cascades are constitutively active. In line with viewpoint, it is know
that expression o f fos is differentially regulated in various cancers. Therefore the c-fos
promoter is an ideal candidate for the designing o f a tum or specific gene expression
promoter because tumor cells, as compared to normal cells, will have the appropriate
cellular environment for its induction.
Cyclooxygenase-2 (Cox-2) Promoter
Cyclooxygenases are the key enzyme in arachadonic metabolism and catalyze the
conversion o f arachadonic acid to prostaglandin H2, the precursors for prostaglandins and
thromboxanes (236). Two isoforms o f Cox exists, Cox-1 and Cox-2. Cox-1 is
constitutively expressed in many tissues (236), however Cox-2 is induced in many
inflammatory reactions (237). Numerous studies have suggested that Cox-2 is regulated
at the transcriptional level. Many growth factors, cytokines and inflammatory agents all
appear to enhance the expression o f Cox-2 by interacting with various regulatory
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sequences in the promoter region o f this gene (238). Evidence for involvement o f Coxs in
cancer was suggested by unusually high amounts o f prostaglandins in various animal and
human tum or tissues, including human colon cancer (239, 240). Recent studies have
presented compelling evidence that Cox-2 is induced and at elevated levels in human
colorectal cancers, azoxymethane-induced mouse tumors and in the polyps o f mouse FAP
(familial adenomatous polyposis) models (241-244). In addition, under physiological
conditions Cox-2 is virtually undetectable in most o f the tissues (245, 246). This evidence
suggest that Cox-2 is differentially expressed in tumors as compared to majority o f
normal tissue. Differential expression o f Cox-2 could be explained by studies which
propose that Cox-2 promoter is differentially regulated in tumors. Further, it has been
suggested that the Cox-2 promoter is regulated by the wnt signaling pathway which is
aberrantly activated in a number o f epithelial tumors (247). In addition, recently, a direct
link between transcriptional regulation, at the promoter level, o f Cox-2 by the wnt
signaling pathway has been demonstrated (26).
In the past the Cox-2 promoter has been used and characterized as a tumor
specific gene expression promoter for expression o f therapeutic genes in different types
o f tumors (248-252). Therefore it is suggestive that the Cox-2 promoter has a potential
utility for a tum or specific promoter and it could be successfully engineered by
combining with various DNA elements to achieve an augmented level o f specificity and
activity.
CEA Promoter
The carcinoembryonic antigen (CEA) has a long history as a potential therapeutic
tool for targeting metastatic colon carcinoma. CEA is a tumor-associated marker that is

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

50

expressed by most colorectal tumors (253, 254). CEA expression is fairly homogenous
with metastatic tumors (254), and its promoter and enhancer sequences have been very
well characterized. The CEA promoter has been mapped and the promoter elements
critical for selective expression o f transgenes in recombinant adenoviruses are located
between nt. -229 to nt. + 111 (the translational start site) (253). The CEA promoter linked
to a therapeutic gene and incorporated into an adenovirus has been used extensively in
multiple studies and shown to be active in only CEA producing cells (255). Related to
our proposed studies one report used a CEA/HSV-TK adenovirus, which was shown to
have no hepatoxicity in nude mice, yet was effective at reducing the tumor volume o f a
human tumor xenograft following GCV administration (256). Although the use o f CEA
to target gene therapy has resulted in specificity, this has come at the cost o f a 10-300
fold loss in activity compared with nonspecific viral promoters such as CMV
(cytomegalovirus) or RSV (Rous sarcoma virus) (255, 257, 258). CEA is found
specifically up regulated in colon tumors and at the same time more than 80% o f colon
tumors show constitutive activation o f Wnt signaling pathway. Therefore, it is reasonable
to speculate that a recombinant Tcf-4 / CEA promoter will have enhanced transcriptional
activity as compared to CEA promoter alone
In addition to colorectal carcinoma, wnt signaling pathway is also shown to be
activated in prostate cancer and is believed to play an important role in the development
o f prostate cancer (205, 207). Therefore, it is logical to think that Tcf-4 / P-catenin
enhancer element can be potentially combined with promoters which are differentially
up-regulated in prostate carcinoma.
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PSMA Promoter
Prostate Specific Membrane Antigen (PSMA) is a membrane glycoprotein with
folate hydrolase activity, predominantly expressed in prostate epithelial cells. Studies at
the mRNA and protein levels support that PSMA is differentially regulated in benign and
malignant prostate abnormalities as well as during tumor progression. In benign prostate
hyperplasia (BPH) PSMA decreases whereas in prostate cancer (CaP) PSMA levels are
increased reaching their highest values in hormone deprived and hormone refractory
states. The mechanism o f regulation o f the gene in the various prostate abnormalities has
yet to be identified. PSMA is most strongly expressed in the prostate with lower levels in
the brain, salivary gland and small intestine (259, 260). Immunohistochemistry has
consistently detected strong PSMA expression in prostate epithelia, with weaker
expression in colon, small intestine, and kidney tubules (260-265). In addition week
expression o f PSMA has also been observed in cardiac muscle and sweat glands (261).
PSMA expression in tumor tissue increases as the prostrate tum or increases in size (260).
Furthermore, expression levels o f PSMA, unlike PSA, has been reported to increase
under conditions o f androgen deprivation (259, 260, 264). The collective evidence
suggests the potential use o f the promoter o f the PSMA gene in gene therapy o f prostate
disease. However, PSMA promoter itself is a week promoter and need to be coupled with
other positive regulatory DNA elements to achieve satisfactory levels o f therapeutic gene
expression. We have combined the Tcf-4/p-catenin enhancer element with the minimal
PSMA promoter to attain higher levels o f gene expression. The significance o f this
approach lies in the fact that approximately 20% o f the prostate show an aberrant
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activation o f wnt signaling pathway. Therefore, combining PSMA promoter and Tcf-4/p*
catenin enhancer element is a rational approach for designing prostate specific gene
expression promoters for the purpose o f gene therapy.
PSA Promoter
Prostate specific antigen is a protein expressed exclusively by benign,
hyperplastic and malignant prostatic epithelium (266). An increase in the serum levels o f
PSA are considered indicative o f the benign hyperplasia or malignant carcinoma o f the
prostate (267) and this has allowed PSA to be used as a diagnostic marker for prostate
disease. Expression o f PSA is reported to be up regulated by androgens and is restricted
exclusively to prostate (268). The restricted expression o f PSA is attributed to the
immediate 5 ’ promoter region o f the PSA gene and is shown to be sufficient to target
expression to prostate tissue (269). Subsequent studies demonstrated that PSA promoter
activity is also regulated by an upstream PSA enhancer element (270). A thorough
analysis o f PSA promoter revealed that coupling o f minimal PSA promoter with its
enhancer increases the specificity and level o f gene expression (271). This suggest that
for designing o f prostate specific gene expression vectors, using PSA promoters,
coupling o f positive regulatory elements is very critical for achieving satisfactory levels
o f therapeutic gene expression. With the idea that wnt signaling pathway is frequently
found activated in prostate carcinoma, it is reasonable to conceptualize that combing Tcf4/p-catenin enhancer element with PSA enhancer will contribute in achieving higher
levels o f specificity and gene expression in prostate carcinoma.
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Transcriptional Targeting Using Tcf-4/fl-Catenin Enhancer
Selective targeting and killing o f tumor cells is one o f the major goals o f all
cancer therapies. Conventional chemotherapy and radiotherapy induce dose limiting
normal cell toxicities, which reduce their clinical effectiveness. Cancer gene therapy has
the potential to avoid or minimize normal cell toxicities. This could be achieved by
employing suitable strategies to target the therapeutic gene directly to the tum or cells.
The majority o f the cancer gene therapy clinical trials have focused on the delivery genes
directly to the tumor site by intratumoral injections using both viral and non-viral
delivery agents, thereby largely avoiding normal tissues. However, direct intratumoral
injections fail to achieve higher levels o f tum or targeting because there are instances in
which it is difficult to reach the tum or and it cannot be applied to disseminated metastatic
tumors which are yet to be detected. A viable alternative to intratumoral injection is
systemic delivery o f a suitably packaged transgene. This would allow targeting o f both
the primary tumor and metastatic deposits, which must be controlled if therapy is to be
successful. W hile increasing the therapeutic ratio, systemic delivery also runs the risk o f
exposing the normal cells to the harmful effects o f the therapy. Cancer gene therapy
offers several technological advances which may be helpful in addressing this issue. A
number o f gene therapy strategies are now being developed to target both viral and
nonviral delivery agents to tum or cells. These include exploitation o f natural viral
tropisms; genetically modifying the virus to ablate native receptor interactions and
incorporating a novel ligand into one o f the viral coat proteins; using tissue specific
ligands or monoclonal antibodies incorporated on to the surface o f liposomes to direct
them to target cells.
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In cancer gene therapy expression o f the therapeutic gene in target cells is an
absolute requirement to minimize normal cell toxicity. Targeted delivery o f the
therapeutic vector to the tum or cells is one way to achieve this goal; however it is still
desirable to have another level o f control to ensure exclusive expression o f the
therapeutic gene in target cells. Transcriptional targeting o f the therapeutic gene is a
promising way to selectively target tumor cells and it involves designing o f recombinant
DNA element (promoters) which would actively express the therapeutic gene in tumor
cells. The basic idea behind these tumor specific gene expression promoters is that they
usually contain cis-acting elements which are activated in diseased states such as cancer.
A decade o f research has well established that genetic mutations result in aberrant
activation o f growth pathways which contribute towards the development o f cancer.
These growth signaling cascades, in general, target promoters o f several oncogenes
resulting in their constitutive activation. The products o f these oncogenes are known to
contribute towards the development o f cancer. Cyclooxygenase-2, c-myc, c-fos, cyclinD
etc are classic examples o f such oncogenes which are found to be constitutively activated,
at transcription level, in variety o f cancers. Therefore, promoters o f such oncogenes are
ideal candidates for being used in designing o f tum or specific gene expression promoters.
It is expected that, owing to the differential activation o f signaling pathways in a cancer
cell environment, these oncogenic promoters will only be activated in cancer cells and
not in normal cells. Thus, such promoters are extremely important DNA sequences for
the purpose o f constructing tumor specific gene expression construct. However, it is also
well known that usually such oncogenic promoters are poor or weak activators o f
transcription. This can be an issue o f concern because failure to express sufficient
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amounts o f the therapeutic gene may result in failure o f the therapy. Besides, there is
always a possibility that such oncogenic promoters can cause a leaky expression o f the
therapeutic gene in normal cells which can result in normal cell toxicity. In general,
activity and specificity are the two major concerns while designing a tumor specific gene
expression promoter. An ideal promoter should be able to achieve therapeutically
significant levels o f therapeutic gene expression specifically in cancer cells and should
not show any biologically significant activity in normal cells. As described earlier,
oncogenic promoters are good candidates but do not entirely fulfill the necessary
requirements from the perspective o f gene therapy. Therefore it is very crucial to
engineer such oncogenic promoters before they can be used in cancer gene therapy.
One o f the ways to accomplish this is to incorporate unique enhancer DNA
sequences in such oncogenic promoters. These enhancer elements are specialized DNA
sequences naturally found to be part o f several gene promoters and are responsible for the
transcriptional activation or repression o f promoters in response to a biological signal.
The ability o f an enhancer element to transcriptionally activate or repress a promoter is
facilitated by its ability to bind to a variety o f proteins. These proteins may range from
chromatin modifying agents to transcription factors and are usually components o f signal
transduction pathways. They have the ability to actively associate or dissociate from
enhancer elements in response to a signal. Activation or repression o f promoter is a very
complex process and it is the result o f a cumulative effect o f the nature o f proteins bound
to enhancer/promoter DNA sequence at any given point o f time. Therefore a biological
signal received at the cell surface may trigger a cascade o f events that may result in
binding o f proteins known to be activators o f DNA transcription leading to transcriptional
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activation o f the promoter. On the other hand it may also repress transcription if the
signals lead to dissociation o f pro-transcription proteins or binding o f factors which have
a cumulative repressive effect on transcription. As mentioned earlier in this text that
aberrant activation o f growth promoting signal transduction pathways results in
differential activation o f genes in cancer. The promoters o f these differentially
transctivated genes usually have specific DNA elements (for example enhancer elements)
binding to an array o f proteins in response to a signal transduced by the activated
signaling pathway. Such enhancer elements can be innovatively used in cancer gene
therapy to control the expression o f therapeutic genes.
Mutational inactivation o f APC and/or beta-catenin is frequently found in
epithelial tumors resulting in transcriptional activation o f Tcf-4/p-catenin gene responsive
genes. Therefore, it is rational to assume that incorporating Tcf-4/p-catenin enhancer in
therapeutic gene expression vectors would result in tumor selective gene expression. In
past several attempts have been made to exploit the tumor selective activation o f the Tcf4/p-catenin pathway for the purpose o f designing tum or selective gene expression
vectors. Typically, these include combing o f Tcf-4/p-catenin enhancer with a promoter to
drive the expression o f a therapeutic gene. In a study it was shown that introduction o f
the cell death gene fadd under the control o f a HSV-TK promoter containing wild-type
Tcf/Lef-binding sites resulted in preferential killing o f colon cancer cells with
hyperactive b-catenin/Tcf activity (272). A synthetic promoter, incorporating Tcf-4/betacatenin binding sites has been designed and shown to successfully express E. coli
Nitroreductase gene in colon cancer xenografts (273). The suppression o f colon cancer
cell growth was demonstrated in nude mice when xenografts were targeted with an
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adenoviral vector carrying HSV-TK gene driven by a recombinant CM V/Tcf-4/p-catenin
promoter (274). These studies have been well designed and successfully demonstrate the
proof-of-principle. However, none o f the studies propose the idea o f combining
oncogenic promoter with Tcf-4/bet-catenin enhancer elements for designing tumor
specific gene expression promoters. This is a very crucial aspect because various
oncogenic promoters are found differentially activated in tumors and incorporating such
DNA elements in therapeutic vectors would help in achieving a stringent control over the
therapeutic gene expression. It is expected that such recombinant promoters will have a
very low activity in normal cells and this would help in further m inimizing the normal
cell toxicity. Furthermore, none o f the studies have conclusively shown the activity o f
recombinant promoters, with Tcf-4/beta-catenin binding sites, in normal colon cells
which is a very important aspect in the strategic targeting o f Tcf-4/p-catenin signaling
pathway for gene therapy. It is expected that recombinant Tcf-4/p*catenin enhancer /
promoter combination designed in this study would be very useful in construction o f gene
expression vectors for strategic delivery o f therapeutic o f choice to cancer cells. Another
hallmark o f the proposed enhancer / promoter design strategy is that it can be adapted to
suit the clinical therapeutic requirements governed by the patient and the type o f tumor.
This can be achieved by combining Tcf-4/p-catenin enhancer with the chosen oncogenic
promoter and therapeutic gene. Choosing an oncogenic promoter partner for Tcf-4/p*
catenin enhancer for treating a patient can be aided by gene array analysis o f a tumor
biopsy taken from the patient. Furthermore, the ability to modulate the levels o f
therapeutic gene expression via genetic and chemical means is another novel aspect o f
the proposed enhancer/promoter system. As described on page number 34, the activity o f
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Tcf-4/p-catenin enhancer elements can be modulated by chemical means and these
modulators could be strategically used in clinic for regulating the activity o f the proposed
enhancer/promoter system.
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CHAPTER II
SPECIFIC AIMS

The goal o f this research is to construct and identify enhancer/promoter
combinations for tumor specific gene expression. Identified combinations will be tested,
in vitro, for their ability to drive the expression o f a therapeutic gene and kill cells.
Further, delivery issues o f the therapeutic gene construct will be addressed by
incorporating these elements into a recombinant adenovirus. The efficacy o f the
recombinant adenovirus to deliver and selectively express the therapeutic gene in target
cells will be evaluated by in vitro assays. Finally, various chemical and genetic
modulators will be screened in an attempt to identify newer methods o f regulating the
activity o f the recombinant enhancer/promoters.
Aim 1: Construction and screening o f optimal recombinant Tcf-enhancer/Promoter
combination
Experiments described in this aim are designed to accomplish a single goal:
identify the optimal Tcf-4 enhancer/promoter combination(s) which have the ability to
drive gene expression specifically in tum or cell as compared to normal cells. To
accomplish these goals we plan to conduct luciferase reporter assays. Various Tcf4/promoter luciferase reporter constructs would be generated by cloning optimized
number o f repeats o f Tcf-4 enhancer element in combination with the chosen oncogenic
promoter in a luciferase reporter construct. To ascertain the efficacy o f these
enhancer/promoter combinations, reporter constructs would be used to screen several
colon and breast tum or cell lines. Since, it is known that in majority o f colon and in fairly
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high number o f breast tumors, inactivating mutations in the APC/beta-Catenin gene
results in stabilization o f p-Catenin which leads to transactivation o f P-catenin/tcf-4
enhancer regulated genes. Therefore, the selected colon and breast tumor lines are likely
to be good model system for screening for optimal Tcf-4 enhancer/promoter
combinations. Further, the results o f these experiments will also provide additional
information: comparative ability o f the all enhancer/promoter combination to drive gene
expression in different cell lines because it is expected that a certain combination might
be optimal in certain cell lines and not in others. All the reporter constructs will also be
tested for their ability to drive gene expression in a small panel o f prim ary human normal
(NCM) cell lines obtained from INCELL. These cell lines have been derived from
normal human colon and are expected to have low or insignificant amounts o f
transcriptionally active beta-catenin. Therefore, the cloned Tcf-4 enhancer/promoter
combinations are expected to be transcriptionally inactive and a lower level o f reporter
luciferase activity is expected in these normal cell lines.
Aim 2: Evaluation o f the ability o f chosen Tcf-enhancer/Promoter combination to
selectively express a therapeutic gene in tumor cells and estimation o f cell killing
These experiments are designed to accomplish two goals: 1) Evaluate the ability
o f the chosen enhancer promoter combination (from Aim # 1) to drive the expression o f a
therapeutic gene selectively in tumor cells and 2) estimate the efficacy o f tumor selective
gene expression in tumor cell killing. Reporter luciferase data from A im #l would help us
to identify enhancer promoter combinations which are selectively active in tum or cells;
next we would use the identified enhancer/promoter elements to drive the expression o f a
therapeutic gene. We plan to use HSV-TK as the therapeutic gene, which would be
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cloned down stream o f the chosen Tcf-4 enhancer/promoter element in a eukaryotic
expression vector. This recombinant therapeutic gene expression construct would be used
to transient transfect normal and tumor cell lines allowing us to evaluate the ability o f the
enhancer/promoter for tumor selective HSV-TK gene expression. Because o f the tumor
selective activity o f the enhancer/promoter we expect to see a selective expression o f
HSV-TK in tum or cells and not in normal cells. In addition, to gene expression analysis,
we would a conduct a functional assay to confirm the activity o f the expressed HSV-TK.
Transfected cells will be treated with labeled [3H] nucleosides followed by the extraction
and assaying o f nucleotides. Ability to phosphorylate nucleosides would reflect the
functionality o f the expressed HSV-TK and the amount o f extracted nucleotides would be
an index o f the levels o f HSV-TK expression in cells. In the next step we will investigate
the ability o f the pTcf-4/promoter-HSV-TK gene construct to selectively kill tum or cells
by conducting GCV cytotoxic cell viability assays. For determination o f GCV
cytotoxicity, tum or cell lines will be transiently transfected with Tcf-4/promoter-HSVTK construct followed by treatment with different doses o f GCV. As a control normal
cell will be transfected similarly followed upon by GCV treatment. GCV treated cells
would be allowed to grow for 36-48 hours followed by counting o f viable cells. We
expect to see increased tum or cell killing as compared to the normal cells, which be could
be explained on the basis o f level o f expression o f HSV-TK in tum or cells as compared to
normal cells.
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Aim 3: Optimization o f delivery o f the therapeutic gene/promoter-enhancer combination
to the tumor
The main objective o f the experiments in this section is to design optimal delivery
method which could deliver the recombinant therapeutic gene construct to the target
cells. Gene delivery by naked DNA transfection is severely limited by the ability o f the
target cells to get transfected. Some cells are more susceptible for naked DNA uptake as
compared to others. However, transfection efficiencies for a specific target cell can be
improved by employing various transfection methods. Nevertheless, transfection
procedures fail to achieve significant levels o f gene delivery o f the therapeutic gene to
target cell and this would severely impede the objectives o f cancer gene therapy which
requires, ideally, targeting every single tumor cell. We plan to use recombinant
adenoviral vectors to address the issue o f delivering our recombinant therapeutic gene
construct to the target cells.
Aim 4: Identification o f strategies for modulating Tcf-4/Beta-catenin responsive
promoters
For several therapeutic implications, it may be necessary to regulate the
expression o f the therapeutic gene, for e.g. stimulation o f the gene expression is possibly
needed, for increasing therapeutic gene expression, in cells which are marginally
responsive. Conversely, the possibility o f having a strategic repressor option in the
context o f viral-based gene therapies could be important. One o f the several ways to
control the expression o f the therapeutic gene in target tissue is to regulate the activity o f
the enhancer/promoter which is driving its expression. Experiments in this specific aim
are, primarily, geared towards identifying strategies to regulate the activity o f the
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recombinant Tcf-4 enhancer/promoter by chemical and genetic means. Short chain fatty
acids like butyrate and trichostatin A have been reported to increase Tcf-4/p-catenin
mediated gene expression. Butyrate is a histone de-acetylase inhibitor which can act
differentially either promoting or repressing Tcf-4/p-catenin mediated gene expression.
Therefore compounds like butyrate and trichostatin A could be potentially used for
increasing therapeutic gene expression by stimulating the Tcf-4 enhancer/promoter. On
the contrary, compounds like doxorubicin and 9-cis-retinoic acid have been reported to
transcriptionally repress expression o f Tcf-4/p-catenin responsive genes. Further, drugs
like aspirin and indomethacin have recently been reported to reduce Tcf-4/p-catenin
mediated signaling by increased stabilization o f phosphorylated P-catenin the levels.
Hence, there are several promising compounds which can be screened for potential
chemical regulators o f recombinant Tcf-4 enhancer/ promoter combinations. The
luciferase reporter DNA constructs designed in specific aim #l contain tcf-4 enhancer
elements coupled with different oncogenic promoters used to drive the expression o f a
reporter luciferase gene. These constructs will be primarily used for screening o f various
compounds for modulatory acitivity on recombinant Tcf-4/promoter combination. The
central idea is to measure the luciferase activity, following transfection o f cells with
reporter DNA, in presence or absence o f the candidate drug. Levels o f luciferase activity
would assist in classifying the candidate compound into stimulators or repressors.
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CHAPTER III
MATERIALS AND METHODS

Plasmids
Luciferase reporter plasmids pTop-flash and pFop-flash were gifted by Dr. Van
de Wetering, Netherlands. Reporter plasmids pGL2-CEA was obtained as a gift from Dr.
Kathy Molnar-Kimber, university o f Pennsylvania, PA. pGL3-PSA and pGL3-PSM A
were gifted by Dr. Tonia Vlahou, Eastern Virginia Medical School, VA.

Cloning Procedures
Restriction Digests
All restriction enzymes used in these studies unless otherwise noted, were bought
from Promega. For most digests, 3-5 units o f enzyme were used per pg o f DNA digested
in a company recommended restriction enzyme buffer and the reaction was incubated for
approximately 2 hours at the appropriate temperature.
Ligation Reactions
All ligation reactions were performed using 20 pg o f T4 DNA ligase (NEB) and
buffer provided by the manufacturer. All ligation reactions had 100-300 ng o f vector
DNA and three to five molar excess o f insert when necessary. The ligation reaction was
incubated at 16° C for at least 16 hours.
Phosphatase Reactions
These reaction was carried to remove 5’ phosphate on restriction digested DNA to
prevent self ligation o f the vector DNA in ligation reactions. Approximately 20 units o f
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calf intestinal phosphatase (NEB) were added to the reaction mixture containing
manufacturer recommended buffer and restriction digested vector DNA. The reaction
mixture was incubated at 37° C for 30 minutes, 20 units o f phosphatase were added, and
the reaction was incubated for an additional 30 minutes. The vector DNA was
subsequently purified on a 1% agarose gel.
Competent Bacteria
E. coli D H 5a competent cells used in these studies were prepared in the
laboratory and JM109 competent cells were purchased (Promega). Single colony o f E.
coli D H 5a cells was revived overnight in LB at 37°C at 200 rpm shaking. 1 ml o f this
culture was subcultured in 100 ml LB and grown till A6oo reached 0.3. The culture was
chilled on ice for 10 min and centrifuged at 4500xg for 15 min at 4°C. The cells were
gently suspended in 15 ml o f ice cold sterile solution o f 100 mM CaCL containing 15%
glycerol, and incubated on ice for 30 min. Cells were harvested again at 4500xg for

15

min and gently suspended in 5 ml o f 100 mM CaCL solution containing 15% glycerol.
Competent cells were aliquoted in small volumes (100-200 pi) in prechilled tubes and
stored at -70°C.
Transformation o f Bacteria
Competent cells, stored at -70°C, were slowly thawed on ice. The DNA (ligation
mix (10 pi) or 100 ng o f plasmid DNA) was added to 100 pi o f competent cells. After
gentle mixing, cells were incubated on ice for 1 h. Cells were given a heat shock at 37°C
for 5 min or 42°C for 90 sec and then chilled on ice for 2 min. The cells were then
allowed to grow in 1 ml o f LB for 1 h at 37°C. Dilutions o f cells were plated on LB-agar
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plates containing specific antibiotics and incubated at 37°C overnight. The recombinants
were screened for the presence o f plasmid by mini-preparation o f plasmid DNA and
restriction endonuclease digestions.
Miniprep Analysis o f Plasmid Constructs
For screening o f E. coli cells harboring the desired plasmid small scale
preparation o f plasmids were made using Qiagen miniprep kit. Briefly, cells were picked
up from a single colony and grown for 12 h in a small volume o f LB containing
appropriate antibiotic. Three ml o f culture was centrifuged in microcentrifuge tubes at
8000xg for 2 min and the supernatant was discarded. The plasmid DNA was then
purified using Qiagen miniprep spin columns following the protocol provided by the
manufacturer in the product literature. The purified plasmids were appropriately
restriction digested and analyzed on agarose gels.
Large Scale Plasmid Purification
For rapid large-scale preparation o f plasmid DNA using the Qiagen m idi
preparation kit, m anufacturer’s instructions were followed. Briefly, 50 ml o f LB medium
with appropriate antibiotics was inoculated with an ovmight culture o f E. coli cells
harboring the desired plasmid. Cells were harvested at 4000xg and suspended in 5 ml o f
resuspension buffer (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 pg/ml RNase A). 5 ml
o f lysis buffer (0.2 M NaOH, 1% SDS) was then added to the suspension, mixed
thoroughly and incubated for 5 min at RT. To this, 5 ml o f neutralization buffer (3 M
potassium acetate, pH 5.5) was added and mixed and then incubated for 10 min on ice.
The mixture was spun at 12,000xg for 30 min and clear supernatant was collected in a
fresh tube. The supernatant was then loaded on Qiagen T ip-100 equilibrated in Buffer
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QBT (0.75 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol) and bound DNA was
washed with buffer QC (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol). Pure
DNA was eluted in buffer QF (1.25 M NaCl, 50 mM Tris-Cl, pH 8.5, 15% isopropanol)
and precipitated with 0.7 volumes o f isopropanol. DNA pellet was washed with 70%
ethanol and dried and dissolved in TE ((10 mM Tris-Cl, pH 8.0, 1 mM EDTA).
Isolation o f DNA Fragments from Agarose Gels
To isolate DNA fragments from a reaction mixture containing other products, the
reactions were stopped with stop dye (50% glycerol, lOOmM EDTA, 0.1% bromophenol
blue and loaded onto a 1% agarose gel. Following electrophoresis, the desired band was
excised with sterile scalpel blade and put in a microcentrifuge tube. The DNA was
purified with the help o f Qiaquick gel extraction kit (Qiagen). Briefly, the gel pieces were
dissolved in solubilization buffer for 15 min at 55°C. Solubilized agarose with DNA was
added to the spin column provided in the kit and was spun at 12,000xg for 1 min. The
flow through was discarded and column was washed with a buffer containing 70%
ethanol. Bound DNA was eluted at 55°C for 5 min in 10 mM Tris, pH 8.0.
PCR amplification o f DNA fragments
PCR master mix (Promega) was used for all the PCR reaction described in these
studies and the reactions were performed following the m anufacturer’s instruction. 100
ng o f template DNA and 100 ng o f each primer were used in 50 pi o f reaction mixture.
The following program was used in all amplication reactions on a thermal cycler (MJ
research). Step 1: 94° C for 2 minutes; Step 2: 92° C for 1 minute; Step 3: 55° C for 1
minute; Step 4: 72° C for 1 minute; Step 5: cycle to step 2, 32 times; Step 6: 72° C for 5
minutes; Step 7: maintain at 4°C.
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Human Normal and Tumor Cell Lines
Normal cell lines (NCM-460, NCM-425, CSC-1) were maintained in INCELL’s
specialty media M310 at 37 ° C and 5% C 0 2 . Colon tumor cell lines (SW480, HCT8,
SW620, H C T116, HT29) were maintained in RPM1 1640 (Cell Grow) supplemented
with 10% fetal bovine serum (Cell Grow), 1% penicillin-Streptomycin (Cell grow), at 37
° C and 5% C 0 2.

Luciferase Vectors and Assays
Luciferase Reporter Vectors
Tcf-4/p-catenin enhancer and pGL3-basic/Tcf: pTop-Flash luciferase reporter
plasmid was used as the source for Tcf-4/p-catenin enhancer fragment. pTop-Flash was
restriction enzyme digested with Sal-I and the reaction mixture was resolved on a 15 %
polyacryamide gel. Resolving gel consisted o f 15% (w/v) acrylamide:bisacrylamide
(29:1), IX TBE, and 0.1% APS. Gel was polymerized with 1 pl/ml o f TEMED. Tcf-4/pcatenin enhancer fragment was excised out o f the gel and eluted in a elution buffer (0.5
M ammonium acetate, ImM EDTA, pH 8.0). pGL3-basic (promega) reporter luciferase
vector was restriction enzyme digested with Sal-I and purified on agarose gel. Sal-I
digested 86 bp. insert o f Tcf-4/p-catenin enhancer fragment was ligated with Sal-I
digested pGL3-basic vector to generate pGL3-basic/Tcf.
p G U -C E A /T c f
pGL3-CEA vector was digested with Sal-I followed by purification on a 1%
agarose gel. Purified Sail digested pGL3-CEA was treated with calf intestinal
phosphatase and purified on a 1% agarose gel. Sal-I digested Tcf-4/p-catenin enhancer
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fragment (86 bp.) was ligated to the restriction digested, CIAP treated pGL3-CEA to
generate pGL3-CEA-Tcf.
pGL3-Cox2 and pG L3-C ox2/Tcf
A 720 bp fragment o f Cox-2 promoter was PCR amplified from human genomic
DNA. SW480 colon cancer cells were used as the source o f genomic DNA which was
isolated following the instructions provided with the Qiagen mammalian cell DNA
extraction kit. Desired Cox-2 promoter fragment was amplified with Xhol (Cox-2/XhoICCGCTCGAGCGGGGGTACGAAAAGGCGGAA) and Bgl-11 (Cox-2/Bgl-IIGAAGATCTTCCGCCAGGTACTCACCTGT) restriction enzyme end primers in a PCR
reaction mix (Promega) with 100 ng o f genomic DNA template. The amplified DNA
fragment was agarose gel purified restriction enzyme digested in a reaction mixture
containing Xho-I and Bgl-11. Following restriction enzyme treatment, 270 bp DNA
fragment was resolved on an agarose gel and purified using Qiagen qiaquick gel
extraction kit. The vector DNA was prepared by treating pGL3-basic plasmid DNA with
Xho-I and Bgl-II. The restriction digested vector DNA was agarose gel purified using
Qiagen Qiaquick gel extraction kit and ligated, with PCR amplified, and restriction
enzyme treated 270 bp Cox-2 promoter DNA to generate pGL3-Cox2.
Sal-I restriction enzyme digested Tcf-4/p-catenin enhancer DNA was cloned in
the Sal-I restriction enzyme site o f pGL3-Cox2 to generate pGL3-Cox2/Tcf.
pG L3-P SA /Tcf
Sal-I restriction enzyme digested Tcf-4/p-catenin enhancer DNA was cloned in
the Sal-I site o f pGL3-PSA luciferase reporter vector to generate pGL3-PSA/Tcf.
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p G U -P S M A /T cf
PSMA promoter (640 bp.) insert was excised out o f pGL3-PSM A promoter using
Kpn-I and Hind-III restriction enzymes. The 640 bp. promoter DNA fragment was
resolved and purified on an agarose gel. For vector DNA, pG L3-Tcf plasmid was
restriction digested with Kpnl and Hind-III, followed by purification on an agarose gel.
Kpn-I and Hind-III digested insert and vector DNA were ligated to generate pGL3PSMA/Tcf.
Reporter Luciferase assays
To evaluate the ability o f the recombinant enhancer/promoter combinations to
express the reporter gene in cancer and normal cells, dual luciferase assays were
performed. The assay relies on an internal control (pRL-TK) vector which carries a gene
for Renilla luciferase expressed from a ubiquitously active eukaryotic promoter (HSVTK). Renilla luciferase generates a signal which is distinct from the luciferase expressed
by the test reporter vector and this signal is used to normalize for transfection efficiencies
o f different cell lines. Optimal transfection conditions for each cell lines were empirically
determined. 2 X 105 cells/well were seeded in 6 well plates. The cells were transfected
overnight with lOpl lipofectamine (Life Tech.) reagent, 2 pg luciferase reporter plasmid
and 200 ng o f pRL-TK in OPTIMEM media (Life Tech.). On following day, regular
maintenance media was replaced. After 48 hours, the cells were lysed and assayed
according to the protocol supplied with the Dual Luciferase Assay Kit (Promega). The
relative light units were recorded with a Turner luminometer.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

71

HSV-TK Constructs and Gene Expression Analysis
Construction o f pCDNA-TK and pc-fos/Tcf-4-HSV-TK
pCDNA3.1(+)-5.4 kb (Invitrogen), was used as the eukaryotic expression vector.
The native CMV promoter was removed by Bglll and BamHI (promega) restriction
digest, followed by gel purification o f the vector backbone excluding the CMV promoter.
Wild type HSV-TK gene (1.1 Kb) was excised from pLTK-ED (275) using 5’ Bglll and
3’ BamHI restriction enzymes and cloned into Bglll and BamHI sites o f CMV promoter
less pCDNA3.1(+) to generate pCDNA-TK. To generate pc-fos/Tcf-4-HSV-TK, Tcf-4-cfos DNA fragment (186 bp.) was PCR amplified with 5’ Bgl-II
(GTAAGATCTGTTCTAGAGTCGACCTGCAGCCCAAG) and 3 ’ Bam-HI
(GTAGGATCCATGGGAGATCCTCTAGAGAGACACTG) primers and using PCR
master mix reagent (promega). The PCR product (186 bp.) was resolved on a 1% agarose
gel, purified and restriction enzyme digested (with Bam-HI and Bgl-II). Restriction
digested and agarose gel purified enhancer/promoter DNA fragment was cloned into the
Bglll site o f pCDNA-TK upstream o f HSV-TK to generate pc-fos/Tcf-4-HSV-TK.
Construction o f pPSMA/Tcf-4-HSV-TK
The luciferase gene o f pG L3-PSM A /Tcf plasmid DNA was removed by
restriction enzyme digestion (Hind-III, Xba-I) and resolving the products on a 1%
agarose gel. The vector backbone without the luciferase gene was excised from the gel
and purified. For insert, the HSV-TK gene (1.1 kb.) was PCR amplified with primers
with Hind-III (CCCAAGCTTGGGATGGCTTCGTACCCCGGCCATC) and Xba-I
(GCTCTAGAGCTCAGTTAGCCTCCCCCATCTG) restriction enzyme end primers.
pLTK-ED (ref) was used as template DNA. Following agarose gel purification, HSV-TK
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gene was restriction digested (Hind-III, Xba-I) and ligated with the prepared vector to
generate pPSMA/Tcf-4-HSV-TK.
Transfection and Gene Expression Analysis
The ability o f the HSV-TK expression vectors for tumor selective expression o f
HSV-TK was evaluated by transiently transfecting vectors in normal and tumor cells
followed by Western analysis. 2 x l0 5 cells were seeded in 6 well plates for 24 hours
followed by overnight transfection with 2pg/well o f DNA, lOpl/well o f Lipofectamine
transfection reagent and OPTIMEM media (Invitrogen). The day after transfection,
regular growth media was replaced. After 48 hours o f transfection, protein extracts were
prepared by boiling in reducing sample loading buffer. Protein samples were subjected to
SDS-PAGE and western blot analysis.
SDS-PAGE Analysis
SDS-PAGE analysis was carried out as described by Laemmli (1970). Resolving
gel consisted o f 15% (w/v) acrylamide:bisacrylamide (29:1), 0.4 M Tris-Cl, pH 8.8, 0.1%
SDS, and 0.1% APS. Gel was polymerized with 1 pl/ml o f TEMED. 5% stacking gel was
made similarly in 0.125 M Tris-Cl, pH 6.8. Samples were boiled in the reducing sample
buffer (4M urea, 20mM DTT, lOOmM Tris pH 8.0, 4% SDS, 0.1% bromophenol blue)
prior to loading onto the gel. The gel was electrophoresed in running buffer (25 mM TrisCl, pH 8.3, 250 mM glycine and 0.1 % SDS) at 15 V/cm for 2 h. The gel was then stained
with Coomassie brilliant blue G-250 (0.05% w/v) for 1 h and destained in methanol:
glacial acetic acid: water (4:1:5).
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Immunoblotting
The samples analyzed by SDS-PAGE were electrotransferred onto nitrocellulose
membrane at 30 mA for 10 h in transfer buffer (20 mM Tris, 150 mM glycine, pH 8.0
and 20% methanol). Non-specific sites were blocked by 5% non-fat milk in TBST ( 0.01
M Tris pH 8.0, 0.14 M Sodium Chloride and 0.1 % Tween-20) for 1 h on a rocker. The
membrane was then incubated with primary rabbit polyclonal IgG against HSV-TK in IX
TBST (1:1000) followed by incubation with HRP conjugated goat anti-rabbit antibody
(1:5000). The blot was washed thoroughly with TBST between successive incubations.
Fluorimetric detection o f bands was attained using ECL western blotting kit (Amersham
Pharmacia Biotech, UK). Blots overlaid with detection reagents were exposed to X-ray
film (Kodak) and were developed using an automated X-ray film developer (Kodak).
M etabolic Labeling with 13H1 GCV
For metabolic labeling procedure (171). Parental and HSV-TK expressing vector
transfected cells (2 x l0 5) were labeled in triplicate with lpC i o f [3H]GCV for 8-10 hours,
and then nucleotides were extracted from pelleted cells in 0.2ml o f 70% methanol at 4°C
for 15 min. An aliquot o f each methanol-soluble supernatant was analyzed for
radioactivity by scintillation counting using a bench top scintillation counter (Beckman).
The residual cell pellets were analyzed for radioactivity, by scintillation counting, for
nucleotides present in DNA.
GCV Cytotoxicity: Cell Viability Assays
1x10s cells/well, tumor and normal cells were seeded in 6 well plates. Next day
cells were transfected as previously described in these studies. Similarly, control cells
were mock transfected with the same amount o f non-specific DNA / lipocfectamine.
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Following 18-20 hours o f transfection, regular growth media was replaced with 0, 1 and
10pm GCV. After 48 hours o f growth, cells were washed once with PBS to dislodge dead
cells, adherent cells were collected by trypsinization and trypan blue stained live cells
were counted using a haemocytometer/microscope.
GCV sensitivity: Clonal dilution Assays
For determination o f GCV sensitivity, cells were seeded in 24 well plates
(2 x l0 5/well) in 1 ml media. On the following day, cells were transfected with appropriate
plasmid DNA constructs and control cells were mock transfected similarly with same
amount o f lipid and non specific control plasmid DNA. The next day, after transfection,
0, 0.1, 1 or 1Opl GCV was be added to each cell line in triplicate. After 24 hours o f GCV
treatment, the media was removed, cells were rinsed in fresh media, trypsinized, and then
media was added to a final volume o f 1 ml/well. Each well o f cells was then sequentially
diluted from 1:10 to 1:10,000 in 1 ml fresh media on a separate 24 well plate. After
approximately 7 days, surviving cell colonies were fixed in 100% methanol, stained with
0.1% methylene blue and were counted.

Adenoviral Vectors and Gene Expression Analysis
Construction o f the Recombinant Adenoviral Vectors
The adenoviral vectors used in the study are E1/E3 deleted replication
incompetent viruses and are constructed by using pAdeasy technology and a pAd-easy
recombinant adenoviral vector construction kit (Qbiogene). Instruction and reagents
provided by the manufacturer were used to construct two recombinant adenoviral vectors;
Ad-Tcf-fos-TK and Ad-CMV-TK. Recombinant adenovirus were constructed in three
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steps, in the first step two vector pShuttle-Tcf-fos-TK and pShuttle-CM V-TK, were
generated.
pShuttlc-Tcf-fos-TK
pc-fos/Tcf-4-HSV-TK construct was restriction enzyme digested (Bgl-II, BamHI), products were resolved on a 1% agarose gel and an insert o f 1.3 kb fragment (Tcf-cfos-TK) was purified. pShuttle vector (provided in the kit) was prepared by Bgl-II
restriction digestion followed by phosphatase treatment and agarose gel purification.
Prepared Tcf-c-fos-TK DNA fragment was liagated in the Bgl-II restriction site o f the
prepared vector to generate pShuttle-Tcf-fos-TK.
pShuttle-C M V- TK
pLTK-ED (ref) plamisd DNA was restriction digested (Bgl-II, BamH-I), products
were resolved on a agarose gel and an insert DNA o f 1.1 kb. o f HSV-TK gene was
purified. Vector was prepared by treating pShuttle-CM V (provided in the kit) with Bgl-II
restriction enzyme and agarose gel purifying the restriction digested DNA. HSV-TK
insert with Bgl-II and BamH-I restriction ends was ligated with purified Bgl-II treated
pShuttle-CM V to generate pShuttle-CMV-TK.
In the second step, using a recombination positive bacterial strain (provided in the
kit), pShuttle-Tcf-fos-TK and pShuttle-CM V-TK were recombined with pAdeasy-1 (33.4
Kb) plasmid to generate the recombinant adenoviral DNA. These recombinant constructs
were transfected in HEK 293 cells to produce adenoviral particles. The recombinant
adenoviruses were amplified and purified as suggested by the manufacturer. The viral
stocks were titered using an adenovirus rapid titration kit (Clontech) and following
instructions provided by the manufacturer.
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Adenoviral Infections and gene expression analysis for HSV-TK
Infecting cells with adenoviruses simply involves placing viruses in contact with
cells. For the first 3-4 hours o f infection, to increase the infection efficiency, the volume
o f the media used was minimized to allow close contact between the cells and
recombinant adenoviruses. Infection was carried at 37° C and 5% C 0 2. Regular media
was then added to cover the cells and were allowed to grow normally. For HSV-TK
expression analysis 2 x l0 5 cells /well were infected with recombinant adenoviruses in 6
well plates. After 48 hours o f infection, protein extracts were prepared by boiling samples
in reducing sample buffer and were analyzed by SDS-PAGE / Western blot analysis.

Screening of Drugs with Modulatory Properties
To evaluate the ability o f the candidate drug to modulate the activity o f
recombinant Tcf-4 enhancer/promoter dual luciferase assays were. 2 X 105 cells/well
were seeded in 6 well plates. The cells were transfected overnight with 1Opl
lipofectamine (Life Tech.) reagent, 2 pg luciferase reporter plasmid and 200 ng o f pRLTK in OPTIMEM media (Life Tech.). The drug, to be tested, was added to the cells in
different concentrations at the time o f transfection. On the following day, regular
maintenance media was replaced. The pRL-TK construct was used as an internal control
for transfection efficiency. After 48 hours, the cells were lysed and assayed according to
the protocol supplied with the dual Luciferase Assay Kit (Promega). The relative light
units were recorded with a Turner luminometer.
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CHAPTER IV
RESULTS

Introduction
The ability to distinguish a normal cell from a tumor cell is one o f the central
requirements in a cancer gene therapy protocol. This can be accomplished by restricting
the entry o f the therapeutic vector into the cells and/or at the level o f transcription by
directing the expression o f the therapeutic gene from a tumor specific promoter (276,
277). Transcriptional control strategies mainly involve designing therapeutic vectors by
incorporating promoter/enhancer elements that show little or no activity in normal cells
under non-pathological conditions, but are turned on or up regulated in certain types o f
tumors. For example, erb-2 and muc-1 promoters, which are frequently found up
regulated in adenocarcinomas due to the altered signaling pathways, have been
successfully exploited in experimental therapeutic models (278, 279). However, some
tumor specific promoters are inefficient activators o f transcription, which severely limits
their applicability. One o f the approaches for improving the transcriptional strength or
specificity is to couple positive regulatory elements o f enhancer domains with the basal
minimal, differentially regulated, promoters o f oncogenes. This strategy has been
successfully used for carcino embryonic antigen (CEA) and prostate specific antigen
(PSA) promoter (271, 280). We have used a similar rationale to design promoters for
gene therapy vectors based on the wnt signaling pathway. It is well established that wnt
signaling pathway is aberrantly activated in a variety o f adenomas o f epithelial origin
(205, 281 -285). This results in stabilization o f P-catenin levels leading to constitutive
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activation o f gene promoters that contain Tcf-4/p-catenin enhancer element. Therefore it
is logical that the Tcf-4/P-catenin enhancer element could be incorporated in the design
o f tumor specific promoters to achieve tumor specificity o f therapeutic gene expression.
The purpose o f the experiments described in this chapter is to establish that the
Tcf-4/p-catenin enhancer element can be combined with minimal promoters o f known
oncogenes to achieve specificity o f gene expression in tumor cells as compared to normal
cells. A Tcf-4/p-catenin enhancer element was combined with various minimal
oncogenic promoters in reporter luciferase constructs. These constructs were used to
screen a panel o f tumor and normal cell lines to evaluate the ability o f the Tcf-4/p-catenin
enhancer / promoter combination to direct gene expression specifically in the tum or cells.
A chosen Tcf-4/P-catenin enhancer / promoter combination was cloned upstream o f an
HSV-TK gene in a therapeutic eukaryotic expression vector to test the ability o f the
recombinant promoter to tumor specific gene expression. To address the issue o f delivery
o f the therapeutic vector to the cells, an adenoviral vector was generated and evaluated
for its ability to deliver and express the therapeutic gene in cells. Finally, the possibility
o f regulating the activity o f recombinant Tcf-4/p-catenin enhancer / promoter with
chemical means was also explored.

Aim 1: Construction and screening of recombinant Tcf-enhancer/Promoter
combinations
Construction and cell line testing o f Tcf-4-enhancer/c-fos recombinant promoter
The Tcf-4/p-catenin enhancer element was coupled with different basal minimal
promoters in a luciferase reporter plasmid to generate various recombinant
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enhancer/promoter combinations as described in materials and methods. These
combinations were then screened in a panel o f normal and tumor cell lines to identify the
most active enhancer/promoter combination based on selectivity o f expression o f the
reporter gene in tumor cells as compared to normal cells. The luciferase reporter plasmids
pLuc-fos/Tcf (pTOP-FLASH) and pLuc-fos/fct (pFOP-FLASH) were kindly provided by
Dr. Mark Van der Wetering. The pLuc-fos/Tcf construct consists o f four tandem repeats
o f the Tcf-4 binding sequence (CCTTTGATCT, 82 bp total), 5’ to a murine c-fos
promoter (186 bp) driving expression o f the luciferase gene. The pLuc-fos/fct is a
negative control plasmid that contains altered T cf enhancer repeat sequences
(CCTTTGGCCT) not recognized by Tcf-4 (18). Therefore pLuc-fos/fct served as an
excellent negative control reporter plasmid and demonstrated that binding o f Tcf-4 factor
to the enhancer element is crucial for the transcription o f the reporter gene. For
transfections, 2 X 105 cells were seeded (in triplicate) and incubated overnight with 2 pg
pTCF/fos-Luc, 1 pg renilla luciferase (pRL-TK), and 8-14 pi lipofectin reagent in OptiMEM media. A Dual-Luciferase Reporter kit and a Turner TD-20e luminometer were
used to determine luciferase activity, with values expressed as the ratio (relative light
units, RLU) o f firefly luciferase activity to Renilla luciferase activity 48 hrs. post
transfection. In addition, to examine the effect o f tandem repeats o f Tcf-4 enhancer on the
activity o f c-fos promoter, a Tcf-4 enhancer deleted vector containing only c-fos
promoter driving the expression o f luciferase gene was made. The Tcf-4 enhancer-deleted
vector, pTOPLESS, was generated by digesting pTOPFLASH with Sal I to remove the
82 bp TCF enhancer sequences. Following gel purification, the pTOPLESS plasmid was
generated by religation o f the Sal I site. The constructed plasmids were used to evaluate
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the ability o f the T cf enhancer sequences to express the luciferase reporter in normal and
cancer cell lines. In dual luciferase assays, as described in the methods section, different
cell lines were transfected with either pLuc-fos/Tcf or pTOPLESS or with just the blank
luciferase reporter vector (pGL3). Table-1 shows the comparative luciferase activity in a
panel o f selected cell lines. The results show that the combination o f Tcf-4/p-catenin
enhancer with the c-fos promoter results in increased luciferase activities as compared to
the luciferase activities o f the c-fos promoter (pTOPLESS) or the blank vector (pGL3)
alone. Shown in the panel are colon cancer cell lines (HCT 8, SW480, SW620, colo 320)
and normal colon cell line (NCM 460). All o f the colon cancer cell lines tested are known
to have APC or P-catenin gene mutations (286) resulting in aberrant constitutive
activation o f the wnt signaling pathway. Therefore a higher Tcf-4 enhancer activity is
expected in these cell lines which is reflected in the increased amount o f luciferase gene
product (higher luciferase activity) produced by pLuc-fos/Tcf. NCM460 is a normal cell
line derived from non diseased colon (272) and is used as a negative control in the
presented experiments. Use o f NCM 460 as a negative control is based on the rationale
that being a normal cell line it does not have APC or P-catenin gene mutations (no wnt
signaling) and is expected to have very low Tcf-4/ P-catenin enhancer activity,
resembling a normal cell situation. Figure 1 is an alternative way o f showing the proof o f
principle. The activity o f pLuc-fos/Tcf and pLuc-fos/fct were compared in normal and
cancer cell lines by conducting dual luciferase assays. Either pLuc-fos/Tcf or pLucfos/fct was co-transfected with pRL-TK (internal control) in selected cell lines. 48 hours
post transfection cell lysates were prepared and relative luciferase ratio (RLU) readings
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Table 1. Fold activation by Tcf-4/p-catenin enhancer element. pLuc-fos/Tcf,
pTOPLESS (c-fos promoter alone, no Tcf-4 enhancer), or pGL3 (blank vector)
luciferase reporter plasmids were co-transfected with pRL-TK in selected cell lines.
Whole cell lysates were prepared 48 hours later and assayed for luciferase activity
using a dual luciferase reporter assay kit. Shown are the fold increases in the
luciferase activities by Tcf-4/p-catenin enhancer element in selected cell lines.

Cell Line

pTOPLESS

pGL3

HCT8
SW480
SW620
Colo320
NCN460

5
34
24
40
1

150
500
420
550
4
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Figure 1. fos/Tcf and fos/fct recombinant promoter activities in normal and
colon tumor cells. Normal and colon cancer cell lines were co-transfected using
pRL-TK with either pLuc-fos/Tcf or pLuc-fos/fct reporter plasmids. Wholecell
lysates were prepared 48 hours post transfection and assayed for luciferase
activities. Shown are the recombinant promoter activities in terms o f relative
luciferase units derived by dividing the firefly luciferase activity value by the
renilla luciferase value.
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were recorded as previously described in the text. pLuc-fos/Tcf has much higher activity
in colon cancer cell lines (colo 320, HCT8, SW480, SW620) as compared to pLucfos/fct. On the other hand pLuc-fos/Tcf did not show any appreciable activity in chosen
normal cell lines (NCM460, NCM425, CSC1).
Construction and cell line testing o f Tcf-4-enhancer/CEA recombinant promoter
The carcinoembryonic (CEA) antigen is a tumor associated antigen and is expressed by a
majority o f colorectal tumors. The feasibility o f the use o f the CEA promoter in the
design o f a tumor specific gene expression promoter was tested. As described in the
methods section, the TCF-4 enhancer element was cloned into the Sal-I restriction site o f
pGL3-CEA to generate pGL3-CEA/Tcf. Dual luciferase assays were performed to
evaluate the activity o f these CEA constructs. A pane o f selected cell lines (table-2) were
transfected with either pGL3-CEA or pGL3-CEA/Tcf, in dual luciferase assays.
Luciferase activities were monitored after 48 hours o f transfection as described earlier. In
order to compare the activities o f the CEA constructs to c-fos/Tcf promoter, the same
panel o f cell lines were also transfected with either pLuc-fos/Tcf or pTOPLESS, in dual
luciferase assays (table-2). The activity o f the recombinant CEA promoter was also tested
in two breast cancer cell lines; MCF-7 and MDA 435. Breast cancer cell lines were
chosen because deregulation o f the wnt signaling pathway has also been reported in
breast carcinoma (284). In luciferase reporter assays, the combination o f the Tcf-4
enhancer element with the CEA promoter did not yield any significant increase in
luciferase activities as compared to the CEA promoter alone. As shown in table-2, by fold
induction, the C EA /Tcf combination did not result in any significant increase in
luciferase activities, in the tested cancer cell lines (MCF-7, MDA-435, SW620), over
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Table 2. Effect o f Tcf-4 enhancer element on the activity o f c-fos and CEA
promoters. Normal and colon cancer cell lines were co-transfected using pRL-TK
with either pLuc-fos/Tcf or pLuc-fos/fct reporter plasmids. Whole cell lysates
were prepared 48 hours post transfection and assayed for luciferase activities. The
promoter activities in terms o f relative luciferase units were derived by dividing
the firefly luciferase activity value by the renilla luciferase value.
Cell Line/Promoter

No TCF
RLU Ratio

Plus TCF
RLU ratio

Fold

C SC -l-Fos
CSC-1-CEA
CSC-1-LTR

0.009
0.01
6.0

0.04
0.01
-

4.4
1.0
-

NCM460-Fos
NCM460-CEA
NCM460-LTR

0.003
0.005
8.7

0.04
0.01
-

13.3
2.0
-

NCM425-Fos
NCM425-CEA
NCM425-LTR

0.06
0.02
16.7

0.39
0.13
-

6.5
6.5
-

MCF7-Fos
MCF7-CEA
MCF7-LTR

0.31
0.05
0.78

1.1
0.08

3.5
1.6
-

MDA435-Fos
MDA435-CEA
MDA435-LTR

0.03
0.04
8.5

0.71
0.05

23.6
1.25
-

MDA436-Fos

0.07

0.68

9.71

MDA231-Fos

0.04

0.96

24

SW620-Fos
SW620-CEA
SW620-LTR

0.32
0.27
7.4

4.2
1.4
-

13.2
5.1
-
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CEA promoter alone. On the other hand, as demonstrated in the previous experiment, the
combination o f the Tcf-4 enhancer with the c-fos promoter resulted in a significant
increase o f luciferase activity in the SW620 and MDA 435 cancer cell lines, when
compared to c-fos promoter alone. Unexpectedly, in the panel o f selected normal cell
lines (CSC-1, NCM460, NCM425), the combination o f c-fos/Tcf also resulted in
appreciable increase in luciferase activities when compared to c-fos alone. The
significance o f these unexpected findings is included in the discussion section o f the
presented study. Furthermore, in order to demonstrate that the selected cell lines were
capable o f plasmid DNA uptake in transfection assays and are transcriptionally active,
dual luciferase assays were performed using pGL3-LTR reporter luciferase assay
plasmid. The pGL3-LTR plasmid containing the wild-type U3 LTR o f the Moloney
murine leukemia virus was a gift from Dr. Robert Saylors, University o f Arkansas for
Medical Sciences. It was expected that LTR would be typically activated in eukaryotic
cells and would express the luciferase gene. As a positive control, dual luciferase assays
were performed by transfecting pGL3-LTR in the same panel o f cell lines (table-2). As
shown in table-2, in all the normal cell lines (CSC-1, NCM460 and NCM 425) and
cancer cell lines (MCF7, MDA435 and SW620) pGL3-LTR showed significant luciferase
activity. These results are significant especially in reference to the normal cell lines
because a lower Tcf-4 enhancer activity could be argued as a result o f poor transfection
efficiency and inability to express the reporter DNA. Therefore in the light o f these
results it is suggested that the chosen cell lines are transfectable, transcriptionally active
and are appropriate controls for analyzing Tcf-4 activity in normal cells.
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Construction and cell line testing o f combination o f Tcf-4-enhancer with Cox-2, PSMA
and PSA promoter
The possibility o f using cyclooxygenase-2 (cox-2), prostate specific membrane antigen
(PSMA) and prostate specific antigen (PSA) promoter, in combination with the Tcf-4
enhancer, for designing o f tumor/tissue specific gene expression promoter was also
examined. Cox-2, is an enzyme, that is induced in many inflammatory reactions (237).
Many growth factors, cytokines and inflammatory agents all appear to enhance the
expression o f Cox-2 by interacting with various regulatory sequences in the promoter
region o f this gene (238). The Cox-2 promoter was selected as a candidate promoter for
gene therapy because o f the deregulation o f cox-2 expression levels commonly found in
tumors o f epithelial origin such as colon cancer (287). Studies have shown that the
minimal cox-2 promoter can be used for designing tumor specific gene expression
promoters (248). In an effort to improve the specificity and activity o f a minimal cox-2
promoter, it was combined with the Tcf-4 enhancer element. A 720-bp minimal cox-2
promoter was amplified from genomic DNA isolated from SW480 cells and cloned in
pGL3-basic vector to generate pGL3-Cox-2. Subsequently, the Tcf-4 enhancer was
cloned into the enhancer cloning site o f pGL3-Cox-2 to generate pGL3-Cox-2/Tcf.
Prostate Specific Membrane Antigen (PSMA) is a membrane glycoprotein with
folate hydrolase activity, predominantly expressed in prostate epithelial cells. Studies at
the mRNA and protein levels demonstrate that PSMA is differentially regulated in benign
and malignant prostate abnormalities as well as during tumor progression. Thus, the
promoter o f the PSMA gene may be o f use in gene therapy o f prostate cancer. However,
available data indicates that the PSMA promoter, by itself, is a weak activator o f
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transcription and may not necessarily be able to achieve therapeutically significant levels
o f gene expression. Therefore, in an effort to achieve higher tumor specific activity o f the
PSMA promoter, it was combined with Tcf-4 enhancer element. A 640-bp minimal
PSMA (cloned in pGL3-PSM A) promoter has been previously defined and was cloned in
pG L3-Tcf to generate pGL3-PSM A/Tcf as described in materials and methods.
Prostate specific antigen is a protein expressed by benign, hyperplastic and
malignant prostatic epithelium (266) and it is well established as a prostate cancer
specific biomarker. Expression o f PSA is regulated by androgens and is restricted to the
prostate (268). PSA expression is attributed to the selective activation o f the PSA
promoter in prostate. Therefore, the PSA promoter is a very attractive candidate for the
design o f a tumor/tissue specific gene expression promoter for the purpose o f gene
therapy. Indeed the PSA promoter has been shown to be a promising candidate for
constructing tumor/tissue specific gene expression promoters (271). However, it is
associated with weak transcriptional activity and in the past, the PSA promoter has been
coupled with enhancers in an effort to improve its activity. With the back ground
knowledge that wnt/p-catenin signaling pathway is activated in a significant number o f
prostate cancer cases, the idea o f combining Tcf-4 enhancer element with a minimal PSA
promoter to construct a tumor/issue specific gene expression promoter was explored.
pGL3-PSA reporter vector, containing a minimal 410 bp PSA promoter, was a gift from
Dr. Antonia Vlahou. pGL3-PSA /Tcf was generated by cloning the Tcf-4 enhancer
element into pGL3-PSA.
The promoter/enhancer activity o f the constructed luciferase reporter plasmids,
pGL3-Cox/Tcf, pG L3-PSM A /Tcf and pGL3-PSA/Tcf, was assessed by screening a panel
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F igure 2. Cell line screening o f the activities o f PSMA, PSA, COX-2 promoters.
Dual luciferase assays were performed in each cell line using plasmids containing
the test promoter with or without the Tcf-4/p-catenin enhancer element. Relative
luciferase unit ratios are shown for each o f the tested promoter. Also shown, for
comparison, are the RLU ratios obtained in dual luciferase assays performed using
plasmid containing the c-fos/Tcf recombinant promoter (pLuc-fos/Tcf. The data
shown is a representative o f multiple experiments.
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o f selected cancer and normal cell lines (figure-2) in luciferase assays. pGL3-Cox2,
pGL3-PSMA and pGL3-PSA reporter constructs were used as controls. The selected cell
lines were transfected and processed for luciferase activities as described in the materials
and methods section. The activities o f the various promoters and promoter/enhancer
combinations were assessed by the fold increase in the luciferase activities. In HCT8
(colon cancer cell line) coupling o f the Tcf-4 enhancer element with the Cox-2 promoter
resulted in a dramatic increase o f luciferase activities (see figure-2) in colon cancer cell
lines HCT8 (15 fold) and SW620 (23 fold). However, combination o f Tcf-4 with Cox-2
caused only marginal increase in luciferase activities in the colon cancer cell line
H CT116 and at the same time it resulted in a marginal decrease o f luciferase activity in
the prostate cancer cell line DU 145. The combination o f the Tcf-4 enhancer with the
PSMA or PSA promoters resulted in a marked increase (PSMA/Tcf-12 fold, PSA/Tcf-9
fold) in luciferase activities, over the control promoters, in the prostate cancer cell line
DU145 (figure-2). In addition, shown in figure-2, are the luciferase activities o f the
indicated plasmids in two normal cell lines NCM460 and CSC1, suggesting that the
combination o f the Tcf-4 enhancer with either the PSMA, PSA or Cox-2 promoters did
not result in any appreciable increase o f luciferase activity in normal cells.
As evident from the results o f the reporter assay based cell line screening o f the
Cox-2/Tcf-4 recombinant promoter, the Cox-2 promoter was found to be a promising
candidate and could be used for designing a tumor specific gene expression promoter.
Therefore the activity o f the recombinant Cox-2/Tcf-4 promoter was compared with cfos/Tcf-4 and CEA/Tcf-4 recombinant promoters in reporter luciferase assays in a panel
o f selected cell lines (figure-3). As indicated from the RLU ratios in figure-3, the activity
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Figure 3. Cell line screening o f the activities o f COX-2, c-fos and CEA promoters.
Dual luciferase assays were performed in each cell line using plasmids containing the
test promoter with or without the Tcf-4/(3-catenin enhancer element. Relative luciferase
unit ratios are shown for each o f the tested promoter. Also shown, for comparison, are
the RLU ratios obtained in dual luciferase assays performed using plasmids containing
the viral LTR promoter (pGL3-LTR ) and c-fos/Tcf recombinant promoter (pLucfos/Tcf).
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o f Cox-2/Tcf-4 promoter was comparable to or higher than the c-fos/Tcf-4 promoter in
the colon cancer cell lines(HCT8, LoVo, CMT93 and SW620). On the other hand, cox2/Tcf-4 promoter activity was found to be lower than the c-fos/Tcf-4 promoter in colon
cancer cell line H C T116 and Colo320. With the exception o f CMT93, Cox-2/Tcf
recombinant promoter activities were found to be higher than the activities o f CEA/Tcf-4
in the selected cell lines. Also, shown in figure-3 are the luciferase activities o f viral LTR
promoter (from pGL3-LTR) in different cell lines. The LTR activity was used for the
purpose o f determining comparative luciferase activities and to serve as a positive
control.
In the prostate cancer cell line DU 145, the combination o f the Tcf-4 enhancer
element with the PSMA promoter showed an appreciable increase in promoter activity
over that o f the PSMA promoter alone. In an effort to further characterize the PSMA/Tcf4 recombinant promoter, luciferase assays were performed using the pGL3-PSM A/Tcf
luciferase reporter construct in a panel o f prostate cancer (Tramp, PC3 and DU 145) and
normal (NCM460 and normal prostate) cell lines in luciferase assays (figure-4). The
PSMA/Tcf-4 recombinant promoter showed an appreciable increase in activity over the
PSMA promoter alone, in the PC3 prostate cancer cell line but did not show any
significant activity in the normal prostate cell line and normal colon cell line (NCM460).
The possibility o f using a mouse model for prostate cancer (TRAMP) was also explored
by including TRAMP cells in the panel o f cell lines assessed for PSMA/Tcf-4 activity.
However, the TRAM P cell did not show any appreciable PSMA/Tcf-4 recombinant
promoter activity as assessed from the RLU ratios (figure-4).
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Figure 4. Cell line screening o f the activities o f the PSMA promoter. Selected
cell lines were co-transfected with pRL-TK. and reporter plasmids containing the
PSMA promoter with or without the Tcf-4 enhancer Tcf-4/p-catenin enhancer
element. Transfected cells were processed 48 hours later using a dual luciferase
assay kit and relative luciferase units were determined. RLU ratios from each
transfection are shown in the figure.
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Evaluation o f NCM460 as a negative control
NCM460 is cell line derived from normal colon mucosa and has been extensively
used in the presented study as a negative control. The rationale behind using NCM460 as
a negative control was that being derived from non-cancerous tissue, mutations in genes
responsible for regulating p-catenin levels are unlikely to be found and it is expected that
a constitutively active P-catenin will not be found in the nucleus. It has been suggested
that in a normal cell P-catenin plays a role in cell to cell junctions and is found as part o f
multi-protein complex at the inner surface o f cell membrane, which includes proteins like
E-cadherin (288). Therefore, to evaluate the cellular localization o f P-catenin in this cell
line immunoflorescence studies were performed by staining for p-catenin as described in
materials and methods. As expected in a normal cell, beta-catenin was found to be
located on the inner side o f the cell membrane and no nuclear staining was observed
(figure-5). To assess whether introduction o f a constitutively active P-catenin (13) can
allow for Tcf-4/p-catenin enhancer mediated transcriptional activity in the NCM460
cells, luciferase reporter assays were performed in the presence o f plasmid expressing
constitutively active P-catenin. NCM460 cell were co-transfected with pLuc-fos/Tcf and
P-catenin expressing plasmid and after 48 hours cells were processed for luciferase
activity. A 100 fold increase in luciferase activity o f pLuc-fos/Tcf was observed in
presence o f constitutively active beta-catenin indicating these cells were capable o f Tcf4/p-catenin transcriptional activity.
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F igure 5. Validation o f NCM-460 colon cells as a negative control. To visualize
the localization o f P-catenin immunoflorescence staining for P-catenin was
performed in NCM460 cells. Cells were stained with a prim ary anti P-catenin
antibody followed by incubation with a secondary FITC labeled anti mouse IgG
antibody.
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Aim #2. Evaluation of the ability of Tcf-enhancer/Promoter combinations to
selectively express a therapeutic gene in tumor cells
Results presented under aim-1 strongly suggested that specific combinations o f
the Tcf-4 enhancer with minimal promoters could result in tumor/tissue specific gene
expression. Such promoter/enhancer combinations are potential candidates for use in
directing therapeutic gene expression. However, these findings are based on luciferase
reporter assays suggesting the potential o f these recombinant promoters in cancer gene
therapy. To further evaluate the tumor specific gene expression efficacy o f these
recombinant promoters, therapeutic gene expression vectors were generated
incorporating the therapeutic gene encoding the Herpes Simplex Virus Thymidine Kinase
expressed from Tcf-4-enhancer/promoter combinations. For experiments presented in
this section the following recombinant plasmid DNA vectors were constructed as
described in material and methods.
a)

pc-fos/Tcf-4-HSV-TK: Consists o f the HSV-TK gene expressed from a
recombinant Tcf-4 enhancer/c-fos promoter combination.

b)

pSc-fos/Tcf-4-HSV-TK: Derived from pc-fos/Tcf-4-HSV-TK in which a
significant portion o f the c-fos promoter was deleted.

c)

pPSMA/Tcf-4-HSV-TK: Consists o f the HSV-TK gene expressed from a
recombinant Tcf-4 enhancer/PSM A promoter combination.

d)

pCDNA-HSV-TK: Negative control plasmid consisting o f only the HSV-TK
gene without any promoter.
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Characterization o f HSV-TK expression constructs
HSV-TK expression analysis
The pc-fos/Tcf-4-HSV-TK was constructed to test the ability o f Tcf-4/p-catenin
enhancer coupled with the c-fos promoter to drive the expression o f HSV-TK selectively
in tumor cells. The new plasmid was used to transiently transfect colon cancer cell lines
(HCT-8, SW480 and SW620) and normal colon cells (NMC-460). After transfection, 48
hours later, whole cell lysates were made from each cell line and were subjected to SDSPAGE, Western blot analysis using anti-HSV-TK antibodies. As shown in figure-6,
transient transfection o f pc-fos/Tcf-4-HSVTK resulted in significant amounts o f HSV-TK in the tested cancer cells lines (HCT-8,
SW620, and SW480). On the contrary, under similar conditions, HSV-TK expression
was not detected in the normal cell (NCM460). Also shown in figure-6 are the results
from similar transient transfection assays using the promoter less negative control
plasmid pCDNA-HSV-TK where no detectable expression was observed in any o f the
tested cell lines. In addition, the ability o f c-fos/Tcf-4 recombinant promoter to express
HSV-TK in breast cancer cell lines was tested. As mentioned earlier in the text, this was
done because evidence o f aberrant activation o f wnt signaling pathway in breast cancer
has been documented. Two breast cancer cell lines were chosen; MDA435 and MCF7.
As presented in figure 7, transient transfection o f pc-fosTcf-4-H SV -TK resulted in
significant expression o f HSV-TK in MCF7 and MDA435. As a control, pCDNA-HSVTK was transiently transfected in both breast cancer cell lines and assayed for expression
o f HSV-TK. As seen in figure 7, no expression, from pCDNA-HSV-TK, was detected in
MCF7 cells; however trace amounts o f HSV-TK were detected in the MDA435. For
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F igure 6. HSV-TK Western blots to assess the gene expression ability o f c-fos/Tcf
recombinant promoter in normal and tumor colon lines. Selected cell lines were
transiently transfected with plasmids encoding HSV-TK gene driven by: cfos/Tcf
(lane 4), truncated c-fos/Tcf (lane 3) or without any promoter (lane 2). W hole cell
lysates were prepared after 48 hours o f transfectionand were subjected to Western
blot analysis using an anti HSV-TK antibody. Lane 1 is an untransfected negative
control.
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Figure 7. HSV-TK Western blot to assess the gene expression ability o f cfos/Tcf recombinant promoter in breast tumor cell lines. Selected cell lines were
transiently transfected with plasmids encoding HSV-TK gene driven by:
cfos/Tcf (lane 3) or without any promoter (lane 2). W hole cell lysates were
prepared after 48 hours o f transfectionand were subjected to Western blot
analysis using an anti HSV-TK antibody. Lane 1 is a untransfected negative
control. Bands corresponding to HSV-TK are labeled.
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comparison o f HSV-TK expression, results from transient transfection o f HSV-TK
expression constructs in NCM460 and SW620 cell lines are also shown in figure 7. These
results demonstrate that c-fos/Tcf-4 recombinant promoter can selectively express the
therapeutic gene, HSV-TK, in examined tum or cell lines. However, selective expression
o f HSV-TK does not necessarily mean that a functional HSV-TK gene product is
expressed which would facilitate tum or cell killing upon treatment with ganciclovir. To
determine whether the expressed HSV-TK was functional GCV metabolic labeling and
sensitivity assays were performed.
GCV Metabolic Labeling and Sensitivity in pc-fos/Tcf-4-HSV-TK transfected cells
To determine whether the expressed HSV-TK was functional, identical
transfection protocols were performed except that at 24 hours post-transfection, 1 pM
[3H] GCV was added for 12 hours. Cells were isolated, counted and then extracted with
70% methanol. The soluble supernatant and insoluble DNA pellet were quantitated for
levels o f [3H] GCV incorporation by scintillation counting. To separate GCV from
phosphorylated GCV metabolites in the methanol soluble fractions, thin layer
chromatography, using PEI-cellulose plates developed in 0.8 M LiCl, was performed. As
shown in Figure 8, only cells transfected with the pc-fos/Tcf-4-HSV-TK construct had
significant levels o f soluble [3H] GCV-phosphometabolites. Again, only minimal
metabolism o f [3H] GCV was found for the NCM460 control cells. Analysis o f [3H] GCV
levels in the methanol insoluble pellet, indicative o f GCV incorporation into cellular
DNA, was also performed. As presented in Figure 9, the levels o f [3H] GCV
incorporated into the DNA were highest in the pc-fos/Tcf-4-HSV-TK transfected tumor
cells, but low in the NCM460 cells. Similar, GCV metabolic labeling, experiments were
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Figure 8. Assessment o f functionality o f HSV-TK expressed by c-fos/Tcf
recombinant promoter in colon cell lines. Expressed HSV-TKwas evaluated for
its ability to phosphorylate GCV. Selected cell lines were transiently transfected
with plasmids encoding HSV-TK gene driven by: cfos/Tcf (pc-fos/Tcf-4-HSVTK), truncated c-fos/Tcf (pSc-fos/Tcf-4-HSV-TK) or without any promoter
(pCDNA-HSV-TK). Following 36 hours after transfection radio labeled GCV
was added to the cell. 6-8 hours later, GCV metabolites were extracted and
counted for radioactivity. Shown are the estimated amounts o f soluble GCV
metabolites for each cell line.
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Figure 9. Assessment o f functionality o f HSV-TK expressed by c-fos/Tcf
recombinant promoter in colon cell lines. DNA incorporation o f radio labeled
GCV was used as an index to asses the functionality o f expressed HSV-TK.
Selected cell lines were transiently transfected with plasmids encoding HSV-TK
gene driven by: cfos/Tcf (pc-fos/Tcf-4-HSV-TK), truncated c-fos/Tcf (pScfos/Tcf-4-HSV-TK) or without any promoter (pCDNA-HSV-TK). Following 36
hours after transfection radio labeled GCV was added to the cell. 6-8 hours later,
insoluble GCV metabolites were separated from soluble metabolites followed by
scintillation counting. Shown are estimated amounts o f incorporated GCV
metabolites for each cell line.
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performed in breast cancer cells line; MCF7 and MDA435, and a higher metabolism o f
[3H] GCV was detected in pc-fos/Tcf-4-HSV-TK transfected cells (figure 10). To
examine whether GCV metabolism resulted in increased tumor cell killing, SW480,
MDA435 and NCM460 cells were transfected with pCDNA-HSV-TK or pc-fos/Tcf-4HSV-TK. After 24 hours, half o f the samples received 10 pM GCV for an additional for
48 hrs. Viable cell numbers were determined using trypan blue dye exclusion and
automated cell counting. As shown in Figure 11, only in the pc-fos/Tcf-4-HSV-TK
transfected SW480 (figure 1 la) and MDA-435 (figure 1 lc) cells did GCV addition have
any significant toxic effect, while no effect was observed in the similarly treated normal
NCM460 (figure 1 lb) and C SC -1(figure 1 Id) cells. As a control, the promoterless
pCDNA-HSV-TK vector was transfected in SW480 (figure 1 la), MDA435 (figure 1 lc),
NCM460 (figure 1 lb) and CSC-1 cells (figure 1 Id) in identical transfection experiments.
Results presented in figure 11 show that pCDNA-HSV-TK construct did not result in any
significant toxicity in the chosen cell lines. The cumulative results presented in Figures 811 indicate functional and tumor cell specific expression o f HSV-TK delivered via the
pc-fos/Tcf-4-HSV-TK plasmids. The results, so far, strongly support the proof o f
principle that a minimal oncogenic promoter can be successfully combined with Tcf-4/p*
catenin enhancer to achieve tumor specific gene expression. With these encouraging
results further experiments were performed using constructs in which the PSMA
promoter was coupled with Tcf-4/p-catenin enhancer (pPSM A/Tcf-4-HSV-TK) to
express HSV-TK.
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Figure 10. Assessment o f functionality o f HSV-TK expressed by c-fos/Tcf
recombinant promoter. Expressed HSV-TK was evaluated for its ability to
phosphorylate GCV in MDA435 and MCF7 breast cancer cell lines. Selected
cell lines were transiently transfected with plasmids in which the HSV-TK gene
was driven by cfos/Tcf (pc-fos/Tcf-4-HSV-TK). pCDNA-HSV-TK is used as .
Following 36 hours after transfection radio labeled GCV was added to the cell.
6-8 hours later, GCV metabolites were extracted and counted for radioactivity.
Shown are the estimated amounts o f soluble GCV metabolites for each cell
line.Also shown, for comparison, soluble GCV amounts from the normal cell
line NCM 460 and the colon cancer cell line SW620.
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Figure 11 (a-b-c-d). GCV sensitivity in pc-fos/Tcf-4-HSV-TK transfected
cells. Selected cell lines were transiently transfected with either pcfos/Tcf-4-HSV-TK or pCDNA-HSV-TK (control) and treated with GCV
24 hours after transfection. Number o f live cells was assessed 72 hours
later. Cell numbers, determined as percentage o f control, are shown for
SW 480 (a), NCM460 (b), MDA435 (c) and CSC1 (d). Figure 11 (c) is
shown on page 105 and 11 (d) on page 106.
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GCV Sensitivity in pPSMA/Tcf-4-HSV-TK. transfected cells
In a significant number o f prostate tumor cases aberrant activation o f wnt
signaling pathway is documented (205). In addition, in prostate carcinoma PSMA is
frequently found to be overexpressed, which is attributed to the increase in transcription
activity o f the PSMA promoter (289). Therefore the ability o f PSMA/Tcf-4 recombinant
promoter to direct tum or specific gene expression in prostate tum or cells was explored.
Two prostate cancer cell lines DU 145 and PC3 were transiently transfected with
pPSM A/Tcf-4-HSV-TK and pCDNA-HSV-TK. After 24 hours, h alf o f the samples
received 10 pM GCV for an additional for 48 hrs. Viable cell numbers were determined
using trypan blue dye exclusion and automated cell counting. As shown in figure 12,
pPSM A/Tcf-4-HSV-TK transfection resulted in significant cellular toxicity upon addition
o f GCV in PC3 cells (figure 12b). On the other hand, under identical conditions
pPSM A/Tcf-4-HSV-TK transfection did not cause any noticeable GCV toxicity in
normal NCM460 cells (figure 12a). Simultaneously, there was no GCV mediated cellular
toxicity observed in NCM460 and PC3 cells when transfected with control promoter less
vector pCDNA-HSV-TK. However, at 10 pm GCV concentration, in DU 145 prostate
cancer cells the combination o f GCV with transfection o f pPSM A/Tcf-4-HSV-TK did
not cause any increased toxicity as compared with the control pCDNA-HSV-TK.
transcfection (figure 12c). This inconsistency in the results could be due to the
differential metabolism o f GCV by DU 145 cells. Therefore, the experiment described in
figure 12c was repeated and this time transiently transfected cells were treated with an
increased dose o f 25 pm GCV. The data presented in figure 12d clearly exihibit that
DU 145 prostate cancer cells show significant cell killing when transiently transfected by
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Figure 12(a-b-c-d). GCV sensitivity in pPSM A/Tcf-4-HSV-TK transfected
prostate cancer cells. Selected cell lines were transiently transfected with
either pPSM A/Tcf-4-HSV-TK or pCDNA-HSV-TK (control) and treated
with GCV 24 hours after transfection. Number o f live cells was assessed 72
hours later. Cell numbers, determined as percentage o f control, are shown
for NCM460 (a), PC3 (b) (page 109) and DU145 (c-d) (pag el0 9 -l 10). As a
control, GCV sensitivity caused by transient pPSMA/Tcf-4-HSV-TK
transfections in normal NCM460 was also determined (figure a). pc-fos/Tcf4-HSV-TK mediated GCV sensitivity in DU 145 cells was compared to
GCV sensitivity caused by pPSMA/Tcf-4-HSV-TK. and is shown in
figure d. For b, c and d, see pages 109-110.
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pPSM A/Tcf-4-HSV-TK and followed by 25 pm GCV treatment. For comparison, in
figure 12D, pc-fos/Tcf-4-HSV-TK/GCV mediated DU 145 cell killing is also shown.
Further, having successfully tested the ability o f pPSMA/Tcf-4-HSV-TK vector to kill
human prostate cancer cells, the PSMA/Tcf-4 vector was assessed for its toxicity in a
mouse prostate cancer cell line (Tramp). The primary objective behind testing the HSVTK expression construct in Tramp cells was to exploit the already established Tramp
mouse model for certain in vivo gene therapy experiments. Tramps cells were transiently
transfected with pPSM A/Tcf-4-HSV-TK, pCDNA-HSV-TK or with blank vector. After
24 hours, half o f the samples received 10 pM GCV for an additional 48 hrs followed by
10 pM o f GCV treatment 24 hours later. Viable cell numbers were determined using
trypan blue dye exclusion and automated cell counting. As shown in figure 13 treatment
o f Tramp cell with pPSM A/Tcf-4-HSV-TK/GCV caused approximately 25% cell death
as compared to the control pCDNA-HSV-TK/GCV treated cells. The marginal toxicity o f
pPSM A/Tcf-4-HSV-TK/GCV system in Tramp cells could be attributed to lower
transfection efficiency o f TRAMP cells and /or to the lower Tcf-4 transcriptional activity
in these cells.
Cumulatively, the results presented in figure 12 suggest that the pPSMA/Tcf-4HSV-TK construct can successfully express a functional HSV-TK gene in specific
prostate cancer cells. In addition, the pPSMA/Tcf-4-HSV-TK/GCV system can result in
significant cell death in prostate cancer cells and shows little or insignificant amount o f
toxicity in normal NCM460 cells.
In summary, the presented results so far are highly suggestive that a recombinant
oncogenic promoter/Tcf-4 enhancer combination can successfully express a functional
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F igure 13. GCV sensitivity in pPSMA/Tcf-4-HSV-TK. transfected Tramp cells.
Tramp cells were transiently transfected with either pPSM A/Tcf-4-HSV-TK or
pCDNA-HSV-TK (control) and treated with GCV 24 hours after transfection.
Numbers o f live cells were assessed 72 hours later. Cell numbers, determined as
percentage o f control, are shown.
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therapeutic gene specifically in tumor cells. In transient transfection experiments, in
combination with GCV the recombinant promoter system shows the ability to selectively
kill tumor cells. However, therapeutic gene facilitated tumor cell killing is severely
compromised by the delivery o f the therapeutic gene expression vector inside the tumor
cells. In other words, effective tumor cell killing cannot be achieved unless the
therapeutic vector is not successfully delivered inside the target tum or cell. Experiments
presented in aim No. 2 have used lipid based transient transfection methods to deliver the
therapeutic vector inside the target cells. Such delivery methods are effective in
demonstrating the proof o f principle under in vitro conditions. However, such
transfection methods do not successfully deliver the DNA vector, in most cases, to
majority o f target cells. Given that one o f the primary objectives in cancer gene therapy
is to target as many as tum or cells, we next looked to optimize the delivery o f the
therapeutic vector to the tum or cells.

Aim #3. Optimization of delivery of the therapeutic gene/promoter-enhancer
combination to the tumor
To improve the delivery o f the therapeutic gene/promoter-enhancer combination
to tumor tissue/cells, recombinant adenoviruses were constructed. As mentioned in the
introduction chapter, there are several advantages o f using adenoviruses for delivering the
therapeutic gene expression constructs. These advantages include: the ability to produce
high titer (1 0 12-1013 virus particles per ml) o f recombinant viruses; postmitotic cells can
be effectively infected including a wide variety o f cell types and the ability to
accommodate up to -8 kb o f foreign DNA, including expression cassettes or other
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regulatory sequences. Further, the current generation o f engineered adenoviruses are
considered relatively safe for the purpose o f gene therapy as they do not integrate into the
genome and are rendered replication incompetent by deletion o f certain essential viral
genes.
Using a pAdeasy recombinant adenoviruses construction kit (Qbiogene) the
following adenoviruses incorporating the specified DNA elements were generated as
described in materials and methods section.
A d-c-fos/Tcf-4-HS V-TK
The c-fos/Tcf-4 promoter-enhancer combination and the HSV-TK gene, was
excised out o f the pc-fos/Tcf-4-HSV-TK plasmid vector. The excised DNA fragment was
incorporated into a promoterless pShuttle vector which was subsequently used for
generating recombinant Ad-c-fos/Tcf-4-HSV-TK adenoviral particles. The hall mark o f
Ad-c-fos/Tcf-4-HSV-TK vector is that it was designed to express HSV-TK gene from a
recombinant c-fos/Tcf-4 promoter.
Ad-CM V-HSV-TK
The HSV-TK gene was incorporated into a pShuttle-CM V vector which was
subsequently used to generate Ad-CM V-HSV-TK viral particles. Ad-CM V-HSV-TK was
used as positive control adenoviral vector because the presence o f a CMV promoter
allowed it to express HSV-TK ubiquitously in tested cell lines.
The adenoviral particles were amplified and quantitated as described in materials
and methods section. To ensure that the generated adenoviral particles were expressing
HSV-TK, colon cancer cells (SW 480, SW620 and NCM460) were infected with Ad-cfos/Tcf-4-HSV-TK and Ad-CMV-HSV-TK and 48 hours later whole cell lysates were
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made from infected and uninfected cells. Prepared lysates were subjected to SDS-PAGE
and Western blot analysis. Blots were probed for HSV-TK with a HSV-TK antibody.
Figure 14 shows the result from Western blot analysis done on whole cell lysates from
HSV-TK expressing adenoviral vectors. As shown in figure 14, Ad-CMV-HSV-TK
expressed HSV-TK in all the chosen cell lines including the normal NCM460 colon cells.
In contrast, Ad-c-fos/Tcf-4-HSV-TK mediated HSV-TK expression was observed only in
SW480 and SW620 colon cancer cell lines, and no detectable expression o f HSV-TK was
seen in NCM460 cells. It can be concluded from the results that Ad-CMV-HSV-TK has
the ability to express HSV-TK in both normal and cancer cell lines. This is because o f the
presence o f strong CMV promoter which is expected to be active in any given eukaryotic
cell environment (290). On the other hand, Ad-c-foc/Tcf-4-HSV-TK vector expresses the
therapeutic gene only in cancer cell lines and not in the NCM60 normal cells.
Having confirmed that the HSV-TK expressing adenoviral vectors can
successfully express the therapeutic gene in chosen cells, the adenoviral vector infected
cells were tested for their GCV sensitivity. Such sensitivity experiments are crucial for
insights into the functional aspects o f the adenovirally delivered and expressed HSV-TK
gene. Effective tum or cell killing is entirely dependent upon the ability o f the expressed
HSV-TK gene to convert the prodrug GCV into toxic metabolites. For the GCV
sensitivity assay, SW480, SW620 and NCM cells were infected with Ad-CMV-HSV-TK
and Ad-c-foc/Tcf-4-HSV-TK adenoviral particles and 24 hours later 0.1 pm and 10.0 pm
GCV was added to the infected cells. Adenovirally infected cells without the addition o f
GCV were assessed as controls. The cells were allowed to grow for the next 48 hours.
Viable cell numbers were determined using trypan blue dye exclusion and automated cell
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Figure 14. Recombinant adenoviral vector infections: HSV-TK
W estern Blot. Normal (NCM460) and tumor colon cells (SW 480 and
SW620) were infected with either Ad-CMV-HSV-TK or Ad-cfos/Tcf-4-HSV-TK. Each cell line was infected with same MOI for
both the recombinant adenoviral vectors. W hole cell lysates were
prepared 48-72 hours later and were subjected to SDS-PAGE/W estem
blot analysis using an anti HSV-TK antibody. Bands Corresponding to
HSV-TK are labeled.
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counting. All o f the Ad-CMV-HSV-TK infected cell lines showed a significant GCV
dose dependent cellular toxicity. However, o f the cell lines infected with Ad-c-fos/Tcf-4HSV-TK, only SW620 and SW480 colon cancer cells showed significant GCV dose
dependent cellular toxicity, whereas normal NCM460 cells showed a minimal GCV
sensitivity (figure 15). Based on the results presented in figure 15 it can be concluded
that the adenoviral vectors, Ad-CMV-HSV-TK and Ad-c-fos/Tcf-4-HSV-TK are capable
o f delivering and expressing a functional HSV-TK in specific cancer cell lines and
exihibit significant cell death upon addition o f GCV. In addition, Ad-c-foc/Tcf-4-HSVTK infection does not result in extensive GCV mediated cellular toxicity in the normal
NCM460 cells.
So far in this study, it has been shown that Tcf-4 enhancer element can be
successfully combined with a minimal oncogenic promoter to generate a tum or specific
gene expression promoter. In aim 1 we showed by reporter gene assays that’s these
promoters can direct tum or specific gene expression. Furthermore, we demonstrated the
ability o f the designed recombinant promoter to specifically express a therapeutic gene,
under in vitro conditions, in tum or cells. In addition studies in specific aim 2 show that
the HSV-TK therapeutic gene expressed in the tum or cells was functional and capable o f
directing tum or cell killing. Finally, in specific aim 3 we constructed recombinant
adenoviruses engineered to deliver the therapeutic gene expression cassette to tumor
cells. The data presented prove that the adenoviral viral vectors successfully express the
chosen therapeutic gene (HSV-TK) and cause significant tumor cell death upon addition
o f the prodrug (GCV). Together, these studies demonstrate that we can generate an
adenoviral vector capable o f directing tumor cell specific killing.
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F igure 15. GCV sensitivity in infected with HSV-TK expressing adenoviral
vectors. Normal (NCM460) and tum or colon cells (SW 480 and SW620) were
infected with either Ad-CM V-HSV-TK or Ad-c-fosATcf-4-HSV-TK. Each cell
line was infected with same MOI for both the recombinant adenoviral vectors. 24
hours after infection cells were treated with GCV and 72 hours later viable cell
number was determined. Numbers o f live cells are shown as percentage o f
control. SW620 and SW480 are colon cancer cell lines where as NCM460 is a
normal colon cell line.
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Aim #4. Identification of strategies for modulating Tcf-4/P-catenin responsive
promoters
Recombinant adenoviruses would help in improved targeting o f the tumor cells
because most o f the tum or cells have up-regulated CAR receptors. To continue
identifying novel strategies which would allow better targeting and control o f therapeutic
gene expression, the idea o f regulating the activity o f the recombinant Tcf-4
enhancer/promoter combination was also explored. The significance o f this approach lies
in the fact that regulating the promoter activity would allow control over the amount o f
therapeutic gene expressed inside the target cell which might be necessary under clinical
situations. For instance, it might be required to turn o ff the expression o f the therapeutic
if accidentally expressed ectopically. On the other hand, a boost in expression o f the
therapeutic gene might provide for increased tum or cell death. In an effort to identify
genetic and chemical modulators for regulating the activity o f recombinant Tcf-4
enhancer/promoters, several candidate compounds were screened. Short chain fatty acids,
like butyrate, have been previously shown to influence the normal homeostasis o f colon
epithelial cells (224). In addition, butyrate has also been shown to influence the wnt/pcatenin signaling pathway (223). In order to test the ability o f butyrate to modulate the
activity o f our recombinant promoters, reporter luciferase assays in the presence or
absence o f sodium butyrate were performed.

Either pLuc-fos/Tcf or pLuc-fos/fct (T cf

enhancer sites are scrambled, a negative control reporter vector) was co-transfected with
pRL-TK (internal control) in selected cell lines. 24 hours post-transfection 1.4 mM
sodium butyrate was added to the cells. 48 hours post transfection cell lysates were
prepared and relative luciferase ratio (RLU) readings were recorded as previously
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described in the text. The data generated from this experiment is presented in figure 16.
The relative luciferase ratios as shown in figure 16 did not presented a clear picture.
Sodium butyrate treatment, in general, did not significantly appear to affect the relative
luciferase units ( RLU-firefly luciferase reporter gene activity divided by the internal
control renilla luciferase activity) in cases when cell lines were transfected with the
negative control plasmid, pLuc-fos/fct. Butyrate seemed to have a variable effect on
expression o f the luciferase gene in cell lines transfected with pLuc-fos/Tcf. For example,
in pLuc-fos/Tcf transfected HCT8 cells, butyrate significantly increases luciferase
expression, as assessed from increased relative light units. In contrast, under similar
conditions, Lovo colon cancer cell line showed only a marginal increase in luciferase
expression. Further, the presence o f butyrate in pLuc-fos/Tcf transfected Colo320,
SW480 and SW620, decreased luciferase expression. However, it should be noted that,
by nature, butyrate is also known as a histone deacetylase inhibitor and it’s generally
known to increase gene expression by opening up the chromatin structure (291).
Therefore relative luciferase units shown in the figure 16 should be interpreted in the
light o f the fact butyrate is also expected to increase transcription o f the Renilla luciferase
gene (pRL-TK, internal control) besides the test firefly luciferase reporter (pLuc-fos/Tcf).
Indeed a look at the firefly luciferase numbers alone revealed that butyrate did enhanced
the expression o f luciferase from pLuc-fos/Tcf in colon cancer cell lines (Lovo,
Colo320, HCT8, SW480 and SW620) (figure 17). Importantly, butyrate did not seem to
affect the luciferase gene expression from pLuc-fos/Tcf or pLuc-fos/fct when transfected
in NCM460 (normal cells). These results are very preliminary but suggest that specific
compounds may be identified that can affect Tcf-4/p-catenin mediated transactivation o f
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Figure 16. Effect o f 1.4 mM Butyrate (RLU Firefly:Renilla) on c-fos promoter
activity with and with out Tcf-4 enhancer element. Dual Luciferase assays were
performed to asses the effect o f butyrate on recombinat c-fos/Tcf-4 promoter
activity. Selected cell lines were co-transfected with pRL-TK and with either
pLuc-fos/Tcf or pLuc-fos/fct. 24 hours later cell were treated with 1.4 mM
sodium butyrate and 48 hours later, cells were processed for dual luciferase
activities. Shown are c-fos/Tcf-4 and c-fos/fct promoter activities, in different cell
lines, in terms o f relative luciferase units.
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F igure 17. Effect o f 1.4 mM Butyrate on c-fos promoter activity with and with out
Tcf-4 enhancer element. The data is derived from experiment performed in figure
16. Effect o f butyrate on the activity o f c-fos/Tcf-4 and c-fos/fct promoter, in
selected cell lines, is shown as uncorrected Firefly Luc values in absence and
presence o f butyrate.
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gene expression. From the data it can be concluded that under the conditions tested
butyrate increases the levels o f luciferase gene expression and this effect may not be
specific to m odulating the transcriptional activity o f the recombinant TCf-4
enhancer/promoter combination. In addition to butyrate, other chemicals which were
previously shown to be associated with colon cancer prevention/treatment such as non
steroidal anti-inflammatory drugs; Indomethacin and cycloxygenase-2 inhibitors;
Celecoxib (292), were also tested. Colo320 and SW620 cells were transiently transfected
with pc-fos/Tcf-4-HSV-TK and 24 hours later treated with appropriate concentrations o f
sodium butyrate, Indomethacin and Celecoxib (figure 18, lane 2-4). W hole cell lysates
were prepared 48 hours post transfection and were subjected to SDS-PAGE and western
blot analysis. The blot was probed with antibodies raised against HSV-TK. Butyrate
caused significant increase in HSV-TK expression levels as compared to untreated
control in Colo320 cells and did not seem to have any effect in SW620 cells (figure 18
lane 2). In contrast, treatment with Indomethacin and Celecoxib appeared to result in
lowering o f HSV-TK gene expression (figure 18, lanes 3, 4). The results shown in figure
17 are not very conclusive; however they do suggest that transcriptional activity o f the
recombinant Tcf-4enhancer/promoter combination can be modulated by chemical means.
Additional experiments, including screening o f more candidate compounds, are needed to
confirm these findings.
The presence o f a constitutively active P-catenin inside a cell is one o f the
primary requirements for the transcriptional activation o f the proposed recombinant Tcfenhancer/promoter elements. Therefore it can reasonably argued that increasing the
expression o f the constitutively active P-catenin may result in enhancement o f the
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Figure 18. Effect o f various modulating agents on expression o f HSV-TK driven
by c-fos/Tcf-4 promoter. HSV-TK Western blot. Colon cancer cells (colo320,
SW480) were transiently transfected with pc-fos/Tcf-4-HSV-TK (lanes 1-4) and
treated with butyrate (lane 2), indomethacin (lane 3) and celecoxib (lane 4). To
asses the effect o f overexpression o f constitutively active P-catenin on c-fos/Tcf-4
promoter driven HSV-TK expression, pc-fos/Tcf-4-HSV-TK was co-transfected
with a plasmid expressing for mutated form o f P-catenin (lane 5). Whole cell
lysates were prepared 48 hours post transfection and were subjected to SDSPAGE/W estem blot analysis. Bands corresponding to HSV-TK are shown.
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recombinant Tcf-enhancer/promoter element driven therapeutic gene expression. This
idea was explored by co-transfecting Colo320 and SW620 cells with pc-fos/Tcf-4-HSVTK and with a plasmid encoding for a constitutively active P-catenin (A-45 P-catenin).
Whole cell lysates were prepared 48 hours post transcription and subjected to Western
blot analysis using an antibody against HSV-TK. Indeed, A-45 P-catenin co-transfection
resulted in increased gene expression o f HSV-TK in SW620 and Colo320 (figure 17, lane
5). However, this enhancement o f c-fos/Tcf-4 driven HSV-TK expression mediated by A45 P-catenin may be a general response o f A-45 p-catenin protein as a known
transcription factor and may not be specific for c-fos/tcf-4 promoter. Additional
experiments are required to explore the nature o f increase o f gene expression caused by
A-45 P-catenin. However these data indicate that the activity o f the recombinant tcf-4
enhancer/promoter elements can be modulated by chemical and genetic means.
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CHAPTER V
DISCUSSION AND CONCLUSION

One o f the most challenging aspects in cancer therapy is how to exclusively target
cancer cells and spare the normal cells? Conventional therapies, owing to their lack o f
specificity in targeting tum or cells, frequently cause serious side effects. Because o f this
narrow therapeutic window, most metastatic and local malignancies becom e refractory to
treatment. In contrast, gene therapy for cancer has the ability to distinguish between
normal and tum or cells. This very aspect o f gene therapy gives it an edge over
conventional cancer therapies as it has the ability to minimize normal cell toxicity by
selectively attacking the tum or cells. However, this aspect o f gene therapy is very
challenging and needs innovative strategies for specific targeting to the site o f the tumor.
One o f the ways this can be achieved is by limiting the expression o f the therapeutic gene
to the tumor cells and sparing the normal cells from the toxic effect o f the therapeutic
gene. This strategic approach o f limiting the expression o f the therapeutic gene to the
tumor cells is known as transcriptional targeting and has been described in detail in the
Introduction. In general, successful expression o f any gene is dependent upon activation
o f specialized DNA sequences known as promoters. Promoters provide the binding sites
for transcription factor/proteins which are required for the successful initiation and
completion o f gene transcription. Activation o f a promoter is a function o f the availability
o f the transcription factor/proteins, inside the target cell, which bind to specific sites in
the promoter DNA to form a transcription activation complex. In continuation, a
universally active promoter implies that the promoter DNA sequence is active in a variety
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o f cells owing to its ability to bind constituitively expressed transcription factor/proteins
that form a transcription initiation complex.
Typically in cancer gene therapy, a toxin gene is coupled with a promoter
incorporated in a gene expression cassette which is delivered to the target tumor cells.
Therefore, activity o f the promoter in the target tissue will govern the expression o f the
therapeutic gene. A universally active promoter is not a worthy candidate for such
therapy protocols because its activity in normal cells would result in expression o f the
toxin therapeutic gene leading to widespread normal cell toxicities. Hence, an ideal
situation would be to have a gene expression promoter which is exclusively activated in
tumor cells. These promoter DNA elements are known as tumor specific gene expression
promoters. As explained in the Introduction, minimal promoters o f various oncogenes,
such as Cyclooxygenase-2, c-myc, c-fos, cyclinD etc, when combined with an enhancer
DNA sequence are ideal candidates for being used in designing o f tum or specific gene
expression promoters. Enhancer elements are naturally found to be part o f several genes
differentially regulated in various types o f cancers. As mentioned earlier in this text,
aberrant activation o f growth promoting signal transduction pathways results in
differential activation o f genes in cancer. The promoters o f these differentially
transactivated genes usually have specific DNA elements (for example enhancer
elements) binding to an array o f proteins in response to a signal transduced by the
activated signaling pathway. Such enhancer elements can be innovatively used in cancer
gene therapy to control the expression o f therapeutic genes.
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Aberrant activation o f the W nt-signaling pathway has been associated with an increasing
number o f neoplasms. Deregulation o f this pathway disrupts normal proteosome
mediated degradation o f P-catenin, resulting in a nuclear localization. P-catenin shows
nuclear localization in a majority o f colorectal carcinomas and has been associated with a
significant proportion o f prostate cancers, melanomas, ovarian cancers, glioblastomas,
and breast cancers (281-285, 293). Nuclear P-catenin pairs with members o f the Lef/Tcf
family o f proteins and trans-activate several cancer promoting genes (19, 20, 22, 24).
This occurs by binding o f the constitutively active P-catenin/Tcf-4 complex to the Tcf-4
enhancer regions present in the promoter regions o f these target genes. In other words
the presence o f a Tcf-4 enhancer contributes to the expression o f these cancer promoting
genes by its ability to bind to the transcriptionally active P-catenin/Tcf-4 complex
resulting in transcriptional activation o f their promoters. Given the fact that the canonical
Wnt signaling pathway is constitutively activated in a large number o f adenocarcinomas
and not in normal cells, the Tcf-4 enhancer element could be a very valuable tool for
design o f tum or specific gene expression promoters.

Specific Aim 1
In this Specific Aim, the effectiveness o f the Tcf-4 transcriptional enhancer
element was evaluated for its ability to act as a tum or specific regulator o f therapeutic
gene expression in a panel o f human tumor and normal colon cell lines. These
experiments were geared towards establishing the proof o f principle that the Tcf-4/p*
catenin enhancer could be used for regulation o f gene transcription in tum or cells. To
achieve the objectives o f this aim, extensive cell line screenings were done using dual
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luciferase assays. The Tcf-4 enhancer element was cloned with a panel o f chosen
minimal promoters from various oncogenes; c-fos, CEA, Cox-2, PSMA and PSA. CEA
(280), Cox-2 (252), PSMA (294) PSA (271, 295) promoters have been previously used
for constructing tum or specific gene expression promoters. On one hand, these candidate
gene therapy promoters have shown vast potential but, in general, they are very weak
activators o f gene transcription. This is especially true for PSMA, PSA and PSMA
promoters, and in previous studies this issue has been addressed by coupling these
promoters with specific enhancer elements to increase the transcriptional activity o f the
native promoters (271, 280, 294, 295).
c-fos promoter
A minimal c-fos promoter has never been used as such, for expressing a therapeutic gene
for the purpose o f gene therapy. Given the fact that promoters o f several members o f the
AP-1 family o f proteins are targets o f various signaling pathways found to be activated in
variety o f cancers(296), c-fos could be a very strong candidate for use in cancer gene
therapy. Our results from luciferase assays show that coupling o f a Tcf-4 enhancer
element with a minimal c-fos promoter results in a significant increase in the
transcriptional activity as compared to the c-fos promoter alone (Table 1). As expected,
owing to the activation o f the Wnt signaling pathway in the chosen colon cancer cell lines
(HCT8, SW480, SW620, and Colo320), a c-fos/Tcf recombinant promoter showed a
higher activity in terms o f the measured luciferase levels. At the same time, no significant
levels o f c-fos/Tcf transcriptional activity was observed in the normal NCM460 colon
cells. This was because NCM 460 cells are derived from normal colon epithelia and do
not have transcriptionally active P-catenin present in the nucleus required to transactivate
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the Tcf-4 enhancer elements (discussed later). In the next step, we compared the activities
o f c-fos/Tcf and c-fos/Fct (Tcf-4 enhancer with mutated Tcf-4 binding sites) in luciferase
assays (figure 1). As expected, we observed a dramatic increase in the transcriptional
activity o f c-fos/Tcf over c-fos/Fct, demonstrating that a functional Tcf-4 enhancer
sequence is essential for the recombinant promoter activity in a tumor cell environment
having a constitutively active P-catenin/Tcf-4 complex. In addition, in normal cells
(NCM460, NCM425) presence o f Tcf-4 enhancer element did not result in any
significant increase in promoter activities. Therefore it can be concluded that in luciferase
assays, coupling o f the Tcf-4 enhancer increases the transcriptional activity o f a minimal
c-fos promoter.
CEA promoter
Encouraged by these results, we next tested the possibility o f using the CEA promoter in
combination with the Tcf-4 enhancer element. The CEA promoter is found typically
activated typically in gastrointestinal cancers and several previous studies have shown the
potential o f the CEA promoter for tum or specific therapeutic gene expression. However,
CEA promoter is also a weak activator o f gene transcription which could be an issue in
cases where a high level o f therapeutic gene expression is required. We tested the
hypothesis that the activity o f a CEA promoter could be improved by coupling it with a
Tcf-4 enhancer element. We tested CEA /Tcf recombinant promoter activity in a panel o f
cell lines (table2) and noticed that it is active only in SW620 colon cancer cells. CEA /Tcf
promoter activity was also assessed in breast cancer cells (MDA435 and MCF7) and no
appreciable increase o f promoter activity was observed as compared to the CEA promoter
activity alone. At the same time, one o f our collaborators (Dr. Kathy Molnar-Kimber) at
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the University o f Pennsylvania tested the activity o f the CEA /Tcf recombinant promoter
in Lovo and Colo320 colon cancer cells. A dramatic increase in CEA promoter activity
was seen in the presence o f the Tcf-4 enhancer element in Colo320 cells and a modest
increase was noticed in Lovo cells. Therefore coupling o f a Tcf-4 enhancer element with
a CEA promoter may be advantageous under some situations. Although the cells in which
CEA /Tcf recombinant promoter did not show significant activity have been shown to
have deregulation o f Wnt signaling pathway, it could be possible that these cells have
very low CEA activity and coupling o f Tcf-4 enhancer is not enough for high levels
transcriptional activation. Results presented in table 2 also show that, except in MCF7
breast cancer cells, the c-fos/Tcf combination is significantly active in the test cancer
cells lines, again emphasizing the point that the minimal promoter coupled with Tcf-4
enhancer element is also an important factor contributing to the overall activity o f the
recombinant promoter.
NCM460 as negative control cell line
The normal colon cells, NCM460, have been extensively used in this study. The
NCM460 cell line is a very useful tool for evaluating the activities o f the candidate
promoter/enhancer combination in a normal cellular environment. This becomes very
important because the goal o f the study was to design novel promoter/enhancer
combinations, active in tumor cells and not in normal cells, which could be used for
driving therapeutic gene expression. The c-fos/Tcf recombinant promoter showed a 10fold increase in activity in NCM460 cells (table 2) which was an unexpected result
because being normal cells, NCM 460 do not have a constitutively active Wnt signaling
pathway (272). However, it is worth mentioning that these results are derived from a dual
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luciferase assay which is a screening tool and not an assay which would directly measure
the levels o f therapeutic gene expression in terms o f cell killing or viability. In other
words, a more functional assay would be a better way to evaluate the activity o f the
designed recombinant promoter/enhancer combinations. Another important parameter
was to assess how transfectaable NCM460 cells were, as it could be argued that if these
cells were not efficiently tran sferab le, then this would result in lower activities o f the
candidate recombinant promoters. We addressed this issue by transfecting NCM460 cells
with a reporter construct in which the luciferase gene was driven by a constitutively
active MMLV LTR promoter (table 2). Significant levels o f luciferase gene expression
was achieved from the LTR promoter indicating successful reporter plasmid DNA
uptake, and also that these cells are not transcriptionally inactive.
Additionally, we showed by immunostaining for P-catenin that there is no nuclear
P-catenin present in NCM460 cells and it was found to be present on inner side o f cell
membranes, indicating that wnt signaling pathway is not deregulated in these cells (figure
5). Further, we co-transfected NCM460 cells with pLuc-fos/Tcf (luciferase gene
expressed by c-fos/Tcf recombinant promoter) and a plasmid DNA encoding
constitutively active beta-catenin. As expected, a dramatic increase in the activity o f cfos/Tcf promoter was observed suggesting that NCM 460 cells do not have constitutively
active P-catenin which is available for the transactivation o f recombinant promoters
consisting o f Tcf-4 enhancer elements. With all the given data it can be concluded that
NCM460 cells are good negative controls for the experiments performed in Specific
A im l.
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Cox-2, PSMA and PSA promoter
Cox-2 is found to be up-regulated in a variety o f epithelial tumors and has been shown to
be a target o f the wnt signaling pathway (26, 247). In addition cox-2 promoter activity
has been shown to be inactive in liver which can be very helpful in minimizing the liver
toxicity in patients being treated with suicide gene therapy (252). Previous studies have
indicated the potential o f using the Cox-2 promoter as a tumor specific gene expression
promoter (248). We hypothesized that coupling o f the Tcf-4 enhancer element with a
Cox-2 promoter would achieve higher transcriptional activities. Indeed, in dual luciferase
assays using plasmid constructs in which the luciferase gene was driven by a Cox-2
promoter or Cox-2/Tcf promoter enhancer combination, we found that the Tcf-4 enhancer
element significantly increased the activity o f the Cox-2 promoter in the colon cancer cell
lines HCT8 and SW620, where as it gives a modest boost to the Cox-2 promoter activity
in the H C T116 colon cancer cell line (figure 3). This was expected given the fact that
Cox-2 in known to be upregulated in gastrointestinal cancers (287), and m oreover the
tested cell lines are also known to have an activated wnt signaling pathway (286).
In our continuing efforts to identify more candidate promoter/Tcf-4 enhancer
combinations, we also tested the activity o f PSA and PSMA promoters in the presence
and absence o f a Tcf-4 enhancer element by performing dual luciferase assays. No
significant PSA or PSMA activity, either in the presence or absence o f Tcf-4 enhancer,
was observed in the tested colon cancer cells (H C T 116, HCT8, and SW620). However,
coupling o f the Tcf-4 enhancer did significantly increase the PSMA promoter activity in
prostate cancer cells DU 145 and PC3 (figure 4).
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Conclusion: Specific Aim 1
Based on the results from experiments performed in specific aim 1 it can be concluded
that coupling o f a Tcf-4 enhancer element to a minimal promoter o f an oncogene is a
viable strategy for designing o f tum or specific gene expression promoters. In this
promoter/enhancer combination the role o f the promoter partner is very significant; as
evidenced by the following observations:
•

Lovo and Colo320 colon cancer cells showed a high C EA /Tcf activity, in
contrast they show comparably less Cox-2/Tcf-4 activity

•

SW620, H C T116 and HCT8 colon cancer cells had a low CEA /Tcf recombinant
promoter activity but high C ox-2/Tcf and c-fos/Tcf recombinant promoter
activity.

•

Prostate cancer cell lines DU 145 and PC3 registered a high PSM A/Tcf
recombinant promoter activity but low PSA /Tcf recombinant promoter activity.

Therefore the emerging theme is, one particular promoter/Tcf-4 recombinant promoter
combination may be active in one specific target cell and may not show the same activity
in a different cell line.

Specific Aim 2
In Aim 1 we established that Tcf-4 enhancer elements can be successfully
combined with minimal promoters o f various oncogenes for the purpose o f engineering
o f a tumor specific gene expression promoter. In the next step, we evaluated the ability o f
the chosen c-fos/Tcf enhancer promoter combination to express the therapeutic gene
HSV-TK specifically in targeted tumor cells. By transient transfection experiments we
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showed successful expression o f c-fos/Tcf driven HSV-TK expression in selected colon
cancer cells (SW 480, HCT8 and SW620) and breast cancer cells (MDA435 and MCF7)
(figures 6&7). At the same time no c-fos/Tcf driven HSV-TK expression was detected in
the normal NCM 460 cells. These results are in perfect agreement with the results
luciferase assays performed in aim 1 using c-fos/Tcf recombinant promoter. However, it
is noteworthy here that although, in luciferase assays, we did noticed a 10 fold increase in
promoter activity upon coupling o f Tcf-4 enhancer element with c-fos promoter, we did
not see any detectable levels o f the therapeutic gene expression as measured by western
blots. Therefore indicating that activity o f the c-fos/Tcf recombinant promoter in normal
cells is not significantly enough for the expression o f HSV-TK. Further by metabolic
labeling assays we demonstrated that the HSV-TK gene product expressed from c-fos/Tcf
recombinant promoter is functional and is capable o f phosphorylating the prodrug GCV
into GCV phosphate (figures 8 and 9). The high level o f HSV-TK metabolically labeled
GCV detected in SW480 cells conform to the high level o f HSV-TK expression seen by
western blotting. However, HCT8 cells did seem to have comparable GCV metabolites,
although they show levels o f HSV-TK expression. This anomaly could be due to the
difference in metabolism o f GCV by HCT8 cells. Several cancer cells are know to
develop drug resistance via effluxing the drug with the help o f specialized pumps present
in their cell membranes. This effectively reduces the bio-availability o f the drug in the
target tissue. In our GCV sensitive cell viability assays we showed that transient
transfection o f colon cancer (SW 480) and breast cancer cells (MDA 435) followed by
GCV treatment results in significant cell death. Whereas, in identical assays no
significant GCV mediated cell killing was observed in the normal NCM460 cells. These
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results are as expected, given that c-fos/Tcf selectively expresses the HSV-TK gene in
tumor cells (here SW480 and MDA435) and not in normal cells (NCM 460), it is likely
that tumor cells will have a significantly higher GCV toxicity as compared to the normal
cells (figure 11).
The ability o f PSM A/Tcf recombinant promoter combination was also tested to
sensitize prostate cancer cells (DU 145 and PC3) to GCV. In transient transfection assays
followed by GCV treatment, using pPSM A/Tcf-4-HSV-TKconstruct, PC3 cells showed
were found to be highly sensitive to GCV (figure 12). This was highly expected because
in our luciferase assays we had already shown that PSM A/Tcf recombinant promoter is
very active in PC3 cells. Although, in luciferase assays, we had seen a high PSM A/Tcf
recombinant promoter activity in DU 145 cells, we did not notice significant cell death at
lOum GCV concentrations. Again this could be an issue o f reduced bioavailability o f
GCV in DU 145 cells owing to the activation o f drug resistance mechanisms commonly
found in cells (figure 12). Therefore, we repeated the GCV sensitivity assay in DU 145
cells, using pPSM A/Tcf-4-HSV-TKconstruct, and increased the GCV treatment levels to
25um. A dramatic increase in DU 145 cell killing was observed, indicating increased level
o f GCV sensitivity. This increase was highly specific to the expression o f HSV-TK in
DU 145 cells because mock or pCDNA-HSV-TK (promoter less) transfected cells were
not found to be sensitive to 25um GCV. In addition, transfection o f pPSM A/Tcf-4-HSVTKconstruct did not cause any significant level o f GCV toxicity in the normal NCM460
cells indicating non-expression HSV-TK in these cells due to weak PSM A /Tcf
recombinant promoter activity.
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Conclusion: Specific Aim 2
From the data provided it can be concluded that c-fos/Tcf and PSM A /Tcf recombinant
promoters can successfully express a functional copy o f the chosen therapeutic gene,
HSV-TK, in tumors cells.

Specific Aim 3
The ultimate aim in this step o f the study was to engineer a delivery system in
which the gene expression cassette could be packed and delivered to the target tumor
cells. Adenoviral vectors are widely used for in vitro and in vivo gene transfer in several
animal models and in clinical trials as well. They are know to efficiently transduce a wide
range o f cell types and have shown enormous potential for being used in cancer gene
therapy for delivery o f the therapeutic gene to the tum or cells (297). However, there are
several issues related to the Biosafety o f a adenoviruses for example adenoviruses are
known to generate an acute inflammatory immune response which can cause widespread
toxicities in the patient (298). However, newer generation adenoviral vectors have a
better safety profile as they are engineered to carry less adenoviral proteins and unable to
replicate inside the host (297). The main objective o f this specific aim was to demonstrate
that a therapeutic gene expression cassette, in which the therapeutic gene is under the
control o f a recombinant c-fos/Tcf promoter-enhancer combination, can be successfully
delivered and expressed in a target cell. Ad-Fos/Tcf-TK was designed to express HSVTK from a c-fos/Tcf recombinant promoter. Ad-CMV-TK was constructed as a control
vector in which HSV-TK gene was under the control o f a CMV promoter. The tested cell
lines were infected with the recombinant adenoviruses and were assessed for HSV-TK
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expression by W estern blotting. Ad-c-fos/Tcf4-HSV-TK was found to successfully
express HSV-TK in the tested colon cancer cells (SW 620 and SW480). Owing to the
high activity o f C -fos/Tcf recombinant promoter and the ability o f adenoviruses to infect
tumor cells, this result was highly expected. However, no expression o f HSV-TK was
detected in normal (NCM460) cells. A logical explanation for this observation could be
the inactivity o f c-fos/Tcf recombinant promoter in these normal cells. However it can
also be speculated that NCM460 cells cannot be infected by adenoviruses resulting in
their failure to deliver the HSV-TK therapeutic gene construct to the normal cells. To
address this issue NCM460 cells were infected with Ad-CMV-TK, followed by a western
blot analysis for the HSV-TK gene expression. As expected, significant levels o f HSVTK protein were detected in NCM460 cells suggesting a successful delivery o f the HSVTK therapeutic gene by Ad-CMV-TK. Further, we established adenovirus mediated
delivery o f HSV-TK causes GCV sensitivity in target cells. Following infection with the
recombinant adenoviruses, cells were treated with GCV and 48 hours later live cells were
counted. Ad-c-fos/Tcf4-HSV-TK (figure 15)was found to cause significant cell death in
colon cancer cell lines (SW 480 and SW620) and was not observed to cause any
significant GCV sensitivity in the normal cells (NCM460). These results are in
accordance with the HSV-TK western blot shown in figure 6 in which, owing to the
inactivity o f the recombinant promoter, Ad-c-fos/Tcf4-HSV-TK was not found to be
active in the normal cells. Therefore, it can be speculated that lack o f Ad-c-fos/Tcf4HSV-TK mediated HSV-TK expression in the normal NCM460 cells resulted in
insignificant cell death. This speculation was further confirmed by the observation that,
owing to the universally active CMV promoter, Ad-CMV-TK caused significant GCV
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toxicity in the normal cells (NCM460) as well as the colon tumor cells (SW 480 and
SW620).
Conclusion Specific Aim 3
The following points can be concluded from the experimental evidence provided in
specific aim 3.
•

The recombinant therapeutic gene expression cassette can be successfully
packaged inside an adenoviral delivery vector.

•

Adenoviruses can successfully deliver and express the therapeutic gene
expression cassette to the colon cancer cells (SW480 and SW620).

•

It is probable that the Adenoviral vectors would be able to deliver and express the
therapeutic gene expression cassette in other types o f cancers especially the ones
in which wnt signaling pathway is found to be aberrantly activated.

Specific Aim 4
Finally, having successfully delivered the therapeutic gene expression cassette to
the tumor cells, the next step was to discern strategies by which the therapeutic gene
expression could be regulated. This regulatory aspect o f therapeutic gene expression
could be very critical under certain clinical situations which may require increasing or
decreasing the level o f therapeutic expression. Chemical modulators like sodium butyrate
have been previously shown to increase the expression o f Tcf-4 responsive genes (223).
Therefore the efficacy o f sodium butyrate to increase the recombinant promoter activity
was explored by conducting luciferase assays. Sodium butyrate was found to increase the
activity o f our recombinant Tcf-4/c-fos promoter combination as well the HSV-TK
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promoter which drives the expression o f the internal control ‘Renilla Luciferase’ gene.
This is evident from the results presented in figure 16 Which show that after adding
sodium butyrate the relative luciferase value actually goes down, this is because sodium
butyrate (general histone deacetylase inhibitor) non specifically increases the rate o f
transcription o f both the HSV-TK promoter (expresses the Renilla luciferase gene), as
well as the transcriptional activity o f the tested Tcf-4/c-fos promoter combination
(expressing the luciferase gene). Although non-specifically, sodium butyrate did increase
the activity o f our tested Tcf-4/c-fos promoter combination (figure 17), therefore it may
be useful for cancer gene therapy under situations where increased therapeutic gene
expression is needed for enhancing tumor cell killing. Further, we screened NSAIDs
(Non-steroidal anti-inflammatory drug-NSAlD) like indomethacin and Celecoxib (Cox-2
inhibitor) for their ability to modulate the transcriptional activity o f our recombinant
enhancer/promoter system. Indomethacin has been suggested to have chemo preventive
properties against colon cancer and is believe to act by upregulating tumor suppressive
gene PTEN, affecting the cell survival and inhibition o f apoptosis by negatively
regulating the AKT/PI3K pathway (292). In addition indomethacin has been directly
shown to down-regulate wnt signaling by stabilizing the phosphorylated forms o f p*
catenin (299). Similarly Cox-2 inhibitors have been increasingly used as a chemo
preventive agent for colon cancer and have been shown to inhibit wnt signaling pathway
by affecting the levels o f nuclear P-catenin (287, 300). In our preliminary experiments we
found marginal reduction in the activity o f the c-foc/Tcf-4 recombinant promoter. This
was evidenced by the reduced HSV-TK levels in western blots performed on SW620 and
Colo320 colon cancer cell lines transfected pc-fos/Tcf-4-HSV-TK and treated with
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Indomethacina and Celecoxib (figure 18). Given the fact that NSAIDs have been shown
to inhibit wnt signaling pathway, these results are highly encouraging and are indicative
that the activity o f our recombinant enhancer/promoter system can be controlled by
chemical means. Taken together, it can be stated that there is a good possibility o f
regulating the activity o f our recombinant enhancer/promoter system, in clinical settings,
by chemical means. However extensive screening and analysis o f these chemical
modulators is needed to further characterize their modulatory properties.
In our on going efforts to find mechanisms to regulate the transcriptional activity o f
our recombinant enhancer/promoter system, we hypothesized that over expressing a
constitutively active form o f P-catenin in the target cell should enhance the transcriptional
activity o f the recombinant enhancer/promoter. Indeed, our results show increased HSVTK expression levels when a plasmid expressing for constitutively active P-catenin was
co-transfected with pc-fos/Tcf-4-HSV-TK in SW620 and Colo320 colon cancer cell
lines. The most logical explanation for this result is that P-catenin over expression
increased the activity o f the pc-fos/Tcf recombinant promoter which is driving the
expression o f the HSV-TK gene. This observation is very interesting and may have
significant clinical implications. For example, an adenoviral delivery vector can be
designed with a dual expression cassette containing the therapeutic gene and gene for
constitutively active P-catenin under the control o f our recombinant Tcf-4
enhancer/promoter system. This system would express higher amounts o f the therapeutic
gene because o f the constitutively active P-catenin. Since the expression o f P-catenin will
also be controlled by the Tcf-4 enhancer/promoter, P-catenin levels will further stimulate
the transcriptional activity o f the recombinant promoter greatly increasing the levels o f
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therapeutic and P-catenin gene expression levels. This dual expression strategy is
particularly more beneficial in cancers which have low levels o f nuclear P-catenin to
activate the recombinant Tcf-4 enhancer/promoter system.
Conclusion Specific Aim 4
•

Sodium butyrate increases the activity o f the c-fos/Tcf-4 recombinant promoter.
Although this effect o f sodium butyrate is non-specific, it can still be used as a
positive regulator o f the Tcf-4 enhancer/promoter system.

•

NSAIDs, which are known to affect the wnt signaling pathway by stabilizing the
levels o f phosphorylated P-catenin, can be used as negative regulators o f the Tcf-4
enhancer/promoter system.

•

Constitutively active P-catenin gene expression enhances the level o f HSV-TK
gene expression, most likely by increasing the transcriptional activity o f the pcfos/Tcf recombinant promoter.

The Big Picture
Because mutations in the APC gene and P-catenin gene are frequently associated
with progression o f colon carcinoma and most other types o f epithelial carcinomas, the
effectiveness o f a Tcf-4/ P-catenin transcriptional enhancer element was evaluated for its
ability to act as a tumor specific regulator o f therapeutic gene expression in a panel o f
human tumor and normal colon cell lines. Using the HSV-TK gene in combination with
GCV, we demonstrated that the Tcf-4/ P-catenin enhancer and c-fos promoter can
efficiently direct expression o f HSV-TK resulting in phosphorylation o f GCV and cell
killing.
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1) Our approach with the Tcf-4/ P-catenin enhancer is based on tum or specific conditions
with transcriptional activity dependent on transcription factor complexes found only in
the tumor phenotype. In several studies, coupling o f the T cf enhancer elements with
constitutive viral promoters (TK., SV40, Ad E1B,E2) in adenoviral vectors have proven
to be effective vehicles for tumor specific gene expression in cell culture and in animal
models (272, 273, 301). We hypothesized that linking the T cf enhancer elements with a
mammalian promoter associated with a tumor phenotype or involved in the wnt signaling
pathway could be even more effective. An increasing number o f genes with Tcf-4/ Pcatenin 5' regulatory sequences have been identified, including c-myc, cyclin D, c-jun,
and MMP-7 (19-22, 24). Promoter sequences from these genes, and others yet to be
identified, could be manipulated for combination testing with the Tcf-4/ -catenin
enhancer.
2) This approach can be very useful in customizing cancer gene therapy treatment based
on the gene expression o f the tum or biopsy taken from the patient. Depending on which
oncogenes are found to be up-regulated in the tumor, a custom gene expression cassette
can be tailor made for the patient by coupling Tcf-4 enhancer element with the chosen
oncogenic promoter.
3) The potential o f this strategy can be further explored by combining the Tcf-4 enhancer
elements with newly discovered/designed tumor/tissue specific gene expression
promoters. There are several potential candidate promoters, for example, epithelial cell
adhesion molecule promoter, stress inducible grp78 promoter and the tyrosine
hydroxylase promoter (302-304).
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4) Owing to the leaky therapeutic gene expression in normal cells, cancer gene therapy
may cause normal cell toxicities. Usually liver cell toxicity is one o f the prime concerns
in cancer gene therapy and our approach can address this issue by selecting special
promoters in combination with Tcf-4 enhancer element. For example, Cox-2 promoter
has been shown to have minimal activity in liver cells, and as already shown in the
presented data Cox-2 promoter, can be successfully combined with Tcf-4 enhancer
element for tum or specific gene expression.
5) We have demonstrated that these innovatively designed therapeutic gene expression
cassettes can be successfully delivered using adenoviral vectors. In a clinical situation,
this would allow stringent control o f the delivery and expression o f the therapeutic gene
expression cassette. In addition, systemically administered adenoviral vectors can reach
widely disseminated tumors which may go undetected by conventional therapies.
However there are certain safety issues associated with the use o f adenoviral vectors as
delivery vehicle, these concerns can be addressed to reasonable levels by using the newer
generation adenoviral vectors (298).
6) Another unique aspect o f Tcf-4/ P-catenin regulation is the modulation o f responsive
genes by chemical modifiers like butyrate, phorbol esters, doxorubicin and retinoids.
Short chain fatty acids like butyrate and trichostatin A have been reported to increase
Tcf-4/ P-catenin mediated gene expression (223, 305). Addition o f the phorbol ester PMA
has also been reported to increase gene expression (305). Conversely, addition o f
NSAIDs has been suggested to inhibit Tcf-4/p-catenin mediated transcription by
stabilizing the levels o f phosphorylated P-catenin. In addition, there are other compounds
which have the potential for being used as negative regulators o f Tcf-4/p-catenin
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mediated transcription. For example, the anti-cancer drug, Adriamycin (226) and
retinoids (227) have been shown to decrease Tcf-4/ -catenin mediated gene expression.
The effects o f these compounds on HSV-TK expression in the Tcf-TK-transfected cells is
currently under investigation. Because o f the demonstrated variability o f transcriptional
regulation o f Tcf-4/ P-catenin expression in different tum or cell lines (as in Figure 1),
addition o f an inducible stimulating agent could enhance expression in marginally
responsive cells. Conversely, the possibility o f having a repressor option in the context o f
patient safety for viral-based gene therapies could be important. Thus, the drug
inducibility (or repression) options conferred with the Tcf-4/ P-catenin enhancer will be
further characterized for potential clinical use o f this element in therapeutic gene
expression.
7) Innovative cancer therapy protocols can be designed by combining our approach with
conventional cancer therapies. For example, a Tcf-4 enhancer element could be combined
with a radioinducible promoter like Egr (306) for expressing the desired therapeutic gene.
This multi-modal therapeutic approach may result in improved therapeutic outcomes.
8) Our recombinant Tcf-4 enhancer/promoter system can be utilized to control the
replication o f conditionally replicative oncolytic adenoviruses. This can be achieved by
placing the expressing o f key genes needed for the replication o f oncolytic adenovirus
under the control o f our recombinant enhancer/promoter system. In an appropriate tumor
cell environment, the Tcf-4 enhancer/promoter would be highly active allowing increased
replication o f the oncolytic adenovirus. On the other hand, in a normal cell environment,
the recombinant promoter will not be active and will prevent normal cell toxicity by not
allowing the oncolytic adenovirus to replicate.
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9) Our gene therapy approach is solely a tumor specific gene expression promoter based
approach. Therefore, it has the flexibility o f being used with any therapeutic gene o f
choice allowing 1) killing o f the tumor cell 2) substituting the mutated gene responsible
for neoplastic transformation or 3) immunomodulating the host immune response to
target and eliminate the tumor.

Future Directions
The results presented in the study successfully demonstrate the ‘proof o f
principle’ that Tcf-4/p-catenin enhancer can be used for the design o f tumor/tissue
specific gene expression promoters for the purpose o f cancer gene therapy. However, it
should be noted that this conclusion is derived solely from in vitro experiments. The
validity o f these in vitro results needs to be tested in animals to demonstrate the
robustness o f the proposed enhancer promoter system. There are several key points which
can be derived from the in vitro data presented, for example 1) aberrant activation o f the
wnt signaling pathway, due to mutational inactivation o f the APC or P-catenin gene in the
target tum or is an absolute requirement for the success o f the proposed system, 2) the
minimal promoter partner is very crucial in determining the over all activity o f the
recombinant promoters, 3) the promoters incorporating the Tcf-4 enhancer element are
not active in the tested normal cells (we will elaborate this point later) and finally, 4) the
therapeutic gene expression construct comprising o f the recombinant promoters
expressing the gene o f choice can be successfully delivered by using an adenoviruses to
the tumor cells under in vitro conditions. As mentioned earlier, each o f these points will
need to be further characterized in animal model systems.
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There are several rodents models for colorectal cancer that are based upon
mutational inactivation o f the APC gene(307). These APC mutation based animal models
would be ideal for testing the tumor specific gene expression ability o f the proposed
promoter/enhancer system under in vivo situations. The APC/min mouse (min mouse) is
one o f the most extensively used animal models for colon cancer studies. These animals
carry germline heterozygous mutations in the APC gene resulting in a truncated APC
gene product and develop more than 100 intestinal tumors mainly in the upper
gastrointestinal tract (GI). The Min mouse has been widely used in colon cancer research
although it does not forms tumors in the large intestine, its use can be justified from the
fact that patients suffering from familial adenomatous polyposis are susceptible to a
broad spectrum o f extra-colonic manifestations, the most clinically relevant o f which are
the desmoid and upper GI tract tumors (307). Therefore, we believe that for our studies,
this model would be highly useful in replicating our in vitro studies under in vivo
situations.
However, to use the min mouse model for our studies, several key issues
including the choice o f therapeutic gene, delivery vector, and route o f administration o f
the vector or drug will have to be worked out before we can observe the expected results.
In addition, there is the issue o f which minimal promoter to be pair with the Tcf-4
enhancer for testing in the animal model. This is a very crucial aspect and stems from the
demonstrated fact that the activity o f the minimal promoter is also an important part o f
the whole recombinant promoter. In other words, if a minimal promoter partner is chosen
which has a fairly high amount o f activity in normal cells/tissues besides being highly
active in the target tumor cells; it may result in normal cell/tissue toxicity and lowers the
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therapeutic index. One o f the inherent positive points o f using the Tcf-4 enhancer
elements for designing such recombinant promoters is the mechanism by which they
control gene expression. Tcf-4 elements in the absence o f nuclear P-catenin, a situation
expected in normal cells, act as transcription repressors. Several proteins like the histone
deacetylases CtBP and Rpd3 are recruited to the TCf-4 elements (308) resulting in the
transcriptional repression o f the promoter. Therefore, this unique gene expression
controlling feature o f Tcf-4 elements can act as a safeguard mechanism by silencing the
expression o f the toxic therapeutic gene in normal cells. Hence, even if the minimal
promoter partner has some activity in normal cells/tissues, we predict it is likely to show
much reduced transcriptional activity when coupled with a Tcf-4 element.
By optimizing the above mentioned factors we expect to see a reduced tum or load
in the min mouse upon treatment with our therapeutic expression vectors along with
reduced normal cell toxicity. However, complete eradication o f the tumors and
minimizing normal cell toxicity may require several intervening steps. For example,
rationally chosen therapeutic gene(s) could result in an enhanced bystander effect
targeting increasing number o f tumor cells or the gene therapy approach could be
combined with other treatment modalities like chemotherapy for better therapeutic
outcome. Cancer immunotherapy is one o f the most promising ways to achieve
substantial levels o f a bystander effect. The proposed therapeutic gene expression system
in this study can be easily adapted for such purposes. Several studies have shown the
benefits o f targeting the tumors with an immunogenic approach. Cytokines, like GM-CSF
(granulocyte-macrophage colony-stimulating factor), when expressed in the tumor micro
environment have been shown to stimulate an intense inflammatory reaction
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characterized by tum or infiltrating granulocytes, macrophages and dendritic cells.
Furthermore, the presence o f dendritic cells (the antigen presenting cells) suggests that
GM-CSF creates an advantageous intracellular environment for tumor antigen
presentation resulting in the activation o f lymphocytes against the tumors (309). Other
promising cytokines which can be used for cancer immunotherapy are IL-12 and IL-21
(310, 311). Genes for such cytokines along with tumor antigens can be incorporated into
the Tcf-4 enhancer/promoter containing vectors for targeting colon tumors. Such cancer
vaccines are expected to be highly effective in targeting widely disseminated tumors.
The possibilities o f using our proposed gene expression system are potentially
unlimited, in theory it can be used to express any desired gene in tumors especially o f the
colon. Therefore, in future studies, it will be quite interesting to see the efficacy o f the
Tcf-4 enhancer containing recombinant promoters to express genes other than HSV-TK.
Efforts are needed to harvest the customizable aspect o f our proposed gene expression
system. Given the possibility o f the spectrum o f therapeutic genes which can be used to
target tumor tissue, a thorough genetic screening o f the patient would be extremely
beneficial in choosing the appropriate therapeutic gene on an individual patient basis.
As far as the question o f m inimizing o f normal cell toxicity, it may not be
possible to attain absolutely no normal cell toxicity, but it can be minimized. The
presented in vitro data clearly shows that the proposed promo ter/enhancer system is not
active in the normal NCM 460 cells. These cells are derived from normal colon cells, are
non cancerous and have been previously used as standard negative control cells in a
published study (272). In addition we have demonstrated that, like normal cells, these
cells do not have nuclear P-catenin and the Tcf-4 enhancer activity can be increased by
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over expression o f constitutively active P-catenin. However, it must be emphasized that
although these cells may have characteristics o f normal colon cells, they may not be a
true representation o f the entire spectrum o f the epithelial cells lining the colon or GI
tract. Two other normal colon cell lines, NCM425 and CSC-1 were also tested in our
study and showed lower activities o f the promoter/enhancer system. However, more
studies are required to assess the ability o f NCM425 and CSC-1 to serve as negative
controls.
In relation to normal cell toxicity, another issue which may impact the usage o f
our proposed promoter/enhancer system is the presence o f a small number o f stem cells at
the base o f each colonic crypt along the length o f intestine. These stem cells differentiate
into several types o f epithelial cells found in the lining o f the GI tract and are responsible
for replenishing the epithelial cells lost during normal wear and tear o f the GI tract (4). It
has been suggested that these stem cells require wnt signaling for the process o f
differentiation, and nuclear staining o f P-catenin has been documented in these cells. At
the same time these cells do not show any APC staining, reinforcing the fact that the
presence o f wild type APC protein is crucial for regulation o f P-catenin levels. As the
cells mature along the crypt-villi axis and move towards the periphery o f villi (the center
o f the GI tract), they progressively show less nuclear P-catenin levels and increased APC
expression. In the given scenario, in theory, our recombinant promoter/enhancer/gene
construct could be toxic to these cells because o f the activated wnt signaling pathway and
m ay result in stem cell toxicity. However, how much stem cell toxicity our proposed
therapy system would cause is a matter o f speculation. This is because these stem cells
have very low minimal levels o f wnt signaling activation which may be significant only
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from a differentiation and development perspective (312). How this background wnt
signaling will activate our recombinant Tcf-4 enhancer/promoter elements, needs to be
determined, but based on known considerations we do not expect it to cause widespread
stem cell toxicity. This is based on the fact that too much wnt signaling usually causes a
normal cell to undergo apoptosis. Therefore, levels o f wnt signaling in these colon stem
cells may not be as comparable to the colon cancer cells (in which mutational inactivation
o f APC/p-catenin causes aberrant activation o f wnt signaling), and this might not
significantly activate our proposed recombinant promoter system. In addition, normal
stem cell toxicity can be further minimized by directly targeting the tumor with the
therapeutic vector by using variety o f means, for example by combining imaging
techiniques like ultrasound biomicroscopy can be used to guide direct injection o f the
vectors into the tumors (313). Furthermore, the transgene expression can also be
monitored by combining molecular imaging with radio-nuclide based gene therapy
approaches and could assist in minimizing normal cell toxicity (314).
Another attractive aspect o f the proposed system is the potential ability to regulate
(induce or suppress gene expression) the levels o f therapeutic gene expression under
clinical situations. Although, the data presented here to support this aspect are very
preliminary and need further characterization, the initial results are suggestive o f the
regulatory potential o f the recombinant promoters containing the Tcf-4 enhancer element.
Among the existing transcriptional gene regulatory systems, the Tet-regulatable system is
the most widely exploited tool for controlling gene expression. For gene therapy purposes
the Tet-regulatory system has been encoded with lentiviruses, adenoviruses, adenoassociated viruses and retroviruses. The Tet system has several advantages. For example,
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tetracycline is non toxic to humans at the dosage levels required for gene activation
(although it can be toxic to humans at high concentrations) and it does not exhibit any
pleiotropic effect on cellular metabolic pathways. The down side o f using this system to
control gene expression in the clinic is the possibility o f the Tet system proteins being
immunogenic in human because o f their bacterial origin (315). At the same time, the Tet
system involves incorporation o f extra DNA sequences encoding the Tet component
proteins which may be critical for the gene delivery vector in terms o f the carrying
capacity. In contrast, for regulation o f the therapeutic gene, the system proposed in this
study requires no extra set o f genes to be included in the therapeutic gene expression
vector. In addition, no potentially immunogenic substances are involved. For example,
short chain fatty acids (like sodium butyrate and retinoic acid) are naturally occurring
substances. However, what adverse affects these substances might have on normal cells
will have to be worked out, for example short chain fatty acids are also known to cause
apoptosis in cells. Therefore, extensive studies are needed both in vitro and in vivo to
demonstrate the feasibility o f using these chemical regulators to control transcriptional
activity o f Tcf-4 enhancer containing promoters.
The proposed Tcf-4 enhancer based recombinant promoter system is a promising
approach for expressing the therapeutic genes specifically in tumors especially o f the
colon. This system needs further characterization under in vivo situations. There are some
hurdles, as described above, which may limit the use o f these Tcf-4 based recombinant
promoters in the clinic. However, with innovative design and application o f
comprehensive knowledge from the fields o f molecular biology, immunology, virology
and molecular medicine, these issues can be rationally addressed. The field o f cancer
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gene therapy is an area o f active translational research and requires concerted efforts o f
scientists from several different areas. In fact, this is one o f the limitations o f successful
implementation o f cancer gene therapies in clinic. For the future more resources and
dedicated efforts are required for the success o f cancer gene therapy. In general, the field
o f gene therapy is very young and has given the mankind a ray o f hope for the treatment
o f a broad spectrum o f human diseases ranging from genetic disorders to heart diseases
and cancer. Given the nature o f the pain and suffering involved in these human diseases,
gene therapy has generated high hopes and great hypes. There is huge burden on the
scientific community to innovatively tap the potential o f gene therapy and the same
assure the public that the patient’s welfare and health is their major goal.
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